[
  {
    "id": "WO2011133444A1",
    "text": "Substituted pyrimidines AbstractThe present invention relates to substituted pyrimidines useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions. Claims\n\n\n\n\n WHAT IS CLAIMED IS:\n\n\n\n\n 1. A compound of formula I and pharmaceutically acceptable salts and solvates thereof \n\n\n\n\n\n\n\n\nwherein \n\n\n A is heteroaryl, optionally substituted with one or more R9 substituents; \n\n\nL is chosen from a bond, aryl, heteroaryl, -(C1-3 alkyl)o-]S(Ci_3 alkyl)0-i-, -(C1-3 alkyl)o- iNRaCO-, -(Ci-3 alkyl)0-l R\na\nCO2-, -(C1.3 alkyl)o-iC02-, -(C1.3 alkyl)o- lNRaS02-, -(C1-3 alkylto-l RaO-, <Cl-3 alkyl)o-iNRaCSNRb-, -{C1.3 alkyl)0- iNRaCONRb-, and -(C1.3 alky o-iNRaCOS-; \n\n\nR2 and R3 are independently selected from hydrogen, halogen, hydroxyl, C\\- alkyl, C3-6 \n\n\n heterocycloalkyl and C3-6 cycloalkyl wherein said alkyl, heterocycloalkyl and cycloalkyl are each optionally substituted with one or more substituents selected from: hydroxyl, -SR\\ -NR*2 or -C02-R*; \n\n\nR1 is selected from \n\n\n halogen, \n\n\n Ci-10 alkyl, \n\n\n -C2-10 alkenyl, \n\n\n -C2-IO alkynyl, \n\n\n cycloalkyl Co_io alkyl(oxy)o_i, \n\n\n heterocyclyl Co-]0 alkyl(oxy)o-l, \n\n\n arylCo-io alkyl(oxy)o.i, \n\n\n C]-io alkoxy (carbonyl)0-iCo-10 alkyl, \n\n\n carboxyl Co-10 alkyl. \n\n\n carboxyl aryl, \n\n\n carboxylcycloalkyl, \n\n\n carboxylheterocyclyl, \n\n\n Ci-ioalkyloxy Co-ioalkyl, \n\n\n hydroxy Cn-loal . \n\n\n hydroxycarbonylCo- 1 oalkoxy, \n\n\n Ci-io alkylthio, \n\n\n Ci-io alkylsulfinyl, \n\n\n aryl Cn_io alkylsulfinyl, \n\n heterocyclyl Co-10 alkylsulfinyl, \n\n\n cycloalkyl Co-io alkylsulfinyl, \n\n\n Q-io alkylsulfonyl, \n\n\n aryl Co-10 alkylsulfonyl, \n\n\n heterocyclylCo-io alkylsulfonyl, \n\n\n cycloalkyl Cn-io alkylsulfonyl, \n\n\n nitro, \n\n\n perfiuoroCi-6alkyl, and \n\n\n perfluoroC i -^alkoxy; \n\n\nwherein in Rl said alkyl, alkenyl, alkynyl, cycloalkenyl, aryl, perfluoralkyl, perfluoroalkoxy, \n\n\n heterocyclyl, and cycloalkyl are each optionally substituted with one or more R9 \n\n\n substituents; \n\n\noptionally, R* and L are linked together to form a ring of 5 to 8 atoms optionally substituted with one or more substituents R9; where said ring has 0, 1 , or 2 heteroatoms independently selected from -NRb-, -O- and -S(0)n-; \n\n\n R9 is selected from halogen, hydroxy, oxo, cyano, aryl, heterocyclyl, cycloalkyl, -C\\-6 alkyl, -C\\-6 alkoxy, aryloxy, heterocyclyloxy, -0(0-l)(Ci.io)perfluoroalkyl, -C02Ra, -NRbRc -CONRbRc -OC02R\na\n, -OCONRbRC -NRdC02R\na\n, -NRdcO RbRc, -SQ)-6 alkyl and -S(0)nR\nd\n, wherein said aryl, heteroaryl, heterocycloalkyl, alkoxy, aryloxy, heteroaryloxy, heterocycloalkyloxy are optionally substituted by one or more substituents RlO; \n\n\n RlO is selected from hydroxy, aryl, heterocycloalkyl, heteroaryl, halogen, oxo, -Cl-6 alkyl, C\\s alkoxy, halogen, CO2H, cyano, 0(C=0)o.iCl-6 alkyl, NO2, trifluoromethoxy, trifluoroethoxy, -O(0- l)(Cl-l0)perfluoroalkyl, Co-io alkylaminocarbonylamino, Q)_io alkyloxycarbonylaminoCo-io alkyl, Co-io alkylcarbonylaminoCo-10 alkyl, Co-io alkylaminosulfonylaminoCo-10 alkyl, Co-10 alkylsulfonylaminoCo-io alkyl, Co-10 alkylsulfonyl, Q)_io alkylaminosulfonyl, Co_io \n\n\n alkylaminocarbonyl, -(C=0)N(Co-6 alkyl)2, -S(Q)-6 alkyl), and NH2; \n\n\nn is 1 or 2; \n\n\n Ra is chosen from hydrogen; -Ci-10 alkyl, -(Cl-6 alkyl)C3-8 cycloalkyl; and \n\n\n -(Ci-6 alkyl)phenyl; and \n\n\nRb, Rc, and Rd are each independently chosen from hydrogen, -Ci-10 alkyl,C3-g cycloalkyl, aryl, and heterocyclyl. \n\n\n\n\n\n\n2. A compound of Claim 1 wherein Rl is selected from: cycloalkyl Co-10 alk l(oxy)o- J, heterocyclyl Co-io alkyl(oxy)o-l, arylCo-iO alkyl(oxy)o-l, perfluorCi-6 alkyl, perfluoro Ci^alkoxy, and Ci-10 alkoxy (carbonyl)O-lCo-lO alkyl, wherein Rl is optionally substituted with one or more R^ substituents. \n\n\n\n\n\n\n\n\n3. A compound of Claim 1 wherein R2 is selected from hydrogen, halogen, hydroxy], -Cj-6 alkyl, C3-6 heterocycloalkyl and C3- cycloalkyl wherein said alkyl, heterocycloalkyl and cycloalkyl are each optionally substituted with one or more substituents selected from: hydroxyl, - SR'. -NR^ or-CC^-R*. \n\n\n\n\n\n\n4. A compound of Claim 1 wherein R.3 is selected from hydrogen, halogen, hydroxyl, -Ci- alkyl, C3-6 heterocycloalkyl and C3-6 cycloalkyl wherein said alkyl, heterocycloalkyl and cycloalkyl are each optionally substituted with one or more substituents selected from: hydroxy], - SRVNR^ or-CC^-R*. \n\n\n\n\n\n\n5. A compound of Claim 1, wherein L is selected from -(Ci-3 alkyl)o_iNRaCO-, _ (Ci-3 allcy])o_iNRaC02-. -(C1.3 alkyl)0-lCO2-, -(C1-3 alkyl)0-lNRaSO2-, -<Ci_3 alkyl)0- i RacSNRb-, and -(Ci-3 alkyl)o-lNRaCONRb-. \n\n\n\n\n\n\n6. A compound of Claim 1, wherein L is selected from -{Ci_3 alkyl)o-iNR\na\nCO-,\n\n\n-{Ci-3 alkyl)o-iNRaC02-, and -(Ci.3 alkyl)0-lCO2-. \n\n\n\n\n\n\n7. A compound of Claim 1, wherein L is -(Ci-3 alky o-lNRaCO-. \n\n\n\n\n\n\n8. A compound of Claim 1, wherein A is selected from azabenzimidazole, benzoimidazolyl, benzofuryl, benzofurazanyl, benzopyrazolyl, benzothiazolyl, benzothienyl, benzotriazolyl, benzothiophenyl, benzoxazolyl, cinnolinyl, furanyl, imidazolyl, indolyl, indazolyl, isobenzofuryl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, dihydroisoquinolinyl, \n\n\ntetrahydroisoquinolinyl, naphthpyridinyl, dihydronaphthyridinyl, tetrahydronaphthyridinyl, oxadiazoh l, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridopyridinyl, pyridazinyl, pyridinyl, pyrimidyl, quinazolinyl, quinolyl, quinoxalinyl, quinoxalinyl, tetrahydropyranyl, tetrahydroisoquinolinyl, tetrazolyl, tetrazolopyridyl, thiadiazolyl, thiazolyl, thienyl, triazoly], azetidinyl, aziridinyl, 1,4-dioxanyl, dihydrobenzoimidazolyl, phenothiazinyl, dihydrobenzofuryl, dihydrobenzothiophenyl, \n\n\ndihydrobenzoxazolyl, methylenedioxybenzoyl, tetrahydrofuryl, tetrahydrothienyl, 2 ,3 -dihydrobenzofuryl, 2,3-dihydrobenzo-l,4-dioxiny], imidazo(2,l-bXl,3)thiazole, and benzo-1 -dioxolyl, wherein A is optionally substituted with one or more R9 substituents. \n\n\n\n\n\n\n9. A compound of Claim 8, wherein A is selected from benzoimidazolyl, benzothiazolyl, benzothienyl, benzotriazolyl, benzothiophenyl, benzoxazolyl, furanyl, imidazolyl, indolyl, indazolyl, isobenzofuryl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthpyridinyl, oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridopyridinyl, pyridazinyl, pyridinyl, \n\n pyrimidyl, tetrazolyl, tetrazolopyridyl, thiadiazolyl, thiazolyl, and thienyl, wherein A is optionally substituted with one or more R9 substituents. \n\n\n\n\n\n\n10. A compound of Claim 9, wherein A is selected from pyrazinyl, \n\n\npyrazolyl, pyridazinyl, pyridinyl, and pyrimidyl, wherein A is optionally substituted with one or more substituents.. \n\n\n\n\n\n\n11. A compound of Claim 9, wherein A is selected from pyrazolyl and pyridazinyl, wherein A is optionally substituted with one or more substituents. \n\n\n\n\n\n\n12. A compound selected from: \n\n\nN-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)-2,2-diphenylacetaraide; \n\n\n 2- chloro-N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)benzamide; \n\n\n 3- chloro-N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)benzamide; \n\n\n4-chloro-N-(4-hydroxy-2-(lH-pyrazol-l-yl)pyrimidm-5-yl)benzamide; \n\n\n 3- (trifluoromemyI)-N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)benzamide; \n\n\n 4- (trifluoromemyl)-N-(4^iydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)benzamide; \n\n\nN-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)-2-(naphthalen-3-yl)acetamide; \n\n\n2-cyano-N-(4-hydroxy-2-( 1 H-pyrazol-1 -yl)pyrimidin-5-yl)benzamide; \n\n\n3-cyano-N-(4-hydroxy-2-(lH-pyrazol-l -yl)pyrimidin-5-yl)benzamide; \n\n\n 4-cyano-N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)benzamide; \n\n\n 2-(trifluoromethyl)-N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)benzamide; \n\n\n N-(4-hydroxy-2-(lH-pyrazol-l-yl)pyrimidin-5-yl)-2-methoxybenzamide; \n\n\n N-(4-hydroxy-2-(lH-pyn^l-l-yl)pyrimidm-5-yl)-3-methoxybenzamide; \n\n\nN-(4-hydroxy-2-(] H-pyrazol- l-yl)pyrimidin-5-yl)-4-methoxybenzamide; \n\n\n N-(4-hydroxy-2-(lH-pyrazol-l-yl)pyrimidin-5-yl)-2-(methylsulfonyl)benzamide; \n\n\n N-(4-hydroxy-2-(lH-pyrazol-l-yl)pyrimidin-5-yl)-3-(methylsulfonyl)ben-Eami \n\n\n N-(4-hydroxy-2-(lH-pyrazol-l-yl)pyrimidin-5-yl)-4-(methylsulfonyl)be \n\n\n N-[4-hydroxy-2-{ 1 H-pyrazol- 1 -yl)pyrimidin-5-yl]biphenyl-2-carboxamide; \n\n\nN-[4-hydroxy-2-(lH-pyrazol-l-yl)pyrimidin-5-yl]biphenyl-3-<»rbox^ide; \n\n\n N-[4-hydroxy-2-(lH-pyrazol-l-yl)pyrimidin-S-yl]biphenyl-4-carb^ \n\n\n N-(4-hydroxy-2-(lH-pyrazol-l-yl)pyrimidin-5-yl)-2-phenoxybenzamide; \n\n\n N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)-3-phenoxybenzamide; \n\n\n N-(4-hydroxy-2-(lH-pyrazol-l-yl)pyrimidin-5-yl)-4-phenoxybenzamide; \n\n\n2-(2-chlorophenyl)-N-(4-hydroxy-2-{ 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)acetamide; \n\n\n 2-(3-chlorophenyl)-N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)acetamide; \n\n\n 2-(4-chlorophenyl)-N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)acetam ide; \n\n2-(3-cyanophenyl)-N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)acetamide; \n\n\n2-(2-(trifluoromethyl)phenyl)-N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)acetamide; \n\n\n2-(3-(trifluoromethyl)phenyl)-N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)acetaniide; \n\n\n2-(4-(trifluoromethyl)plienyl)-N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)acetamide; \n\n\nN-(4-hydroxy-2-(lH-pyrazol-l-yl)pyrimidin-5-^^ \n\n\nN-(4-hydroxy-2-(lH-pyrazol-l-yl)pyrim \n\n\n N-(4-hydroxy-2-( 1 H-pyrazol- 1 -ylJpyrimidiii-S-yl^^methoxyphenyl^cetainide; \n\n\n N-(4-hydroxy-2-( 1 H-pyrazol-1 -yl)pyrimidin-5-yl)-2-phenylpropanamide; \n\n\n N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)-2-phenylbutanamide; \n\n\nN-(4-hydroxy-2-( 1 H-pyrazol-l-yl)pyrimidin-5-yl)-3-methyl-2-phenylbutanamide; \n\n\n N-(4-hydroxy-2-( lH-pyrazol-1 -yl)pyrimidin-5-yl)-3-metbyl-2-phenylpentanarnide; \n\n\n N-(4-hydroxy-2-( 1 H-pyrazol-1 -yl)pyrimidin-5-yl)-2-methyl-2-phenylpropanamide; \n\n\n N-(4-hydroxy-2-( lH-pyrazol- 1 -yl)pyrimidin-5-yl)-l-phenylcyclopropanecarboxamide; \n\n\n N-(4-hydroxy-2-( 1 H-pyrazol- 1 -ylJpyrimidin-S-yl^^naphthalen- 1 -yl)acetamide; \n\n\n2-(benzo[d][l ,3]dioxol-5-yl)-N-(4-hydroxy-2-(lH-pynrol-l^^ \n\n\n N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)-2-(pyridin-4-yl)acetamide; \n\n\n 2-(biphenyl-4-yl)-N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)acetairjide; \n\n\n N-{4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)heptanamide; \n\n\n N-{4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)-3-phenylpropanamide; \n\n\nN-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)-4-phenylbutanamide; \n\n\n N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)cyclohexanecarboxamide; \n\n\ntert-butyl4-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-ylcarbamoyl)piperidine- 1 -carboxylate; \n\n\n 2- cyclohexyl-N-(4-hydiK>xy-2-( lH-py razo 101.01- 1 -yl)pyrimidin-5-yl)acetamide; \n\n\ntert-butyl 3-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-ylcarbamoyl)piperidine- 1 -carboxylate; \n\n\ntert-buryl4-((4-hydroxy-2-{ 1 H-pyrazol- 1 -yl)pyrimidin-5-ylcarbamoyl)me1hyl)piperidine- 1 -carboxylate; tert-butyl 3-(4-hydroxy-2-( lH-pyrazol-l-yl)pyrimidin-5-ylcarbamoyl)py^ \n\n\n 1 ,2,3,4-tetrahydix>-N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)naphthalene- 1 -carboxamide;\n\n\n2^-dihydro-N-(4-hydroxy-2-(lH-pyrazol-l-yl)pyrimidin-5-yl)-lH-indene-l \n\n\n 1 ,2,3 ,4-tetrahydro-N-(4-hydroxy-2-( 1 H-pyrazol- 1 -y l)pyrimidin-5-yl)naphthalenc-2-carboxamide; 2,3-dihydro-N-(4-hydroxy-2-(l H-pyrazol-1 -yl)py^ \n\n\n 4-chloro-N-[4-hydroxy-2-(lH-pyrazol-l-yl)pyrimidin-5-yl]benzenesulfonam \n\n\nl-(4-chlorophenyl)-N-[4-hydroxy-2-(lH-pyrazol-l-yl)pyrimidin-5-yl]meth \n\n\n 3- chlorc)-N-[4-hydi xy-2-(lH-pyrazol-l-yl)pyrimidin-5-yl]benzenesulfonam \n\n\nN-[4-bydroxy-2-( 1 H-pyrazol-1 -yI)pyrimidin-5-yl]- 1 -[4-{trifluoromethyl)phenyl]methanesulfonamide; 1 -(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrim idin-5-yl)-3-phenylurea; \n\n\n1 -benzy l-3-(4-bydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)urea \n\n1 -(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)-3-( 1 -phenylethyl)urea; \n\n\n1 -cyclohexyl-3 -(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)urea \n\n\n1 -cyclopentyl-3-(4-hydroxy-2-( lH-pyrazol-1 -yl)pyrimidin-5-yl)urea; \n\n\nert-butyl-3-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yI)urea \n\n\n3-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl 1 , 1 -diphenylurea \n\n\n 3- (4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)- 1 -isopropyl- 1 -phenylurea; \n\n\nphenyl 4-hydroxy-2-(l H-pyrazol- l-yl)pyrimidin-5-yI carbamate; \n\n\ncyclohexyl 4-hydroxy-2-{]H-pyra-K)l-l-yl)pyrimidin-5-yl carbamate; \n\n\ncyclopentyl 4-hydroxy-2-(lH-pyrazol-l-yl)pyrimidin-5-yl carbamate; \n\n\ntert-butyl 4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl carbamate; \n\n\nbutyl 4-hydroxy-2-(lH-pyrazol-l-yl)pyrimidin-5-yl carbamate; \n\n\n 4- methoxyphenyl 4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl carbamate; \n\n\n3,3-dimethylbutyl 4-hydroxy-2-{l H-pyrazol- l-yl)pyrimidin-5-yl carbamate; \n\n\nphenethyl 4-hydroxy-2-(l H-pyrazol- l-yl)pyrimidin-5-yl carbamate; \n\n\nbiphenyl-4-yl 4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl carbamate; \n\n\nnaphthalen-2-yl 4-hydroxy-2-(l H-pyrazol- l-yl)pyrimidiri-5-yl carbamate; \n\n\n1 -benzhydryl-3-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)thiourea; \n\n\n1 -(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)-3-( 1 -phenylethyl)thiourea\n\n\n1- (4-hydroxy-2-( 1 H-pyrazol- 1 -yl)r>yrimidm-5-yl)-3-(2-phenylpropan-2-yl)thiourea; benzhydryl 4-hydroxy-2-(lH-py-\n,\nazol-l-yl)pyrimidme-5-carboxylate \n\n\n N-(4-hydroxy-2-(pyridin-2-yl)pyrimidin-5-yl)-2^-diphenylacetamide; \n\n\n 5- ( 1 -phenyl- 1 H-pyrazol-4-yl)-2-( 1 H-pyrazol- 1 -yl)pyrimidin-4-ol; \n\n\n5-( 1 -benzyl- 1 H-pyrazol-4-yl)-2-( 1 H-pyrazol- 1 -yl)pyrimidin-4-ol; \n\n\n5-phenyl-2-( 1 H-pyrazol- 1 -yl)pyrimidin-4-ol; \n\n\nN-(4-chlorophenyl)-2-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)acetamide; N-cyclohexyl-2-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)acetamide; \n\n\n 2- (4-hydroxy-2-(lH-pyra\n--\nol-l-yl)pyrimidin-5-yl)-N-isopiOpylacetamide; \n\n\n4-hydroxy-2-(pyridazm-3-yl)-N-tosylpyrimidme-5-carboxamide; \n\n\nand pharmaceutically acceptable salts and solvates thereof. \n\n\n\n\n\n\n13. A compound selected from: \n\n\nN-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)-2^-diphenylacetamide; \n\n\n 2- chloroN-(4-hydroxy-2-{ 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)benzamide; \n\n\n3-chloro-N-(4-hydroxy-2-(lH-pyrazol-l-yl)pyrimidin-5-yl)benzamide; \n\n\n 3- (trifluoromethyl)-N-(4-hydroxy-2-( 1 H-pyrazol- l-yl)pyrimidin-5-yl)benzamide; \n\n N-(4-hydroxy-2-(lH-pyrazol-l-yl)pyrim \n\n\n 2-(trifluoromethyl)-N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidm-5-yl)benzamide; \n\n\n N-[4-hydroxy-2-(lH-pyrazol-l-yl)pvrimidin^ \n\n\n N-(4-hydiOxy-2-(lH-pyrazol-l-yl)pyrimidin^^ \n\n\nN-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)-4-phenoxyben2amide; \n\n\n 2-(2-chIorophenyl)-N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)acetamide; \n\n\n 2-(3-chloropbenyl)-N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyii-nidin-5-yl)acetamide; \n\n\n 2-(4-chlorophenyl N^4-hydroxy-2-(lH-p^ \n\n\n 2-(3-cyanophenyl)-N-(4-hydroxy-2-(lH-pyrazol-^^ \n\n\n2-(2-{trifluoromethyl)plienyl)-N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)acetamide;\n\n\n2-(3-(trifluoromethyl)phenyl)-N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)acetamide;\n\n\n2-{4-{trifluoromethyl)phenyl)-N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)acetaniide;\n\n\nN-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)-2-(2-methoxyphenyl)a 5etamide; \n\n\n N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)-2-(3-methoxyphenyl)a«tarnide; \n\n\nN-(4-hydroxy-2-(l H-pyrazol-l-yl)pyrimidin-5-yl 2-(4-meth \n\n\n N-(4-hydroxy-2-(l H-pyrazol-1 -yl)pyrimidin-5-yl)-2-phenylpropanamide; \n\n\n N-(4~hydroxy-2-( 1 H-pyrazol-1 -yl)pyrimidin-5-yl)-2-phenylbutanamide; \n\n\n N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)-3-rnethyl-2-phenylpentanamide; \n\n\n N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yljpyrimidm \n\n\nN-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)-2-(naphthalen- 1 -yl)acetamide; \n\n\n 2-(benzo[d][ 1 ,3]dioxol-5-yl)-N-(4-hydroxy-2-( lH-pyrazol-1 -yl)pyrimidin-5-yl)acetamide; \n\n\n 2-(biphenyl-4-yl)-N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)acetarnide; \n\n\n N-(4-hydroxy-2-(lH-pyrazol-l-yl)pyrimidin-5-yl)heptanarnide; \n\n\n N-(4-hydroxy-2-{ 1 H-pyrazol- 1 -yl)pyrirnldiri-5-yl)-4-phenylbutanarnide; \n\n\ntert-butyl4-(4-hydroxy-2-( lH-pyrazol-1 -yl)pyrimidin-5-ylcarbamoyl)piperidine-l -carboxylate;\n\n\n2- cycIohexyl-N-(4-hydroxy-2-( 1 H-pyrazol 01.01- 1 -yl)pyrimidin-5-yl)acetamide; \n\n\n 1,2,3 ,4-tetrahy dro-N-(4-hydroxy-2-{ 1 H-pyrazol- 1 -yl)pyrimidin-5 -y l)naphthalene- 1 -carboxamide; 2,3-dihydro-N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidiii-5-yl)- lH-indene- 1 -carboxamide; \n\n\n2,3-dihydrc-N-<4-hydroxy-2-( lH-pyrazol- 1 -yl)pyrimidin-5-yl)- 1 H-indene-2-carboxamide; \n\n\n1 -benzyl-3-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)urea; \n\n\nl-(4-hydroxy-2-(lH-pyrazol-l-yl)pyrimid^ \n\n\n 3- (4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl 1 , 1 -diphenylurea \n\n\nl-beiizhydr l-S-^hydroxy^-OH-pyniro ^ \n\n\nl-(4-hydroxy-2-( 1 H-pyrazol-1 -yl)pyrimidin-5-yl)-3-(l -phenylethyl)thiourea; \n\n\nand pharmaceutically acceptable salts and solvates thereof. \n\n\n\n\n\n\n14. A pharmaceutical composition comprising a compound of Claim 1 and pharmaceutically acceptable carri \n\n IS. A method of enhancing endogenous production of erythropoietin in a mammal which comprises administering to the mammal an amount of a compound of Claim 1, or a \n\n\n\n\n\n\npharmaceutically acceptable salt or solvate thereof, that is effective for enhancing endogenous production of erythropoietin. \n\n\n\n\n\n\n1 . A method for the prevention or treatment of anemia in a mammal which comprises administering to the mammal an effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt or solvate thereof. \n\n\n\n\n\n\n17. Use of a compound of Claim 1 , or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of medicaments for the treatment of conditions mediated by HIF prolyl hydroxylase. Description\n\n\n\n\n TITLE OF THE INVENTION \n\n\nSUBSTITUTED PYRJMIDINES \n\n\nCROSS-REFERENCE TO RELATED APPLICATIONS \n\n\n This application claims the benefit of International Application No. \n\n\n PCT/CN2010/071974, filed April 21, 2010, the disclosure of which is incorporated by reference herein in its entirety. \n\n\nBACKGROUND OF THE INVENTION \n\n\n The insufficient delivery of oxygen to cells and tissues is associated with anemia, which is defined as a deficiency in the blood's oxygen-carrying capacity, and ischemia, in which restrictions in blood supply are caused by a constriction or blockage of blood vessels. Anemia can be caused by the loss of red blood cells (hemorrhage), excessive red blood cell destruction (hemolysis) or deficiencies in erythropoiesis (production of red blood cells from precursors found in the bone marrow). The symptoms of anemia can include weakness, dizziness, fatigue, pallor, impairment of cognitive function and a genera] reduction in quality of life. Chronic and/or severe anemia can lead to the exacerbation of myocardial, cerebral or peripheral ischemia and to heart failure. Ischemia is defined as an absolute or relative shortage of oxygen to a tissue or organ and can result from disorders such as atherosclerosis, diabetes, thromboembolisms, hypotension, etc. The heart, brain and kidney are especially sensitive to ischemic stress caused by low blood supply. \n\n\n The primary pharmacological treatment for anemia is administration of some variant of recombinant human erythropoietin (EPO). For anemias associated with kidney disease, chemotherapy- induced anemia, anemia from HTV-therapy or anemia due to blood loss, recombinant EPO is administered to enhance the supply of the hormone, correct the shortage of red blood cells and increase the blood's oxygen-carrying capacity. EPO replacement is not always sufficient to stimulate optimal erythropoiesis (e.g., in patients with iron processing deficiencies) and has associated risks. \n\n\n Hypoxia-inducible factor (HTF) has been identified as a primary regulator of the cellular response to low oxygen. HTJF is a heterodimeric gene transcription factor consisting of a highly regulated a-subunit (HEF-a) and a constitutively expressed β-subunit (HIF-β, also known as ARNT, or aryl hydrocarbon receptor nuclear transporter). HTF target genes are reported to be associated with various aspects of erythropoiesis (e.g., erythropoietin (EPO) and EPO receptor), glycolysis and angiogenesis (e.g., vascular endothelial growth factor (VEGF)). Genes for proteins involved in iron absorption, transport and utilization as well as heme synthesis are also targets of H1F. \n\n\n Under normal oxygenation, HTF-a is a substrate in a reaction with molecular oxygen, which is catalyzed by a family of iron(TJ)-, 2-ketoglutarate- and ascorbate-dependent dioxygenase enzymes called PHD-1 (EGLN2, or egg laying abnormal 9 homolog 2, PHD2 (EGLN1), and PHD3 (EGLN3). Proline residues of HTF-a are hydroxylated (e.g., Pro-402 and Pro-564 of HIF-Ια) and the resulting product is a target of the tumor suppressor protein von-Hippel Lindau, a component of an E3 \n\n ubiquhin ligase multiprotein complex involved in protein ubiquitination. Under low oxygenation, the HEF-a hydroxylation reaction is less efficient and HIF- a is available to dimerize with HIF-β. HEF dimers are translocated to the cell nucleus where they bind to a hypoxia-responsive enhancer element of HIF target genes. \n\n\n Cellular levels of HIF are known to increase under conditions of hypoxia and after exposure to hypoxia mimetic agents. The latter includes, but is not limited to, specific metal ions (e.g., cobalt, nickel, manganese), iron chelators (e.g., desferrioxamine) and analogs of 2-ketoglurate (e.g., N- oxaryl glycine). The compounds of the present invention inhibit the HIF prolyl hydroxylases (PHD-1 , PHD-2, PHD-3) and can also serve to modulate HIF levels. These compounds therefore have utility for the treatment and/or prevention of disorders or conditions where HIF modulation is desirable, such as anemia and ischemia. As an alternative to recombinant erythropoietin therapy, the compounds of the present invention provide a simpler and broader method for the management of anemia. \n\n\nSUMMARY OF THE INVENTION \n\n\n The present invention concerns compounds of formula I \n\n\n\n\n\n\n\n\nwhich inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier. \n\n\nDETAILED DESCRIPTION OF THE INVENTION \n\n\n The present invention provides compounds of formula I and pharmaceutically acceptable salts and solvates thereof: \n\n\nwherein \n\n\n\n\n\n A is heteroaryl optionally substituted with one or more R? substituents \n\n\n L is chosen from a bond, aryl, heteroaryl, -(C1.3 alkyl)o-iS(Ci-3 alkyl)o-l-, -(C1.3 alkylJo-lNRaCO-, (Ci-3 alkyl)0-lNRaCO2-, -(C1.3 alkyl)0-lCO2-, -(Cj.3 alkyl)0-lNRaSO2-, -(C1.3 alkylJo. iNRaO-, -(C1.3 alky o-lNRaCsNRb., - Ci-3 alkyl)0-lNRaCONRb-, and -(C1.3 alkyl)o- iNRaCOS-; \n\n R2 and are independently selected from hydrogen, halogen, hydroxy!, Cj-g alkyl, C3-6 heterocycloalkyl and C3-6 cycloalkyl wherein said alkyl, heterocycloalkyl and cycloalkyl are each optionally substituted with one or more substituents selected from: hydroxy I, -SR.*, -NR*2 or-C02-R*; \n\n\nR1 is selected from \n\n\n halogen, \n\n\n Ci-io alkyl, \n\n\n -C2_io alkenyl, \n\n\n -C2-IO alkynyl, \n\n\n cycloalkyl Co-io alkyl(oxy)0-l, \n\n\n heterocyclyl Co_io alkyl(oxy)o-], \n\n\n arylCo-io alkyl(oxy)0-l, \n\n\n Cj-io alkoxy (cxarbonyl)o.iCo.io alkyl, \n\n\n carboxyl Qj-io alkyl, \n\n\n carboxyl aryl, \n\n\n carboxylcycloalkyl, \n\n\n carboxylheterocyclyl, \n\n\n Ci-ioalkyloxy Co-ioalkyl, \n\n\n hydroxy Co-ioalkyl, \n\n\n hydrox carbonylCo- 1 oalkoxy, \n\n\n Ci-io alkylthio, \n\n\n Ci-io alkylsulfinyl, \n\n\n aryl Cfj-10 alkylsulfinyl, \n\n\n heterocyclyl Cfj-io alkylsulfinyl, \n\n\n cycloalkyl Cfj-io alkylsulfinyl, \n\n\n Ci-io alkylsulfonyl, \n\n\n aryl Co-10 alkylsulfonyl, \n\n\n heterocyclylCo-10 alkylsulfonyl, \n\n\n cycloalkyl Co-10 alkylsulfonyl, \n\n\n nitro, \n\n\n perfluoroCmsalkyl, and \n\n\n perfluoroC 1 ^alkoxy ; \n\n\nwherein in Rl said alkyl, alkenyl, alkynyl, cycloalkenyl, aryl, perfluoralkyl, perfluoroalkoxy, \n\n\n heterocyclyl, and cycloalkyl are each optionally substituted with one or more R? substituents; \n\n optionally, R* and L are linked together to form a ring of 5 to 8 atoms optionally substituted with one or more substituents R?; where said ring has 0, 1 , or 2 heteroatoms independently selected from -NR -, -O- and -S(0)\nn\n-; \n\n\n is selected from halogen, hydroxy, oxo, cyano, aryl, heterocyclyl, cycloalkyl, -Ci-6 alkyl, -Cl-6 alkoxy, aryloxy, heterocyclyloxy, -0(0-l)(Ci-io)perfluorc*lkyl, -C02 \na\n, -NRbRc, -CONRbR\nC\n \n\n\n-OC02R\na\n, -OCONRbRc, - dC02R\na\n, - dCO bRc -SQ)-6 alkyl and -S(0)nR\nd\n, wherein said aryl, heteroaryl, heterocycloaJkyl, alkoxy, aryloxy, heteroaryloxy, heterocycloalkyloxy are optionally substituted by one or more substituents RlO; \n\n\nRlO is selected from hydroxy, aryl, heterocycloalkyl, heteroaryl, halogen, oxo, -Ci-6 alkyl, Cj-6 alkoxy, halogen, CO2H, cyano, O(00)o.i C 1 -6 alkyl, NO2, trifluoromethoxy, trifluoroethoxy, -O(0- l)(Ci.io)perfluoroalkyl, Cfj-lO alkylaminocarbonylamino, Q)-10 alkyloxycarbonylaminoCo-io alkyl, Crj-io alkylcarbonylaminoCo-io alkyl, Co-10 alkylaminosulfonylaminoCo-io alkyl, Cfj-io aJkylsulfonylaminoCo-lO alkyl, Co-io alkylsulfonyl, Co-10 alkylaminosulfonyl, Co.10 \n\n\n alkylaminocarbonyl, -(C=0)N(Co-6 alkyl^ -S(C()-6 alkyl), and H2; \n\n\nn is i or 2; \n\n\n Ra is chosen from hydrogen; -Cl-10 alkyl, -(Cj-6 alkyl)C3-8 cycloalkyl; and \n\n\n -(Ci-6 alkyl)phenyl; and \n\n\n Rb, Rc, and Rd are each independently chosen from hydrogen, -Cl-10 alkyl,C3-8 cycloalkyl, aryl, and heterocyclyl. \n\n\nIllustrative but nonlimiting examples of compounds of the invention are the following: N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)-2,2-diphenylacetarnide; \n\n\n 2- chloro-N-(4-hydiOxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)benzamide; \n\n\n 3- chloro-N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)benzamide; \n\n\n4-chloro-N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)benzamide; \n\n\n 3- (trifluoromethyl)-N-(4-hydroxy-2-(lH-pyrazol-l-yl)pyrimidjn-5-yl)benz \n\n\n 4- (trifluoromethyl)-N-{4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)benzamide; \n\n\nN-(4-hydroxy-2-(l H-pyrazol- 1 -yl)pyrimidin-5-yl)-2-(naphthalen-3-yl)acetamide; \n\n\n2-cyano-N-(4-hydroxy-2-< 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)benzamide; \n\n\n3-cyano-N-(4-hydroxy-2-(lH-pyrazol-l-yl)ryrimidin-5-yl)benzami \n\n\n 4-cyano-N-(4-hydroxy-2-( 1 H-pyrazol- 1 -y l)pyrimidin-5 -y1)benzamide; \n\n\n 2-(trifluoromethyl)-N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)benzamide; \n\n\n N-(4-hydroxy-2-( 1 H-pyrazol- 1 -y l)pyrimidin-5 -yl 2-methoxybenzamide; \n\n\n N-<4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)-3-methoxybenzamide; \n\n\nN-(4-hydroxy-2-(lH-pyra2ol-l-yl)pyrimidin-5-yl)-4-methoxybenzamide; \n\n\n N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)-2-(methylsulfonyl)benzamide; \n\n\n N-(4-hydroxy-2-( I H-pyrazol- 1 -yl)pyrimidin-5-yl)-3-(methylsulfonyl)benzamide; \n\n N 4-hydroxy-2-{ 1 H-pyra∞l- 1 -y l)pyri \n\n\n N-[4-hydroxy-2-( 1 H-pyrazoJ- 1 -yl)pyrimidm-5-yl]biphenyl-2-carboxam ide; \n\n\nN-[4-hydroxy-2-( 1 H-pyra∞l- 1 -yl )pyri^ \n\n\nN-[4-hydroxy-2-(lH-pyi¾-∞l-l-yl)pyrimidin-5-yl]biphenyl^^^ \n\n\nN 4-hydroxy-2-(lH-pyrazol-l-yl)pyrimidin-5-yl 2-phenoxybenzamW \n\n\nN-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyiimidin-5-yl)-3-phenoxybenzamide; \n\n\nN-(4-hydroxy-2-(lH-pyrazol-l-yl)pyrimW^ \n\n\n 2-(2-chlorophenyl)-N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yI)pyrimidin-5-yl)acetamide; \n\n\n2-(3-chlorophenyl)-N-(4-hydroxy-2-(lH-pyra∞^ \n\n\n2-(4-chlorophenyl)-N-(4-hydiOxy-2-(lH-pyrazol-l-yl)pyrimidi \n\n\n 2-(3-cyanophenyl)-N-(4-hydroxy-2-( 1 H-pyrazol- 1 -y1)pyrimidin-5-yl)acetamide; \n\n\n2-(2-(trifluoromethyl)phenyl N-(4-hydrox^^ \n\n\n 2-(3-{trifluoromethyl)phenyl)-N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)acetamide; \n\n\n 2-(4-(trifluoronieithyl)phenyl)-N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yI)pyrimidin-5-yl)acetam.de; \n\n\nN-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)-2-(2-rnethoxyphenyl)acetamide; \n\n\n N-(4-hydroxy-2-(lH-pyrazol-l-yl)pyrimidin-5-yl)-2-(3-me1 oxyph \n\n\n N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl 2-(4-me1hoxyphenyl)acetarnide; \n\n\n N-(4-hydroxy-2-(lH-pyrazol-l-yI)rjyrimidin-5-yl 2-phenylpropan \n\n\n N-(4-hydroxy-2-(lH-pyrazol-l-yl)pyrimidin-5-yl 2-phenylbutai-am \n\n\nN-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl>-3-me1hyl-2-phenylbutanamide; \n\n\n N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)-3-methyl-2-phenylpentanamide; \n\n\n N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl 2-methyl-2-phenylpropanamide; \n\n\n N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)- 1 -phenylcycloproDanecarboxam.de; \n\n\n N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)-2-(naphthalen- 1 -yl)acetamide; \n\n\n2-(benzo[d] [ 1 ]dioxol-5-yl)-N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)acetaniide; \n\n\n N-(4-hydroxy-2-(lH-pyn^l-l-yl)pyrimid»n-5-yl)-2-(pyridin-4-yl)a∞ \n\n\n 2-(biphenyl-4-yl)-N-(4-hydroxy-2-(lH-pyrazol-l-yl)pyrimidin-5-yl)a(»tami \n\n\n N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)heptanamide; \n\n\n N-(4-hydroxy-2-(l H-pyrazol- l-yl)pyrimid^ \n\n\nN-(4-hydroxy-2-{ 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)-4-phenylbutanamide; \n\n\n N-(4-hydroxy-2-(l H-pyrazol- 1 -yl)pyrimidin-5-yl)cyclobexanecarboxamide; \n\n\ntert-buty 14-(4-hydroxy-2-( 1 Η-pyrazol· \n\n\n 2-cyclohexy l-N-(4-hydroxy-2-( 1 H-pyrazo 101.01- 1 -yl)pyrimidin-5-yl)acetamide; \n\n\ntert-butyl 3-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-ylcarbamoyl)piperidine- 1-carboxylate; \n\n\ntert-butyl4-((4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-ylcarbamoyl)methyl)piperidine- 1 -carboxylate; tert-butyl 3-(4-hydroxy-2-(lH-pyrazol-l-yl)pyrimidin-5-ylc^^ \n\n 1 ^2^,4-tetrahydro-N-(4-hydroxy-2-( 1 H-pyrazol-1 -yI)pyrimidin-5-yl)naphthalenfr-l-<¾irt)Oxamide; 2,3-dihydro-N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)- 1 H-indene- 1 -car oxamide; \n\n\n1 ^,3,4-tetrahydro-N-(4-hydroxy-2-( ] H-pyrazol- 1 -yl)pyrimidin-5-yl)naphthalene-2-carboxamide; 2 -dihydro-N-(4-hydroxy-2-( I H-pyrazol- 1 -yl)pyrimidin-5-yl)- 1 H-indene-2-carboxamide; \n\n\n4-chlon N-[4-hydroxy-2-(lH-pyra∞ \n\n\n 1 -(4-chlorophenyl)-N-[4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidm-5-yl]methanesulfonamide; \n\n\n3-chloro-N-[4-hydroxy-2- H-pyrazol-l-yl)pyr^ \n\n\n N-[4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl]- 1 -[4-(trifluoromethyl)phenyl]methanesulfonaniide; l-(4-hydroxy-2-{l H-pyrazol- l-yl)pyrimM \n\n\n1 -benzyl-3-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)urea; \n\n\n 1 -(4-hydroxy-2-{ 1 H-pyrazol- 1 -yl)pyrimidirj-5-yl)-3-( 1 -phenylethyl)urea; \n\n\n 1 -cycIohexyl-3-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)urea; \n\n\n 1 -cyclopentyl-3-{4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)urea; \n\n\nert-buty ] -3 -(4-hy drox -2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)urea; \n\n\n3-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyriinidin-5-yl)- 1 , 1 -diphenylurea; \n\n\n 3- (4-hydroxy-2-( 1 H-pyrazol-1 -yl)pyrimidin-5-yl)- 1 -isopropyl- 1 -phenylurea; \n\n\nphenyl 4-hydroxy-2-(l H-pyrazol- l-yl)pyrimidin-5-yl carbamate; \n\n\ncyclohexyl 4-hydroxy-2-(lH-pyrazol-l-yl)pyrimidin-5-yl carbamate; \n\n\ncyclopentyl 4-hydroxy-2-(l H-pyrazol- l-yl)pyrimidin-5-yl carbamate; \n\n\ntert-butyl 4-hydroxy-2-(lH-pyrazol-l-yl)pyrimidin-5-yl carbamate; \n\n\nbutyl 4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-y] carbamate; \n\n\n 4- methoxyphenyl 4-hydroxy-2-(lH-r¾ azol-l-yl)pyrimidjn-5-yl carbamate; \n\n\n3,3-dimethylburyl 4-hydroxy-2-(l H-pyrazol- l-yl)pyrimidin-5-yl carbamate; \n\n\nphenethyl 4-hydroxy-2-(l H-pyrazol- l-yl)pyrimidin-5-yl carbamate; \n\n\nbiphenyl-4-yl 4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl carbamate; \n\n\nnaphthalen-2-yl 4-hydroxy-2-(l H-pyrazol- l-yl)pyrimidin-5-yl carbamate; \n\n\n 1 -benzhydryl-3-(4-hydroxy-2-{ 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)thiourea; \n\n\n 1 -(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)-3-( 1 -pbenylethyl)th iourea; \n\n\n 1 -(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)-3-(2-pbenylpropan-2-yl)thiourea; \n\n\nbenzhydryl 4-hydroxy-2-(l H-pyrazol- l-yl)pyrimidine-5-carboxylate; \n\n\n N^hydroxy^-ipyridin^-y^pyrimidm-S-yl^^-dipbenylacetamide; \n\n\n 5- ( 1 -phenyl- 1 H-pyrazol-4-yl)-2-( 1 H-pyrazol- 1 -yl)pyrimidin-4-ol; \n\n\n5-( 1 -benzyl- 1 H-pyrazoI-4-yl)-2-( 1 H-pyrazol- 1 -yl)pyrimidin-4-ol; \n\n\n5-phenyl-2-( 1 H-pyrazol-1 -yl)pyrimidin-4-ol; \n\n\nN-(4-chlorophenyl)-2-(4-hydroxy-2-(lH-pyrazol-l-yl)pyrimidin-5-yl)acetamide; \n\n\nN-cyclohexyl-2-(4-hydroxy-2-{lH-pyrazol-l-yl)pyrimidin-5-yl)acetamide; \n\n 2-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)-N-isopropylacetamide; \n\n\n 4-hydroxy-2^yridazin-3-yI N-tosylpyrimidine-5-cai^ \n\n\nand pharmaceutically acceptable salts and solvates thereof. \n\n\n As used herein except where noted, \"alkyl\" is intended to include both branched- and straight-chain saturated aliphatic hydrocarbon groups, including all isomers, having the specified number of carbon atoms. Commonly used abbreviations for alkyl groups are used throughout the specification, e.g. methyl may be represented by \"Me\" or CH\n3)\n ethyl may be represented by \"Et\" or CH\n2\nCH\n3\n, propyl may be represented by \"Pr\" or CH\n2\nCH\n2\nCH\n}\n, butyl may be represented by \"Bu\" or CH2CH2CH2CH\n3\n , etc. \"Ci_6 alkyl\" (or \"Cj-Cg alkyl\") for example, means linear or branched chain alkyl groups, including all isomers, having the specified number of carbon atoms. Ci-6 alkyl includes all of the hexyl alkyl and pentyl alkyl isomers as well as n-, iso-, sec- and t-butyl, n- and isopropyl, ethyl and methyl. \"C1-4 alkyl\" means n-, iso-, sec- and t-butyl, n- and isopropyl, ethyl and methyl. The term \"alkylene\" refers to both branched- and straight-chain saturated aliphatic hydrocarbon groups, including all isomers, having the specified number of carbons, and having two terminal end chain attachments. For illustration, the term ^nsubstitoted A-Qalkylene-B\" represents A-CH2-CH2-CH2-CH2-B. The terra \"alkoxy\" represents a linear or branched alkyl group of indicated number of carbon atoms attached through an oxygen bridge. \n\n\n Unless otherwise specifically noted as only \"unsubstituted\" or only \"substituted\", or when substituents are enumerated, alkyl (either as a stand alone radical or as part of a radical such as alkoxy, alkylthio and aralkyl) groups are unsubstituted or substituted with 1 to 3 substituents on each carbon atom, with halo, C1-C20 \nCF\n3» N¾ N(Ci-C6 alkyl)2, Ν<¾, oxo, CN, N3, -OH, -0(Ci-C6 alkyl), C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C6 alkynyl, (Cfj-Cg alkyl) S(O)0-2-, (Co-C\n6\n alkyl)S(O)0- 2(Co-C\n6\n alkyl)-, (C0-C6 alkyl)C(0)NH-, H\n2\nN-C(NH , -0(Ci-C6 alkyl)CF3, (C0-C6 alkyl)C(0)-, (Co- C6 alkyl)OC(0)-, (Q)-C6 alkyl)0(Ci-C6 alkyl)-, (C0-C6 alkyl)C(0)i.2(Co-C6 alkyl)-, (Co-C* alkyl)OC(0)NH-, -NH(C]-C6 alkyl)NHC(0)NH(Ci-C6 alkyl), NHC(0)OCi-C6 alkyl, -NH(Ci-C6 alkyl) HS02(Ci-C6 alkyl), - C0-C6 alkyl)NHS02(Ci-C6 alkyl), aryl, aralkyl, heterocycle, \n\n\nheterocyclylalkyl, halo-aryl, halo-aralkyl, halo-heterocycle, halo-heterocyclylalkyl, cyano-aryl, cyano- aralkyl, cyano-heterocycle and cyano-heterocyclylalkyl. \n\n\n The term \nu\nCQ\" as employed in expressions such as \"Co_6 alkyl\" means a direct covalent bond; or when the term appears at the terminus of a substituent, Co-6 alkyl means hydrogen or Cl-6alkyl. Similarly, when an integer defining the presence of a certain number of atoms in a group is equal to zero, it means that the atoms adjacent thereto are connected directly by a bond. For example, in the structure , wherein s is an integer equal to zero, 1 or 2, the structure is\n\n\n\n\n\n \n\n when s is zero. \n\n\n The term \"C3-8 cycloalkyl\" (or \"C3-Cg cycloalkyl\") means a cyclic ring of an alkane having three to eight total carbon atoms (i.e., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl). The terms \"C3-7 cycloalkyl\", \"C3-6 cycloalkyl\", \"C5-7 cycloalkyl\" and the like have analogous meanings. \n\n The term \"halogen\" (or \"halo\") refers to fluorine, chlorine, bromine and iodine \n\n\n(alternatively referred to as fluoro (F), chloro (CI), bromo (Br), and iodo (I)). \n\n\n The term \"aryl\" refers to aromatic mono- and poly-carbocyclic ring systems, wherein the individual carbocyclic rings in the polyring systems are fused or attached to each other via a single bond. Suitable aryl groups include phenyl, naphthyl, and biphenylenyl. \n\n\n The term \"carbocycle\" (and variations thereof such as \"carbocyclic\" or \"carbocyclyl\") as used herein, unless otherwise indicated, refers to (i) a C3 to Cg monocyclic, saturated or unsaturated ring or (ii) a C7 to C12 bicyclic saturated or unsaturated ring system. Each ring in (ii) is either independent of, or fused to, the other ring, and each ring is saturated or unsaturated. The carbocycle may be attached to the rest of the molecule at any carbon atom which results in a stable compound. The fused bicyclic carbocycles are a subset of the carbocycles; i.e., the term \"fused bicyclic carbocycle\" generally refers to a C7 to C] 0 bicyclic ring system in which each ring is saturated or unsaturated and two adjacent carbon atoms are shared by each of the rings in the ring system. A fused bicyclic carbocycle in which one ring is saturated and the other is saturated is a saturated bicyclic ring system. A fused bicyclic carbocycle in which one ring is benzene and the other is saturated is an unsaturated bicyclic ring system. A fused bicyclic carbocycle in which one ring is benzene and the other is unsaturated is an unsaturated ring system. Saturated carbocyclic rings are also referred to as cycloalkyl rings, e.g., cyclopropyl, cyclobutyl, etc. Unless otherwise noted, carbocycle is unsubstituted or substituted with C]_6 alkyl, Ci-6 alkenyl, C]-6 alkynyl, aryl, halogen, N¾ or OH. A subset of the fused bicyclic unsaturated carbocycles are those bicyclic carbocycles in which one ring is a benzene ring and the other ring is saturated or unsaturated, with attachment via any carbon atom that results in a stable compound. Representative examples of this subset include the following: \n\n\n\n\n\n\n\n\n The term \"heterocycle\" (and variations thereof such as \"heterocyclic\" or \"heterocycly ) broadly refers to (i) a stable 4- to 8-membered, saturated or unsaturated monocyclic ring, or (ii) a stable 7- to 12-membered bicyclic ring system, wherein each ring in (ii) is independent of, or fused to, the other ring or rings and each ring is saturated or unsaturated, and the monocyclic ring or bicyclic ring system contains one or more heteroatoms (e.g., from 1 to 6 heteroatoms, or from 1 to 4 heteroatoms) selected from N, O and S and a balance of carbon atoms (the monocyclic ring typically contains at least one carbon atom and the ring systems typically contain at least two carbon atoms); and wherein any one or more of the nitrogen and sulfur h t t i ti ll idi d d e or more of the nitrogen \n\n heteroatoms is optionally quaternized. Unless otherwise specified, the heterocyclic ring may be attached at any heteroatom or carbon atom, provided that attachment results in the creation of a stable structure. Unless otherwise specified, when the heterocyclic ring has substituents, it is understood that the substituents may be attached to any atom in the ring, whether a heteroatom or a carbon atom, provided that a stable chemical structure results. \n\n\n Non limiting examples of heterocyclylic moieties include, but are not limited to, the following: azepanyl, azabenzimidazole, benzoimidazolyl, benzofuryl, benzofurazanyl, benzopyrazolyl, benzothiazolyl, benzothienyl, benzotriazolyl, benzothiophenyl, benzoxazolyl, carbazolyl, carbolinyl, chromanyl, cinnolinyl, furanyl, imidazolyl, indolinyl, indolyl, indolazinyl, indazolyl, isobenzofuryl, isochromanyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazoryl, naphthpyridinyl, oxadiazolyl, oxazoryl, oxazolinyl, isooxazolinyl, oxetanyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolyl, pyridazinyl, pyridopyridinyl, pyridazinyl, pyridinyl, pyrimidyl, pyrrolyl, quinazolinyl, quinolyl, quinoxalinyl, quinoxalinyl, tetrahydropyranyl, tetrahydroisoquinolinyl, tetrazolyl, tetrazolopyridyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, azetidinyl, aziridinyl, 1,4-dioxanyl, hexahydroazepinyl, piperazinyl, piperidinyl, pyrrolidinyl, mo holinyl, thiomo holinyl, dihydrobenzoimidazolyl, dihydrobenzofuryl, dihydrobenzothiophenyl, dihydrobenzoxazolyl, dihydrofuryl, dihydroimidazolyl, dihydroindolyl, dihydroisooxazolyl, dihydroisothiazolyl, dihydrooxadiazolyl, dihydrooxazolyl, dihydropyrazinyl, dihydropyrazolyl, dibydropyridinyl, tetrabydroquinolinyl, tetrahydroisoquinolinyl, dihydropyrimidinyl, dihydropyrrolyl, dihydroquinolinyl, dihydrotetrazolyl, dihydrothiadiazolyl, dihydrothiazolyl, dihydrothienyl, dihydrotriazolyl, dihydroazetidinyl, methylenedioxybenzoyl, tetrahydrofuryl, tetrahydrothienyl, tetrahidroquinolinyl, 2,3-dihydrobenzofuryl, 2,3-dihydrobenzo-l,4-dioxinyl, imidazo(2,l-bXl,3)thiazole, and benzo-l,3-dioxoryl. \n\n\n Saturated heterocyclics form a subset of the heterocycles; i.e., the term \"saturated heterocyclic\" generally refers to a heterocycle as defined above in which the entire ring system (whether mono- or poly-cyclic) is saturated. The term \"saturated heterocyclic ring\" refers to a 4- to 8-membered saturated monocyclic ring or a stable 7- to 12-membered bicyclic ring system which consists of carbon atoms and one or more heteroatoms selected from N, O and S. Representative examples include piperidinyl, piperazinyl, azepanyl, pyrrolidinyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, \n\n\nisoxazolidinyl, morpholinyl, thiomorpholiny], thiazolidinyl, isothiazolidinyl, and tetrahydrofuryl (or tetrahydrofuranyl). \n\n\n Heteroaromatics form another subset of the heterocycles; i.e., the term \"heteroaromatic\" (alternatively \"heteroary ) generally refers to a heterocycle as defined above in which the entire ring system (whether mono- or poly-cyclic) is an aromatic ring system. The term \"heteroaromatic ring\" refers a 5- or 6-membered monocyclic aromatic ring or a 7- to 12-membered bicyclic which consists of carbon atoms and one or more heteroatoms selected from N, O and S. In the case of substituted heteroaryl rings containing at least one nitrogen atom (e.g., pyridine), such substitutions can be those resulting in N-oxide formation. Representative examples of heteroaromatic rings include pyridyl, pyrrolyl, pyrazinyl, \n\n pyrimidinyl, pyridazinyl, thienyl (or thiophcnyl), thiazolyl, furanyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isooxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, and thiadiazolyl. \n\n\n Representative examples of bicyclic heterocycles include benzotriazolyl, indolyl, isoindolyl, indazolyl, indolinyl, isoindolinyl, quinoxalinyl, quinazolinyl, cinnolinyl, chromanyl, isochromanyl, tetrahydroquinolinyl, quinolinyl, tetrahydroisoquinolinyl, isoquinolinyl, \n\n\n2,3-dihydroDenzofuryl, 2\nr\n3-dihydrobenzo-l,4-dioxinyI (i.e., imia¾zo(2,l-b)(l,3)thiazole, (i.e., \n\n\n and benzo-l,3-dioxolyl (i.e., In certain contexts herein, is alternatively\n\n\n\n\n\n\n\n\n\n\n\n\n\n referred to as phenyl having as a substituent methylenedioxy attached to two adjacent carbon atoms. \n\n\n The terms \"arylalkyl\" and \"alkylaryl\" include an alkyl portion where alkyl is as defined above and include an aryl portion where aryl is as defined above. Examples of arylalkyl include, but are not limited to, benzyl, phenylethyl, phenylpropyl, naphthylmethyl, and naphthyletbyl. Examples of alkylaryl include, but are not limited to, toluene, ethylbenzene, propylbenzene, methylpyridine, ethylpyridine, propylpyridine and butylpyridine. \n\n\n Unless otherwise specifically noted as only \"unsubstituted\" or only \"substituted\", or when substituents are specifically enumerated, cycloalkyl, aryl (including phenyl) and heterocycle\n\n\n(including heteroaryl) groups are unsubstituted or substituted. As used herein, the terms \"substituted C3- Cjo cycloalky , \"substituted aryl (including phenyl)\" and \"substituted heterocycle\" are intended to include the cyclic group containing from 1 to 3 substituents in addition to the point of attachment to the rest of the compound. Preferably, the substituents are selected from the group which includes, but are not limited to, halo, C] -C20 alkyl, CF3, NH2, (Ci-C6 alkyl)2, ΝΟ2» oxo, CN, N3, -OH, -0(Ci-C6 alkyl), C3-C10 cycloalkyl, C2-C6 alkenyl, C2-C alkynyl, (Q)-C\n6\n alkyl) S(0)o-2-\n>\n aryl-S(O)0-2-\n>\n (Co-C\n6\n alk l)S(0)o-2(Co-C\n6\n alkyl)-, (Co-C\n6\n alkyl)C(0)NH-, H2N-C(NH , -0(C -C6 alkyl)CF3, (Co-Q, alkyl)C(O)-, (C0-C6 alkyl)OC(0)-, (C0-C alkyl)2NC(0)- (C()-C6alkyl)0(Ci-C6 alkyl , (Q>-C6 alkyl)C(0)i.2(Co-C6 alkyl)-, (Co-C¾ alkyl)OC(0)NH-, aryl, aralkyl, heteroaryl, heterocyclylalkyl, halo- aryl, halo-aralkyl, halo-heterocycle, halo-heterocyclylalkyl, cyano-aryl, cyano-aralkyl, cyano-heterocycle and cyano-heterocyclylalkyl. \n\n\n Unless expressly stated to the contrary, an \"unsaturated\" ring is a partially or fully unsaturated ring. For example, an \"unsaturated monocyclic C5 carbocycle\" refers to cyclohexene, cyclohexadiene, and benzene. \n\n\n Unless expressly stated to the contrary, all ranges cited herein are inclusive. For example, a heterocycle described as containing from \"1 to 4 heteroatoms\" means the heterocycle can contain 1, 2, 3 or 4 heteroatoms. \n\n\n When any variable occurs more than one time in any constituent or in any formula depicting and describing compounds of the invention, its definition on each occurrence is independent of \n\n its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. \n\n\n The term \"substituted\" (e.g., as in \"aryl which is optionally substituted with one or more substituents ...\") includes mono- and poly-substitution by a named substituent to the extent such single S and multiple substitution (including multiple substitution at the same site) is chemically allowed. \n\n\n The term \"oxy\" means an oxygen (O) atom. The term \"thio\" means a sulfur (S) atom. The term \"oxo\" means \"=0\". The term \"carbonyl\" means \"CO.\" \n\n\n When any variable (e.g., R\n2\n, R.3, etc.) occurs more than one time in any substituent or in formulas Ι-ΠΪ, its definition in each occurrence is independent of its definition at every other occurrence. 10 Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. \n\n\n Under standard nomenclature used throughout this disclosure, the terminal portion of the designated side chain is described first, followed by the adjacent functionality toward the point of attachment For example, a Ci-5 alkylcarbonylamino Ci_<; alkyl substituent is equivalent to j \n5\n \n\n\n\n\n\n\n\n\n In choosing compounds of the present invention, one of ordinary skill in the art will recognize that the various substituents, i.e. Ill, R^, R , etc., are to be chosen in conformity with well- known principles of chemical structure connectivity. \n\n\n Lines drawn into the ring systems from substituents indicate mat the indicated bond can\n\n\n20 be attached to any of the substitutable ring atoms. If the ring system is polycyclic, it is intended mat the bond be attached to any of the suitable carbon atoms on the proximal ring only. \n\n\n It is understood that substituents and substitution patterns on the compounds of the instant invention can be selected by one of ordinary skill in the art to provide compounds that are chemically stable and that can be readily synthesized by techniques known in the art, as well as those\n\n\n25 methods set form below, from readily available starting materials. If a substituent is itself substituted with more than one group, it is understood that these multiple groups can be on the same carbon or on different carbons, so long as a stable structure results. The phrase \"optionally substituted with one or more substituents\" should be taken to be equivalent to the phrase \"optionally substituted with at least one substituent\" and in such cases one embodiment will have from zero to three substituents. \n\n\n 30 In one embodiment, A, includes, but is not limited to, the following: azabenzimidazole, benzoiraidazolyl, benzofuryl, benzofurazanyl, benzopyrazolyl, benzothiazolyl, benzothienyl, benzotriazoryl, benzothiophenyl, benzoxazolyl, carbazolyl, carbolinyl, chromanyl, cinnolinyl, furanyl, imidazolyl, indolinyl, indolyl, indolazinyl, indazolyl, isobenzofuryl, isochromanyl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthpyridinyl, oxadiazolyl, oxazolyl, oxazoline, isoxazoline,\n\n\n35 oxetanyl, pyranyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridopyridinyl, pyridazinyl, pyridinyl, pyrimidyl, \n\n pyrrolyl, quinazolinyl, quinolyl, quinoxalinyl, quinoxalinyl, tetrahydropyranyl, tetrazolyl, tetrazolopyridyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, azetidinyl, aziridinyl, 1,4-dioxanyl, hexahydroazepinyl, piperazinyl, piperidinyl, pyrrolidinyl, morpholinyl, thiomo holίn l, \n\n\ndihydrobenzoimidazolyl, dihydrobenzofuryl, dihydrobenzothiophenyl, dihydrobenzoxazolyl, dihydrofuryl, dihydroimidazolyl, dihydroindolyl, dihydroisooxazolyl, dihydroisothiazolyl, \n\n\ndihydrooxadiazolyl, dihydrooxazolyl, dihydropyrazinyl, dihydropyrazolyl, dihydropyridinyl, \n\n\ntetrahydroquinolinyl, tetrahydroisoquinolinyl, dihydropyrimidinyl, dihydropyrrolyl, dihydroquinolinyl, dihydrotetrazolyl, dihydrothiadiazolyl, dihydrothiazolyl, dihydrothienyl, dihydrotriazoly], \n\n\ndihydroazetidinyl, methylenedioxybenzoyl, tetrahydrofuryl, tetrahydrothienyl, tetrahidroquinolinyl, 2,3-dihydrobenzofuryl, 2,3^ihydrobenzo-l,4-dioxinyl, imidazo(2,l-bXl,3)<hiazole, and benzo-1,3- dioxolyl, wherein A is optionally substituted with one or more R9 substituents. \n\n\n In a variant of this embodiment, tbe heterocyclyl moiety in A includes azabenzimidazole, benzoimidazolyl, benzothiazolyl, benzothienyl, benzotriazolyl, benzothiopbenyl, benzoxazolyl, furanyl, imidazolyl, indolyl, indazolyl, isobenzofuryl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthpyridinyl, oxadiazoly], oxazolyl, pyrazinyJ, pyrazolyl, pyridazinyl, pyridopyridinyl, pyridazinyl, pyridinyl, pyrimidyl, quinazolinyl, quinolyl, quinoxalinyl, quinoxalinyl, tetrahydroisoquinolinyl, tetrazolyl, tetrazolopyridyl, thiadiazolyl, thiazolyl, thienyl, dihydrobenzoimidazolyl, phenothiazinyl, dihydrobenzofiiryl, dihydrobenzothiophenyl, dihydrobenzoxazolyl, methylenedioxybenzoyl, \n\n\ntetrahydrofuryl, tetrahydrothienyl, 2,3-dihydrobenzofuryl, 2,3-dihydrobenzo-l,4-dioxinyl, imidazo(2,l- bXl,3)thiazole, and benzo-l,3-dioxolyl, wherein A is optionally substituted with one or more R9 substituents. \n\n\n In another embodiment, A is selected from: benzoimidazolyl, benzothiazolyl, benzothienyl, benzotriazolyl, benzothiophenyl, benzoxazolyl, furanyl, imidazolyl, indolyl, indazolyl, isobenzofuryl, isoindolyl, isoquinolyl, isothiazolyl, isoxazolyl, naphthpyridinyl, oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridopyridinyl, pyridazinyl, pyridinyl, pyrimidyl, tetrazolyl, tetrazolopyridyl, thiadiazolyl, thiazolyl, and thienyl, wherein A is optionally substituted with one or more R9 substituents. \n\n\n In another embodiment, A is selected from: pyrazinyl, pyrazolyl, pyridopyridinyl, pyridazinyl, pyridinyl, pyrimidyl, tetrazolyl, tetrazolopyridyl, thiadiazolyl, thiazolyl, and thienyl, wherein A is optionally substituted with one or more R9 substituents. \n\n\n In another embodiment, A is selected from pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, and pyrimidyl, wherein A is optionally substituted with one or more R9 substituents. In a variant of this embodiment, A is selected from pyrazolyl, pyridinyl, pyridazinyl, and pyrimidyl, wherein A is optionally substituted with one or more R? substituents. In yet another variant of this invention, A is chosen from pyrazolyl and pyridazinyl, wherein A is optionally substituted with one or more 9 substituents. \n\n\n In one embodiment of the invention, Rl is selected from halogen, C\\.\\Q alkyl, -C2_i o alkenyl, -C2-10 alkynyl, cycloalkyl Co-ifj alkyl(oxy)o_i, heterocyclyl Co-lO alkyl(oxy)0-l» arylCfj-lO alkyl(oxy)o-i, Ci-io alkoxy (ca carboxyl aryl, \n\n carboxylcycloalkyl, carboxylheterocyclyl, Ci-ioalkyloxy Co-ioaltyl\n*\n hydroxy Co-ioalkyl, hydroxycarbonylCo-loalkoxy, Ci-io alkylthio, Cj-io alkylsulfinyl, aryl Crj-io alkylsulfinyl, heterocyclyl Co_io alkylsulfinyl, cycloalkyl Co-10 alkylsulfinyl, Ci-io alkylsulfonyl, aryl Co-io alkylsulfonyl, heterocyclylCo-io alkylsulfonyl, cycloalkyl Co-io alkylsulfonyl, n ro, perfluoroC] . \n\n\n6*lkyl\n>\n \n811(1\n perfluoroC i-galkoxy; wherein in Rl is optionally substituted with one or more R9 substituents. \n\n\n In another embodiment, Rl is selected from halogen, Ci-io alkyl, -C2-io alkenyl, - ∑- 10 alkynyl, cycloalkyl Co-io alkyl(oxy)o-l, heterocyclyl Co-ifj alkyl(oxy)fj-l, arylCrj-lO alkyl(°xy)0-l, Ci-io alkoxy (carbonyl)0-lCo-io alkyl, carboxyl Co_io alkyl, carboxyl aryl, carboxylcycloalkyl, carboxylheterocyclyl, C i . i oalkyloxy Co. i oalkyl, hydroxy Cfj- 1 Oalkyl, hydroxycarbonylCo- 1 oalkoxy, Ci-io alkylthio, Ci_]0 alkylsulfinyl, aryl Co-io alkylsulfinyl, heterocyclyl Cfj-io alkylsulfinyl, cycloalkyl Co-io alkylsulfinyl, Ci-io alkylsulfonyl, aryl Co-io alkylsulfonyl, heterocyclylCo-io alkylsulfonyl, cycloalkyl Co_io alkylsulfonyl, nitro, perfluoroC i-6alkyl, and perfluoroC i_6alkoxy; \n\n\nwherein in Rl is optionally substituted with one or more R9 substituents. \n\n\n In another embodiment, Rl is selected from halogen, phenylmethyl, pyridinyL, phenyl,\n\n\nCi-io alkyl, naphtholinyl Ci-6 alkyl, cyclopropyl, phenyl Cl-6 alkyl, cyclohexyl, piperidinyl, pyrrolidinyl, 1^,3,4-tetrahydronaphthalinenyl, 2,3-dihydro-lH-indinyl, benzyl, phenylethyl, cyclopentyl, tertbutyl, wherein in Rl is optionally substituted with one or more R9 substituents. \n\n\n In another embodiment of the invention, Rl is selected from: cycloalkyl Co-10 \n\n\nalkyl(oxy)o-i, heterocyclyl Co-iO alkyl(oxy)0-l, arylCo-io alkyl(oxy)0-l, perfluorCi-6 alkyl, perfluoro Ci^alkoxy, and Ci-io alkoxy (carbonyl)o_iCo_io al » wherein Rl is optionally substituted with one or more R9 substituents. \n\n\n In one embodiment of the invention, R\n2\n is selected from hydrogen, halogen, hydroxy!, - Ci-<5 alkyl, C3-6 heterocycloalkyl and C3-6 cycloalkyl wherein said alkyl, heterocycloalkyl and cycloalkyl are each optionally substituted with one or more substituents selected from: hydroxy!, -SR\\ - R^ or-CC^-R*. \n\n\n In another embodiment, R3 is selected from hydrogen, halogen, hydroxy!, -Cj-6 alkyl, C3-6 heterocycloalkyl and C3-6 cycloalkyl wherein said alkyl, heterocycloalkyl and cycloalkyl are each optionally substituted with one or more substituents selected from: hydroxyl, -SR\\ -NR*2 or -C02-R'- In one emobidiment of the invention L is selected from: is chosen from -(C1.3 alkyl)o- i RaCO-, -(C1.3 alkyl)0-l RaCO2-, -(Ci-3 alkyl)0-lCO2-, -<C\\.\n3\n alkyl)0-l RaSO2-, -(C1.3 alkyl)0- iNRaCSNRb-, and -(C1.3 alkyl)o-lNRaCONRb.. \n\n\n In another embodiment, L is selected from -(CI -3 alkyl)0-lNRaCO-, \n\n\n-{Cl-3 alkyl)0-l RaCO2-, and -(Cl-3 alkyl)0-lCO2-. In a variant of this embodiement, L is—(CI -3 aIkyl) -lNRaCO-. \n\n\n In one embodiment, R9 is selected from halogen, hydroxy, oxo, cyano, aryl, heterocyclyl, cycloalkyl, -Cl-6 alkyl, -Cl-6 alkoxy, aryloxy, heterocyclyloxy, -0(0-1 XC 1-10)perfluoroalkyl, -C02Ra, \n\n -OC02Ra, -OCO RbRc, , -SCO-6 alkyl and -S(0)nRjd, wherein R9 is optionally substituted by one or more substituents RIO. \n\n\n In another embodiment, R9 is selected from halogen, hydroxy, cyano, aryl, heterocyclyl, cycloalkyl, -Cl-6 alkyl, -Cl-6 alkoxy, aryloxy, heterocyclyloxy, -O(0-lXCl-10)perfluoroalkyl, -C02Ra, and -OC02Ra wherein R9 is optionally substituted by one or more substituents RIO. \n\n\n In one embodiment, RlO is selected from hydroxy, aryl, heterocycloalkyl, heteroaryl, halogen, oxo, -Cl-6 alkyl, C -6 alkoxy,C02H, cyano, 0(C=0)o.iCi-6 alkyl, trifluoromethoxy, trifluoroethoxy, -0(0-l)(Ci.io)perfluoroalkyl, Cfj-io alkylaminocarbonyl, -(C=0)N(Co-6 a]kyl)2, -S(Co- 6 alkyl), and N¾. \n\n\n In another embodiment, R\n10\n is selected from hydroxy, aryl, heterocycloalkyl, heteroaryl, halogen, oxo, -C\\-6 alkyl, Cj-6 alkoxy,C02H, cyano, 0(00)o.iCi-6 alkyl, trifluoromethoxy, trifluoroethoxy, -0(0-l)(Ci_io)perfluoroalkyl, Crj-io alkylaminocarbonyl, and H2. \n\n\n Another embodiment of the invention includes the following compounds: N-{4-hydroxy-2-( 1 H-pyr¾zol-l-yl)pyrimidm-5-yl)-2,2-diphenylacetamide; \n\n\n2-chloro-N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)benzamide; \n\n\n3-chloro-N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)benzamide; \n\n\n 3-(trifluoromethyl)-N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)benzamide; \n\n\n N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)-2-(naphthalen-3-yl)acetamide; \n\n\n 2-(trifluoromethyl)-N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yI)benzamide; \n\n\nN-[4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl]biphenyl-4-carboxamide; \n\n\n N-(4-hydroxy-2-( 1 H-pyrazol-1 -yl)pyrimidin-5-yl 3-phenoxybenzamide; \n\n\n N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)-4-phenoxybenzamide; \n\n\n 2-(2-chlorophenyl)-N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)acetamide; \n\n\n 2-(3-chlorophenyI)-N-(4-hydroxy-2-(lH-pyrazol-l-yl)pyrimidin-5-yl)acetamide \n\n\n2-(4-chlorophenyl)-N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)acetamide; \n\n\n 2-(3-cyanopheny l)-N-(4-hydroxy-2-( 1 H-pyra^ \n\n\n 2-(2-(trifluoromethyl)phenyl)-N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)acetamide; \n\n\n 2-(3-{trifluoromemyl)phenyl)-N-(4-hydroxy-2-(lH-pyrazol-l-yl)pyrimidin-5-^ \n\n\n 2-(4-(trifluoromethyl)phenyl)-N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)acetarnide; \n\n\nN-(4-hydroxy-2-(lH-pyrazol-l-yl)pyrimidin-5-yl)-2-(2-memoxyphenyl)acetami \n\n\n N-(4-hyd^xy-2-(lH-pyrazol-l-yl)pyrimidin-5-yl)-2-(3-memoxyphenyl)acetamid^ \n\n\n N-(4-hydroxy-2-(lH-pyrazol-l-yl)pyrimidin-5-yl)-2-(4-methoxyphenyl)acetomide^ \n\n\n N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)-2-phenylpropanamide; \n\n\n N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)-2-phenylbutanamide; \n\n\nN-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)-3-methyl-2-pheny lpentanamide; \n\n\n N-(4-hydroxy-2-(l H-pyrazol-l-yl)pyrimidin-5-yl)-2-methyl-2-phenylpropanamide; \n\n\n N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yI)pyrimidin 5 yl) 2 (naphthalen 1 y l)acetamide; \n\n 2-(benzo[d] [ 1 ,3 ]dioxol-5-yl)-N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)acetamide; \n\n\n 2-(biphenyl-4-yl N-(4-hydroxy-2-(lH-p^ \n\n\n N-(4-hydroxy-2-{ 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)heptanamide; \n\n\n N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)-4-pheDylbutanamide; \n\n\ntert-buty 14-(4-hydroxy-2-(l H-pyrazol-1 -yl)pyrimidin-5-ylcarbamoyl)piperidine- 1 -carboxylate; \n\n\n 2-cyclohexyl-N-(4-hydroxy-2-( 1 H-pyrazo 101.01-1 -yl)pyrimidin-5-yI)acetamide; \n\n\n 1 ,2,3,4-tetrahydro-N-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)naphthalene- 1 -carboxamide; \n\n\n 2,3-dihydro-N-(4-hydroxy-2-( 1 H-pyrazol-1 -yl)pyrimidin-5-yl)-l H-indene- 1 -carboxamide; \n\n\n 2,3-dihydro-N-(4-hydroxy-2-(IH-pyrazol-l-yl)pyrimidin-5-yl)-lH-inden \n\n\n1 -benzyl-3-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)urea; \n\n\n 1 -(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)-3-( 1 -phenylethyl)urea; \n\n\n S-i^hydroxy^-ilH-pyi-azol-l-yl^yrimidin-S-ylJ-l.I-diphenylurea; \n\n\n 1 -benzhydryl-3-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)thiourea; \n\n\n 1 -{4-hydroxy-2-(lH-pyra2»l-l-yl pyrimidin-5-yl)-3-(l -phenylethyl)thiourea; \n\n\nand pharmaceutically acceptable salts and solvates thereof. \n\n\n Structural representations of compounds having substhuents terminating with a methyl group may display the terminal methyl group either using the characters \"CH3\", e.g. \"-CH3\" or using a straight line representing the presence of the methyl group, e.g.\n\n\n\n\n\n\n\n\n \n\n have equivalent meanings. \n\n\n For variable definitions containing terms having repeated terms, e.g., (CRiRJ)r, where r is the integer 2, Ri is a defined variable, and Rj is a defined variable, the value of Ri may differ in each instance in which it occurs, and the value of Rj may differ in each instance in which it occurs. For example, if Ri and Ri are independently selected from the group consisting of methyl, ethyl, propyl and butyl, then (CRiR!)2 can be \n\n\n\n\n\n Optical Isomers - Diastereomers - Geometric Isomers - Tautomers \n\n\n Compounds described herein may contain an asymmetric center and may thus exist as enantiomers. Where the compounds according to the invention possess two or more asymmetric centers, they may additionally exist as diastereomers. The present invention includes all such possible stereoisomers as substantially pure resolved enantiomers, racemic mixtures thereof, as well as mixtures of diastereomers. The above Formula I is shown without a definitive stereochemistry at certain positions, The present invention includes all stereoisomers of Formula I and pharmaceutically acceptable salts and solvates thereof. Unless specifically mentioned otherwise, reference to one isomer applies to any of the possible isomers. Whenever the isomeric composition is unspecified, all possible isomers are included. Diastereoisomeric pairs of enantiomers may be separated by, for example, fractional crystallization from \n\n a suitable solvent, and the pair of enantiomers thus obtained may be separated into individual stereoisomers by conventional means, for example by the use of an optically active acid or base as a resolving agent or on a chiral HPLC column. Further, any enantiomer or diastereomer of a compound of the general Formula I may be obtained by stereospeciMc synthesis using optically pure starting materials or reagents of known configuration . \n\n\n When compounds described herein contain olefinic double bonds, unless specified otherwise, such double bonds are meant to include both E and Z geometric isomers. \n\n\n Some of the compounds described herein may exist with different points of attachment of hydrogen, referred to as tautomers. For example, compounds including carbonyl -CH2C(0)- groups (keto forms) may undergo tautomerism to form hydroxyl -CH=C(OH groups (enol forms). Both keto and enol forms, individually as well as mixtures thereof, are included within the scope of the present invention. \n\n\nSalts \n\n\n Pharmaceutically acceptable salts include both the metallic (inorganic) salts and organic salts; a list of which is given in Remington's Pharmaceutical Sciences, 17th Edition, pg. 1418 (1985). It is well known to one skilled in the art that an appropriate salt form is chosen based on physical and chemical stability, flowabilhy, hydro-scopicity and solubility. The term \"pharmaceutically acceptable salts\" refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids. When the compound of the present invention is acidic, its corresponding salt can be conveniently prepared from inorganic bases or organic bases. Salts derived from such inorganic bases include aluminum, ammonium, calcium, copper (ic and ous), ferric, ferrous, lithium, magnesium, manganese (ic and ous), potassium, sodium, zinc and the like salts. Preferred are the ammonium, calcium, magnesium, potassium and sodium salts. Salts prepared from organic bases include salts of primary, secondary, and tertiary amines derived from both naturally occurring and synthetic sources. Pharmaceutically acceptable organic non-toxic bases from which salts can be formed include, for example, arginine, betaine, caffeine, choline, N,N -dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimeraylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, dicyclohexylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine and the like. \n\n\n When the compound of the present invention is basic, its corresponding salt can be conveniently prepared from inorganic or organic acids. Such acids include, for example, acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid and the like. \n\n\nPreferred are citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric, and tartaric acids. \n\n Solvates \n\n\n The present invention includes within its scope solvates of compounds of Formula I. As used herein, the term \"solvate\" refers to a complex of variable stoichiometry formed by a solute (i.e., a compound of Formula I) or a pharmaceutically acceptable salt thereof and a solvent that does not interfere with the biological activity of the solute. Examples of solvents include, but are not limited to water, ethanol, and acetic acid. When the solvent is water, the solvate is known as hydrate; hydrate includes, but is not limited to, hemi-, mono, sesqui-, di- and trihydrates. \n\n\nProdrugs \n\n\n The present invention includes within its scope the use of prodrugs of the compounds of this invention. In general, such prodrugs will be functional derivatives of the compounds of mis invention which are readily convertible in vivo into the required compound. Thus, in the methods of treatment of the present invention, the term \"administering\" shall encompass the treatment of the various conditions described with a compound of formula I or with a compound which may not be a compound of formula L, but which converts to a compound of formula I in vivo after administration to the patient Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in \"Design of Prodrugs,\" ed. H. Bundgaard, Elsevier, 1985. \n\n\n In the compounds of generic Formula I, the atoms may exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature. The present invention is meant to include all suitable isotopic variations of the compounds of generic Formula I. For example, different isotopic forms of hydrogen (H) include protium (lH) and deuterium (2H). Protium is the predominant hydrogen isotope found in nature. Enriching for deuterium may afford certain therapeutic advantages, such as increasing in vivo half-life or reducing dosage requirements, or may provide a compound useful as a standard for characterization of biological samples. \n\n\nIsotopically-enriched compounds within generic Formula I can be prepared without undue experimentation by conventional techniques well known to those skilled in the art or by processes analogous to those described in the Schemes and Examples herein using appropriate isotopically-enriched reagents and/or intermediates. \n\n\nUtilities \n\n\n Compounds of the present invention are inhibitors of hypoxia-inducible factor (RTF) prolyl hydroxylases, and as such are useful in the treatment and prevention of diseases and conditions in which HIF modulation is desirable, such as anemia and ischemia. Compounds of the invention can be used in a selective and controlled manner to induce hypoxia-inducible factor stabilization and to rapidly and reversibly stimulate erythropoietin production and secretion. Accordingly, another aspect of the present invention provides a method of treating or preventing a disease or condition in a mammal, the treatment or prevention of which xylase inhibition, which \n\n comprises administering an amount of a compound of Formula I that is effective for inhibiting HGDF prolyl hydroxylase. This aspect of the present invention further includes the use of a compound of Formula I in the manufacture of a medicament for the treatment or prevention of a disease or condition modulated by HIF prolyl hydroxylase. \n\n\n In one embodiment is a method of enhancing endogenous production of erythropoietin in a mammal which comprises administering to said mammal an amount of a compound of Formula I that is effective for enhancing endogenous production of erythropoietin. \n\n\n Another embodiment is a method of treating anemia in a mammal which comprises administering to said mammal a therapeutically effective amount of a compound of Formula I. \"Anemia\" includes, but is not limited to, chronic kidney disease anemia, chemotherapy-induced anemia (e.g., anemia resulting from antiviral drug regimens for infectious diseases, such as HTV and hepatitis C virus), anemia of chronic disease, anemia associated with cancer conditions, anemia resulting from radiation treatment for cancer, anemias of chronic immune disorders such as rheumatoid arthritis, inflammatory bowel disease, and lupus, and anemias due to menstruation or of senescence or in other individuals with iron processing deficiencies such as those who are iron-replete but unable to utilize iron properly. \n\n\n Another embodiment is a method of treating ischemic diseases in a mammal, which comprises administering to said mammal a therapeutically effective amount of a compound of Formula I. Combination Therapy \n\n\n Compounds of Formula I may be used in combination with other drugs that are used in the treatment/prevention/suppression or amelioration of the diseases or conditions for which compounds of Formula I are useful. Such other drugs may be administered, by a route and in an amount commonly used therefor, contemporaneously or sequentially with a compound of Formula I. When a compound of Formula I is used contemporaneously with one or more other drugs, a pharmaceutical composition containing such other drugs in addition to the compound of Formula I is preferred. Accordingly, the pharmaceutical compositions of the present invention include those that also contain one or more other active ingredients, in addition to a compound of Formula I. \n\n\nRoute of Administration/Dosage \n\n\n The compounds of this invention can be administered for the treatment or prevention of afflictions, diseases and illnesses according to the invention by any means that effects contact of the active ingredient compound with the site of action in the body of a warm-blooded animal. For example, administration can be oral, topical, including transdermal, ocular, buccal, intranasal, inhalation, intravagjnal, rectal, intracisternal and parenteral. The term \"parenteral\" as used herein refers to modes of administration which include subcutaneous, intravenous, intramuscular, intraarticular injection or infusion, intrastemal and intraperitoneal. For the purpose of this disclosure, a warm-blooded animal is a member of the animal kingdom possessed of a homeo static mechanism and includes mammals and birds. \n\n\n The compounds can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents. They can be tered with a \n\n pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice. \n\n\n The dosage administered will be dependent on the age, health and weight of the recipient, the extent of disease, kind of concurrent treatment, if any, frequency of treatment and the nature of the effect desired. Usually, a daily dosage of active ingredient compound will be from about 0.1-2000 milligrams per day. Ordinarily, from 10 to 500 milligrams per day in one or more applications is effective to obtain desired results. These dosages are the effective amounts for the treatment and prevention of afflictions, diseases and illnesses described above, e.g., anemia. \n\n\nPharmaceutical Composition \n\n\n Another aspect of the present invention provides pharmaceutical compositions which comprises a compound of Formula I and a pharmaceutically acceptable carrier. The term \"composition\", as in pharmaceutical composition, is intended to encompass a product comprising the active \n\n\ningredients), and the inert ingredients) (pharmaceutically acceptable excipients) that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients. Accordingly, the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of Formula I, additional active ingredients), and pharmaceutically acceptable excipients. \n\n\n The pharmaceutical compositions of the present invention comprise a compound represented by Formula I (or a pharmaceutically acceptable salt or solvate thereof) as an active ingredient, a pharmaceutically acceptable carrier and optionally other therapeutic ingredients or adjuvants. The compositions include compositions suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration, although the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being administered. The pharmaceutical compositions may be \n\n\nconveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy. \n\n\n The active ingredient can be administered orally in solid dosage forms, such as capsules, tablets, troches, dragees, granules and powders, or in liquid dosage forms, such as elixirs, syrups, , emulsions, dispersions, and suspensions. The active ingredient can also be administered parenteral ly, in sterile liquid dosage forms, such as dispersions, suspensions or solutions. Other dosages forms that can also be used to administer the active ingredient as an ointment, cream, drops, transdermal patch or powder for topical administration, as an ophthalmic solution or suspension formation, i.e., eye drops, for ocular administration, as an aerosol spray or powder composition for inhalation or intranasal administration, or as a cream, ointment, spray or suppository for rectal or vaginal administration. \n\n\n Gelatin capsules contain the active ingredient and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Bo sustained release products \n\n to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract. \n\n\n Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance. \n\n\n In general, water, a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene gycols are suitable carriers for parenteral solutions. Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances. Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents. Also used are citric acid and its salts and sodium EDTA. In addition, parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propylparaben, and chlorobutanol. \n\n\n Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, A. Osol, a standard reference text in Ihis field. \n\n\n For administration by inhalation, the compounds of the present invention may be conveniently delivered in the form of an aerosol spray presentation from pressurized packs or nebulisers. The compounds may also be delivered as powders which may be formulated and the powder composition may be inhaled with the aid of an insufflation powder inhaler device. The preferred delivery system for inhalation is a metered dose inhalation (MDI) aerosol, which may be formulated as a suspension or solution of a compound of Formula I in suitable propellents, such as fluorocarbons or hydrocarbons. \n\n\n For ocular administration, an ophthalmic preparation may be formulated with an appropriate weight percent solution or suspension of the compounds of Formula I in an appropriate ophthalmic vehicle, such that the compound is maintained in contact with the ocular surface for a sufficient time period to allow the compound to penetrate the corneal and internal regions of the eye. \n\n\n Useful pharmaceutical dosage-forms for administration of the compounds of this invention include, but are not limited to, hard and soft gelatin capsules, tablets, parenteral injectables, and oral suspensions. \n\n\n A large number of unit capsules are prepared by filling standard two-piece hard gelatin capsules each with 100 milligrams of powdered active ingredient, 150 milligrams of lactose, 50 milligrams of cellulose, and 6 milligrams magnesium stearate. \n\n\n A mixture of active ingredient in a digestible oil such as soybean oil, cottonseed oil or olive oil is prepared and injected by means of a positive displacement pump into gelatin to form soft gelatin capsules containing 100 milligrams of the active ingredient The capsules are washed and dried. \n\n\n A large number of tablets are prepared by conventional procedures so that the dosage unit is 100 milligrams of active ingredient, 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 milligrams of microcrystalline cellulose, 1 1 milligrams of starch and 98.8 milligrams of lactose. Appropriate coatings may be applied to increase palatability or delay absorption. \n\n A parenteral composition suitable for administration by injection is prepared by stirring 1.5% by weight of active ingredient in 10% by volume propylene glycol. The solution is made to volume with water for injection and sterilized. \n\n\n An aqueous suspension is prepared for oral administration so that each 5 milliliters contain 100 milligrams of finely divided active ingredient, 100 milligrams of sodium carboxymethyl cellulose, 5 milligrams of sodium benzoate, 1.0 grams of sorbitol solution, U.S.P., and 0.02S milliliters of vanillin. \n\n\n The same dosage forms can generally be used when the compounds of this invention are administered stepwise or in conjunction w h another therapeutic agent. When drugs are administered in physical combination, the dosage form and administration route should be selected depending on the compatibility of the combined drugs. Thus the term coadministration is understood to include the administration of the two agents concomitantly or sequentially, or alternatively as a fixed dose combination of the two active components. \n\n\n Compounds of the invention can be administered as the sole active ingredient or in combination with a second active ingredient, including other active ingredients known to be useful for improving the level of erythropoietin in a patient. \n\n\nAbbreviations Used in the Description of the Preparation of the Compounds of the Present Invention: \n\n\nAcOH Acetic acid \n\n\n AgjO Silver oxide \n\n\n Aq Aqueous \n\n\n Bn Benzyl \n\n\n BnBr benzylbroraide \n\n\n BnCl benzylchloride \n\n\n BnOH benzylalcohol \n\n\n Brine Saturated aqueous sodium chloride solution \n\n\n CDI Carbony] diimidazole \n\n\n DBU 1 ,8-diazabicyclo[5.4.0]undec-7-ene \n\n\n DEAD diethylazodicarboxylate \n\n\n DCM Dichloromethane \n\n\n DIPEA N,N-diisopropylethylaime \n\n\n DMAP 4-.V,#-dimemylaminopyridine \n\n\n DMF N,tf-dimethylformamide \n\n\n DMSO Dimethyl sulfoxide\n\n\n \n\n DPPA Diphenyl phosphoryl azide \n\n EDC or EDCI l-(3-dimethylaminopropyl 3-etoylcart>oiimide hydrogenchloride salt \n\n\n EtOAc or EA Ethyl acetate \n\n\n Et (et) Ethyl \n\n\n EtOH Ethanol \n\n\n Et\n2\n0 or ether Diethyl ether \n\n\n Etj triethylamine \n\n\n G Grains \n\n\nh or hr Hour \n\n\n HATU CK7-Azaben-»1riazol-l-yl -V,-V,^N'-tetrame ^ \n\n\n hexafluorophosphate \n\n\n HC1 Hydrochloric acid \n\n\n HOBt 1-hydroxybenzatriazole \n\n\n HPLC High-performance liquid chromatography \n\n\nj\n'\n-PrOH or IPA Isopropyl alcohol \n\n\n K2CO3 Potassium carbonate \n\n\n KOH Potassium hydroxide \n\n\n LiOH Lithium hydroxide \n\n\n Mg Milligrams \n\n\nmL Milliliters \n\n\n Mmol Millimole \n\n\n MeOH Methanol \n\n\n Min Minutes \n\n\nms or MS Mass spectrum \n\n\n Mg Microgram(s) \n\n\nuL Microliters \n\n\n NaOEt Sodium ethoxide \n\n\n NaOMe Sodium methoxide \n\n\n Na\n2\nS0\n4\n Sodium sulfate \n\n\n NHAc Acetamido \n\n\n NHCbz Benz loxycarboxamido \n\n\n NaOH Sodium hydroxide \n\n\n NaN\n3\n Sodium azide \n\n\n N¾OH ammonium hydroxide \n\n\n Pd/C Palladium on carbon \n\n\n Pd(OH>2 Palladium hydroxide \n\n\n Ph Phenyl group \n\n Triphenyphosphine \n\n\n Retention time \n\n\n Rt Room temperature \n\n\n TEA Triethylamine \n\n\n TFA Trifluoroacetic acid \n\n\n THF Tetrahydrofuran \n\n\n TMSCHNj (trimethylsilyl)diazomethane \n\n\nv v Volume/Volume \n\n\n V Volume \n\n\nSynthesis \n\n\n The compounds of mis invention may be prepared by employing reactions as shown in the following schemes, in addition to other manipulations that are known in the literature or exemplified in the experimental procedures. The illustrative schemes below, therefore, are not limited by the compounds listed or by any particular substituents employed for illustrative purposes. Substituent numbering as shown in the schemes does not necessarily correlate to that used in the claims and often, for clarity, a single substituent is shown attached to the compound in place of multiple substituents which are allowed under the definitions of Formula I defined previously. \n\n\n The following schemes and descriptions illustrate methods which may be employed for the synthesis of the novel compounds described in this invention. All substituents are as defined above unless indicated otherwise. Several strategies based upon synthetic transformations known in the literature of organic synthesis may be employed for the preparation of the title compounds of general formula I. The choice of the method employed is influenced by the selection of the desired substituent groups (R\n1\n through R\n3\n, L and A) in the title of formula I. \n\n\n\n\n\n\n\n\n Pyrimidine intermediates useful for the preparation of compounds of formula I of the present invention are either purchased or prepared using suitable procedures reported in the literature (sometimes with minor modifications). One generally useful method for the synthesis of pyrimidines suitable for the preparation of the title compounds of general formula I wherein the substituent R3 is a hydroxy] group is illustrated in Scheme 1. \n\n\nScheme ¾ \n\n\n\n\n\n\n\n\n\n\n This method involves the initial synthesis of substituted 4-hydroxypyrimidine-5- carboxylates of general formula 1S-4 and 1S-6. The synthesis of 4-hydroxypyrimidine-5-carboxylates exemplified in scheme 1 is based upon reported methods (Dostert, P.; Imbert, T.; Ancher, J.F.; Langlois, M.; Bucher, B.; Mocquet, G. Eur. J. Med Chem. 1982, 77, 437-44. Juby, P.F.; Hudyma, T.W.; Brown, M.; Essery, J.M.; Partyka, R.A. J. Med Chem. 1979, 22, 263-9). \n\n\n In this method, an amidine or a suitable salt thereof of general formula lS-1 is reacted with an optionally substituted diethyl methylenemalonate of general formula 1S-2. This reaction is usually conducted using a suitable base such as sodium or potassium ethoxide in ethanol, although other reaction conditions may also be applied. The alkoxide base and the alcohol solvent are chosen to correspond to the esters present in reagent 1S-2 to prevent the formation of mixtures of esters in the product of general formula 1S-3. When required, the reaction is conducted at elevated temperature, typically at the reflux temperature of the solvent until reaction is complete (generally within 1-4 hours). It is also convenient to conduct this reaction under microwave heating in sealed reaction vessels. In this instance, the reaction is generally conducted at temperatures between 80 and 120 °C and the reactions are typically completed in 5-30 minutes. \n\n\n Compounds of general formula 1S-3 are useful intermediates to prepare compounds of formula I of the present invention. For example, compounds of general formula 1S-3 may be hydrolyzed using a suitable base (e.g. sodium or potassium hydroxide) to give acids of formula 1S-4; alternatively, they are converted to compounds of formula 1S-5, in which the hydroxy! group of the pyrimidine core is protected with a desired protecting group (e.g. PG is benzyl, para-methoxybenzyl, trityl, or tert-butyl- dimethyl silyl). Hydrolysis of compounds of formula 1S-5 gives acids of general formula 1S-6, which is readily achieved under suitable ester hydrolysis reaction conditions (Wuts, P.G.M.; Greene, T.W., Protecting Groups in Organic Synmesis, John Wiley and Sons, 4* Edition, 2007). \n\n\n When amidines of general formula lS-1 are not commercially available, they may be prepared by a variety of method k i h li A idi only prepared from nitriles \n\n using the Pinner reaction and variations thereof (see Amidines and N-substituted amidines. Dunn, Peter J. in Comprehensive Organic Functional Group Transformations 1995, 5, 741-82, 1161-308 Editors): atrizky, Alan R.; Meth-Cohn, Otto; Rees, Charles Wayne. Publisher: Elsevier, Oxford, UK). Amidines may also be prepared from esters using the method reported by Gielen et al. (Gielen, H.; Alonso-Alija, C; Hendrix, M.; Niewohner, U.; Schauss, D. Tetrahedron Lett. 2002, 43, 419-21). \n\n\n In instances where the substituent A is selected to be a five-membered heterocyclic ring, it is possible that this heterocyclic group be bonded to the carbon atom at the 2-posttion of the pyrimidine ring through either a carbon-carbon or a carbon-nitrogen bond. In the case of attachment through a carbon-carbon bond, the precursor for the substituent A is an amidine of general formula lS-1 and the method using lS-1 for the synthesis of the title compound of general formula I is as described in the preceding reaction schemes. \n\n\n When a substituent A is attached through a carbon-nitrogen bond, the precursor for the substituent A is a guanidine of general formula 2S-7. In this example, the synthesis begins with the condensation of the guanidine derivative of general formula 2S-7 with compounds of general formula 2S- 8 (or a diethyl ethoxymethylenemalonate of general formula 1S-2 when it is desired that R3 = OH) to afford the substituted pyrimidine-5-carboxylate derivative of general formula 2S-9. Ester hydrolysis as described above affords compounds of formula 2S-10, which is useful to prepare compounds of general formula I wherein the group A is a five-membered heterocyclic group attached to the pyrimidine 2- position with a carbon-nitrogen bond. \n\n\n\n\n\n\n\n\n In cases when the guanidine derivative (2S-7) bearing the desired substituents is not commercially available, h may be synthesized using reported methods for guanidine synthesis (e.g. the guanidinylation of amines). Numerous methods for the guanidinylation of amines are reported (see Katritzky, A.R.; Rogovoy, B.V. ARKIVOC 2005, 4, 49-87; http://www.arkat- usa.org ark/journal 2005 I04 Zefirov/ 1256/1256.pdf). One general method is shown in Scheme 3, which \n\n entails the reaction of compounds of formula 3S-11 with 3,5-dimethyl-l-pyrazolylformamidinium nitrate to afford a guanidine of general formula 3S-12 using the method described by Fletcher et al. (Fletcher, D.L; Ganellin, C.R.; Piergentili, A.; Dunn, P.M.; Jenkinson, D.H. Bioorg. Med Chem. 2007, 15, 5457- 79). \n\n\n\n\n\n\n\n\n It is recognized that the title compounds of general formula I prepared as described above may be further modified using known methods and that the starting materials selected for use in the reaction schemes above may contain functional groups to enable said further transformation. For instance, aromatic rings in the title compounds of general formula I may be subjected to a variety of aromatic substitution reactions such as nitration, halogenation and the like. Aromatic substituent groups in the title compounds of general formula I bearing leaving groups such as halogens, triflates or the like, can be employed in a variety of metal-catalyzed cross coupling reactions to incorporate new substitution patterns. For example, palladium-catalyzed cross coupling reactions such as those described by Suzuki, Stille, Buchwald and others, may be used to introduce a variety of new substituent groups. Substituent groups that may be introduced using such cross-coupling methods include, but are not limited to, alkyl, alkenyl, alkynyl and aryl groups as well as acyl groups (e.g. carboxylic acids, esters, amides, or ketones), hydroxyl and amino or substituted amino groups. \n\n\n Other pyrimidines with various substituents at the 5-position (wherein R\" is not a carboxylate) are also prepared via cyclization reactions described in Schemes 1 & 2, which are exemplified in Scheme 4. \n\n\n\n\n\n\n\n\n\n\nFor example, compounds of formula 4S-15 are prepared when amidines lS-1 are cyclized with esters 4S-14 wherein X = O-alkyl under reaction conditions exemplified as in Scheme 1. Alternatively, compounds of formula 4S-14 wherein X = N(alkyl)2 are also cyclized with amidines lS-1 to give compounds of formula 4S-15 (Chen, W.; Feng, J.; Tu, H. Huaxue Tongbao, 2006, 69, 623-6). The esters 4S-14 can be prepared by reaction of esters 4S-13 with a substituted carboxamide dimethyl acetal. \n\n\n The methods presented in reaction Schemes 1 and 2 may be further generalized when it is desired to prepare compounds of general formula I where neither of the R.3 or R4 substiruents are hydroxyl groups. \n\n\nScheme 5 R* \n\n\n \n\n Reaction Scheme 5 illustrates the process beginning with a beta-ketoester of general formula 5S-16 bearing the R.3 substituent. The ester of general formula 5S-16 is condensed with a carboxamide dimethyl acetal of general formula 2S-8 to afford the vinylogous amide of general formula 5S-17. The intermediate 5S-17 is then reacted with an amidine derivative of general formula lS-1 using the method of Schenone et al. (Schenone, P.; Sansebastiano, L.; Mosti, L. J. Heterocyclic Chem. 1990, 27, 295) to afford the alkyl pyrimidine-5-carboxylate of general formula 5S-18. Hydrolysis of compounds of formula 5S-18 under suitable conditions (e.g. KOH or NaOH in EtOH-H\n2\n0, heating when necessary) produces compounds of formula 5S-19. The compounds of general formula 5S-19 are then converted to the title compounds of general formula I using the methods described previously. \n\n\n In one aspect, compounds of formula I are prepared via pyrimidine ring formation reactions (e.g. Schemes 1, 2, 4, 5) with the desired substituents (e.g. A, R\n2\n, R\n3\n and L) at various positions. In another aspect, the desired substituents on the pyrimidine core can be introduced after the pyrimidine ring is formed, which can be achieved using synthetic methods reported in the literature. For example, the hydroxy! group present at the pyrimidine 4-position in compounds of general formulae 1S-3, 1S-4, or 4S-15 may be converted to a halogen substituent upon reaction with a suitable halogenating reagent (e.g. POCb, BBr\n3\n, etc.). \n\n\n Compounds of general formula I wherein L is an amino or an amino derivative can be prepared from suitable pyrimidine derivatives such as 1S-4, 1S-6, 2S-10 and 5S-19 using synthetic methods reported in the literature. For example, carboxylic acids of formula 5S-19 are converted to their corresponding amines of formula 6S-20 using suitable methods such as Curtis rearrangement reactions, Scheme 6. The amino group in compounds of formula 6S-20 is further derivatized using common synthetic methods such as amide bond formation reactions (e.g. CDI couplings, EDCI couplings, reactions with acyl chlorides, etc.), sulfonamide bond formation reactions (e.g. reactions with sulfonyl chlorides in the presence of a suitable base), reductive amination reactions with a suitable carbonyl compounds (e.g. aldehydes and ketones). For example, compounds of formula I wherein L is -NHCO- and/or -NHSOr are prepared from compounds of formula 6S-20 as depicted in Scheme 6. In another aspect, carboxylic acids such as compounds of formula 5S-19 can be converted to their corresponding acyl azide such as compounds of formula 6S-22, and under suitable thermal rearrangement reaction conditions acyl azides such as 6S-22 can be converted to their corresponding isocyanate, and subsequent reactions of the resulting isocyanate with various nucleophiles such as alcohols, amines and thiols can produce compounds of formula 6S-23 wherein L is a carbamate (-NHCOO-), urea (-NHCONH-), or thiocarbamate (-NHCOS-). (March's advanced organic chemistry, Wiley-interscience, 2007; \n\n\nComprehensive Organic Transformations: a guide to functional group preparetions by Richard Larock, Wiley-VCH, 2000) \n\n\n\n\n\n\n\n\n\n\n General Methods \n\n\n Reactions sensitive to moisture or air were performed under nitrogen using anhydrous solvents and reagents. The progress of reactions was determined by either analytical thin layer chromatography (TLC) performed with E. Merck precoated TLC plates, silica gel 60F-254, layer thickness 0.2S mm or liquid chromatography-mass spectrum (LC-MS). Analytical HPLC/MS - Standard Method: Mass analysis was performed on a Waters Micromass* ZQ™ with electrospray ionization in positive ion detection mode. High performance liquid chromatography (HPLC) was conducted on an Agilent 1100 series HPLC on Waters C18 XTerra 3.5 urn 3.0 x50 mm column with gradient 10:90-100 v/v CH\n3\nC H\n2\n0 + v 0.05 % TFA over 3.75 min then hold at 100 C¾CN + v 0.05 % TFA for 1.75 min; flow rate 1.0 mL/min, UV wavelength 254 nm (all HPLC MS data was generated with this method unless indicated otherwise). Analytical HPLC/MS - Basic Method: Mass analysis was performed on a Waters Micromass* ZQ™ with electrospray ionization in positive ion detection mode. High performance liquid chromatography (HPLC) was conducted on an Agilent 1100 series HPLC on Waters C 18 XBridge 3.5 urn 3.0 x 50 mm column with gradient 10:90-98:2 v/v CH\n3\nCN H\n2\nO + v 0.025 % H4OH over 3.25 min then hold at 98:2 CH3C + v 0.025 % NH\n4\nOH for 2.25 min; flow rate 1.0 mUmin, UV wavelength 254 nm. Concentration of solutions was carried out on a rotary evaporator under reduced pressure. Flash chromatography was performed using a Biotage Horizon or SP1 Flash Chromatography apparatus (Dyax Corp.) on silica gel (32-63 uM particle size, KP-Sil 60 A packing material type) in pre-packed cartridges or using an ISCO CombiFlash™ Sq 16x or CombiFlash* Companion™ apparatus on silica gel (32-63 μΜ, 60 A) in pre-packed cartridges. Microwave reactions were carried out on a Biotage Initiator™ 2.0 or CEM Discover™ system. Preparative HPLC/MS - Standard Method: Mass analysis was performed on a Waters Micromass* ZQ™ with electrospray ionization in positive ion detection mode. High performance liquid chromatography (HPLC) was conducted on a Waters Prep. HPLC System on Waters C18 Sunfire 5 um 30 x 100 mm column with gradient 10:90-100 v/v CH\n3\nCN/H\n2\n0 + v 0.1 % TFA over 12 min; flow rate 50 mL min, UV wavelength 210-400 nm. \n\n Preparative HPLC/MS - Non-Polar Method \n\n\n Mass analysis was performed on a Waters Micromass* ZQ™ with electrospray ionization in positive ion detection mode. High performance liquid chromatography (HPLC) was conducted on a Waters Prep. HPLC System on Waters C18 Sunfire 5 um 30 x 100 mm column with gradient 40:60-100 v/v CH\n3\nCN H\n2\n0 + v 0.1 % TFA over 10 min then hold at 100 C¾CN + v 0.1 % TFA for 4 min; flow rate 50 mL min, UV wavelength 210-400 nm. \n\n\nPreparative HPLC/MS - Basic Method \n\n\n Mass analysis was performed on a Waters Micromass* ZQ™ with electrospray ionization in positive ion detection mode. High performance liquid chromatography (HPLC) was conducted on a Waters Prep. HPLC System on Waters C18 XBridge 5 um 50 x 150 mm column with gradient 10:90-35:65 v/v CH\n3\nCN/¾0 (pH = 10 with NH\n4\nOH) over 10 min; flow rate 120 mL min, UV wavelength 210-400 nm. \n\n\n\n\n\n\n\n\n Step A: 2-Tosv^23 iihvdn)Pvridazine-3-carbonitrile \n\n\n A solution of pyridazine (5 mL, 69.12 mmol) (Sigma-Aldrich), aluminum chloride (28 mg, 0.21 mmol) and TMSCN (16.75 mmol) in DCM (60 mL) was stirred under a nitrogen atomosphere at 0 \n•\nC for 20 min. A solution of TsCl (22.75g, 119.7 mmol) in DCM (40 mL) was added dropwise. The reaction was warmed to room temperature, stirred for an additional 60h, and concentrated in vacuo. The residue ws washed with EtOH (150 mL) and the resulting solids were filtered to afford the title \n\n compound 1-b (15 g, 83%). Ή NMR (300 MHz, CDC1\n3\n) 57.93 (d, J = 8.4 Hz, 2H), 7.38 (d, J = 1.8 Hz, 2H), 6.23-6.21 (m, 2H), 5.79 (d,J- 6.3 Hz, 1H), 2.44 (s, 3H). LC-MS: (M + H)\n+\n= 262. \n\n\nStep B: PvridazlBe-3-carbonttrile (1-c) \n\n\n To a solution of compound 1-b (9.0 g, 34.4 mmol) in THF (100 mL) was added DBU\n\n\n(6.5ml, 68.9mmol). The reaction was stirred at room temperature under a nitrogen atmosphere for 1 h. Saturated aqueous NH CI (100 mL) was poured into water (150 mL). The aqueous medium was extracted with EtOAc, dried, filtered and concentrated. The residue was washed with hexane (100 mL) to afford the title compound 1-c (2.7 g, 75%). Ή NMR (300 MHz, CDC1\n3\n) δ 9.40 (dd, J - 1.5, 5.1 Hz), 7.88 (dd, J~ 1.8, 8.4 Hz), 7.70 (dd, J - 5.1, 8.4 Hz). LC-MS: (M + H)\n+\n=106. \n\n\nStep C: Pvridazine-3-^rhn\n¾\nimiH\nfl\nniide hydrochloride <U-d) \n\n\n To a solution of compound 1-c (2.7 g, 25.7 mmol) in MeOH (25 mL) was added sodium methoxide (139 mg, 0.257 mmol). The reaction was stirred at room temperature overnight when ammonium chloride (1.65 g, 30.8 mmol) was added. The reaction was refluxed for 3 h, cooled to room temperature and concentrated to afford the crude product of 1-d (3.8 g, 93%).Ή NMR (300 MHz, DMSOt¾) δ 9.38 (dd, J = 1.5, 5.1 Hz, 1H), 8.30 (dd, J = 1.5, 8.7 Hz , 1H), 7.92 (dd, J = 5.1, 8.4 Hz, 1H). LC-MS: (M + H)\n+\n 123. Sfrp P\nt\n Methvl 4-hvdrory-2 DYridaan-3-vnDvrimidine-5-carb xvlate \n\n\n A mixture of crude compound 1-d (20.0 g, 34.4 mmol), diethyl ethoxymethylenemalonate (35.0 g 162 mmol) and sodium methoxide (10.0 g, 185 mmol) in MeOH (1000 mL) was refluxed overnight. The reaction mixture was cooled and concentrated to remove the solvent and the residue was added to water (500 mL), extracted with EtOAc (500 mL). The organic phase was adjusted to pH= 2 by addition of aq. HC1. The solids were filtered to afford the product 11-e (15.0 g, 39%). LC-MS: (M + H) \n+\n =233. \n\n\nStep E: 4-fbeiizyloxy 2^Dyridazin-3-vnpYriinidine-S-carboiyllc acid ( 1-f) \n\n\n A mixture of compound 11-e ( 1.5g, 6.316 mmol) and PPh\n3\n (3.39 g, 12.98 mmol) in THF ( 50 mL) was drop wise added with DEAD ( 2.26 g, 12.98 mmol) and stirred at room temperature for 30 min. Then BnOH (0.84 g, 7.75 mmol) was added and the mixture was stirred for additional 12 h at room temperature. The reaction mixture was concentrated. The residue was purified by chromatography column with eluent PE: EA = 2:1 to afford crude 11-f. \n\n\n A solution of the crude compound (2.1 g, crude) in MeOH (30 mL) was added with aqueous LiOH (0.55 g, 12.9 mmol, 1M) and stirred at room temperature for overnight. The reaction mixture was concentrated, dissolved in water (30 mL), and extracted with EtOAc (50 mL). The aqueous \n\n layer was adjusted to pH= 2 by addition of aq. HC1. The solids were filtered to afford the product 1-f (400 mg, 21%) LC-MS: (M+H)\n+\n - 309. \n\n\nStep F; 4-flieiizyloiv 2- PYridaziiH3-yl)pyrimidine-5-carborylic acid ( 1-g) \n\n\n A mixture of compound 1-f (200 mg, 0.649 mmol), DPPA ( 196 mg, 0.71 mmol), Et\n3\nN ( 197 mg, 1.95 mmol) and BnOH (105 mg, 0.97 mmol) in THF/ toluene (20 mL, 1:1) was stirred at 65 Ό overnight The reaction mixture was concentrated and purified by chromatography column with eluent PE: EA = 2:1 to afford the product 1-g (160 mg, 60%). LC-MS: (M+H)\n+\n = 414. \n\n\nSteo G: 4^benzvloxvV2-fDvridazin-3-vriDvrimidine-S-carboxvUc add (1-V \n\n\n A solution of compound 1-g (160 mg, 0.387 mmol) in MeOH (5 mL) was added with Pd/ C (10%, 0.15 g) and stirred under hydrogen for 5 h. The mixture was filtered and the solution was concentrated to afford the crude product 11-h (450 mg). LC-MS: (M+H)\n+\n - 190. Example 2 \n\n\n\n\n\n\n\n\n Step A; 4-hvdroxy-2-f lH-pYrazoI-l-yl)pyrimidine-S-carboxylic acid (2-c) \n\n\nTo lH-pyrarole-l-carboximidamide hydrochloride (Sigma-Aldrich), 2-a, (44.22 g, 299 mmol) in EtOH (500 mL) was added sodium methoxide ( 102 mL, 448 mmo), 25 wt% in MeOH) and diethyl ethoxymethylenemalonate (Sigma-Aldrich), 2-b, (61.0 mL, 299 mmol, 99%). The reaction was heated for about 40 min at 75 °C and then cooled slightly (71 °C) before adding potassium hydroxide \n\n (33.5 g, 597) in water (] 25 mL). The reaction was heated to 75 °C for lh. During this time an additional portion of EtOH (100 mL) was added to improve mixing. The reaction was cooled to 40 °C before adding aqueous HC1 (81.3 mL, 991 mmol, 37%) in portions. The reaction aged for 1 h 40 min and then Et20 (180 mL) was added. The solids were filtered and rinsed with EtOH, Et20, and then hexane. The solid was men suspended in aqueous HC1 (300 mL, 0.67 M), filtered and washed with aqueous HC1 (300 mL, 1 ), 2:1 Et\n2\n0:EtOH (350 mL), 1:1 Et EtOH (200 mL), Et\n2\n0 (150 mL) and then hexane (150 mL) to afford the compound, 2-c. HPLC/MS: 207.2 (M+l); Rt - 0.61 min. \n\n\n Step B; Benzvl 4^iizvloxvV2 1H-Dvrazo^l-vnDvrimidine-S-carboxvlatc (2-d) \n\n\nTo a solution of 4-hydroxy-2^1H-pyrazol-l-yl)pyrimidine-5-<iariwxylic acid, 2-c, (lg, 4.85mmol) in DMF (40ml) was added K2CO3 (2.34g, 16.98mmol) and benzyl bromide ( 1.83g, \n\n\n 10.67mmol). The mixture was heated at 70°C for 16 hours. The solution was then cooled to room temperature and diluted with water followed by extraction with ethyl acetate. The combined organic layer was washed with water, dried over sodium sulfate and concentrated under vacuum to provide the crude product, 2-d, as a solid (1.2g). Step C; 4^η.^οχν 2 1Η-ρνΓ¾^1-1-νηρντΰηίάίηΒ-5-θ8Γ5ο νΗ€ acid (2-e) \n\n\nTo a solution of benzyl 4-(benzyloxy 2-(lH-pyraz l-l-yl)ryrimidine-5-carb^ 2-d, (2g crude) in EtOH(20mJ)/THF (20ml) water (20ml) was added KOH (0.87g, 15.5mmol). The mixture was stirred at room temperature for 12 hours. The mixture was then concentrated under vacuum and the residue was diluted with water and basified to pH=2 with HC1 followed by extraction with ethyl acetate. The organic layer was brine washed, dried over sodium sulfate and concentrated under vacuum. The residue was purified on a silica gel column with the eluent of petroleum ether/ethyl acetate=7/l to afford the compound 2-e (200mg, 13%). \n\n\nStep D: 4-(b nzvloiv>-2-ilH-pvrazQl-l-vnDvrimidin-5-amine (2-f) \n\n\n4-(benzyloxy 2-(lH-pyra2ol-l-yl)pyrimidine-5-carboxylic acid, 2-e, (200mg, 0.68mmol) was dissolved in THF (20ml) and treated with Et\n3\nN (204mg, 2.02mmol) and DPPA (204mg, 0.74mmol). The mixture was heated at 66°C for 12 hours. Then water was added and the resulting mixture was continued to stir at reflux for 2h. After that the mixture was concentrated under vacuum. The residue was diluted with aq. \n2\nC0\n3\n followed by extraction with ethyl acetate. The organic layer was dried over sodium sulfate and concentrated under vacuum. The residue was purified on silica gel column with the eluent of dichloromethane/methanol=50/l(Rf=0.7) to provide compound 2-f (72mg, 40%). \n\n\n\n\n\n\n\nSteo E; N^4-hvdro3cv-2^1H-DYrazo^l-vl Dvrimidin-5.vlV-2^iDhenvIacetamide r2-n \n\n\n2,2-diphenylacetic acid (110 mg, 0.52 mmol) was dissolved in DMF (10 mL) and EDC (100 mg, 0.52 mmol) and HOBt (70 mg, 0.52 mmol) were added. The mixture was stirred at rt for 5 mins before Et3N (130 mg, 1.3 mmol) and compound 2-f (115 mg, 0.43 mmol) were added. The resulting mixture was stirred at the ambient temperature for 24 h. The resulting mixture was diluted with water followed by extraction with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate and concentrated under vacuum. The residue was purified on silica gel column with the eluent of ethyl acetate/petroleum ether=l/3 (R\nf\n= 0.7) to afford an intermediate (80 mg, 40%). The intermediate, prepared as above, was hydrogenated with hydrogen balloon in methanol\n\n\n(15 mL) and Pd/C (20 mg) at room temperature for 16 hours. The mixture was filtered and the filtrate was concentrated under vacuum. The residue was purified by prep-HPLC to provide the product, 2-1, as a white solid (10 mg). Ή NMR (300 MHz, CDjOD): δ 8.78(s, lH), 8.48(d, J 2A Hz, 1H), 7.83(s, 1H), 7.24(m, 10H), 6.58(s, IH), 5.37(s, 1H). LC-MS: (M+H)\n+\n =372. \n\n\n \n\n Step A: Ethvl 4-hvdrorv-2 1H-Dvrazol-l-vnDvrimidine-5-carboxvlate (3-a¾ \n\n\n1 H-pyrazole- 1 -carboximidamide hydrochloride, compound 2-a from Example 2, (22.11 g, O.lSmol) in EtOH (250ml) was added sodium methoxide (12.3g, 0.23mol) and diethyl \n\n\nethoxymethylenemalonate, compound 2-b from Example 2, (30ml, 0.1 Smol). The reaction was heated for about 40 min at 75 °C and then cooled to room temperature. The mixture was filtered and the solid was washed with ethanol and ether and dried under vacuum to give compound 3-a (21 g, 60%). \n!\nH NMR (DMSO-d6, 300ΜΗζ,):δ 8.50(m, 2H), 7.70(s, 1H), 6.47(m, 1H), 4.13(m, 2H), 1.24(m, 3H). \n\n\nSteP B; Ethvl 4-H enzvlo¾vV2-riH-Dvrazol-l-vnpvrimidine-S-carboivlate (3-b) To a solution of ethyl 4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidine-5-carboxylate, 3-a,\n\n\n(0.62g, 2.7mmol) in DMF (7ml) were added benzyl chloride (0.5g, 3.99mmol) and Et\n3\nN (0.8g, \n\n\n7.97mmol). The resulting mixture was then heated at 60°C for 12 hours. Then the mixture was cooled to room temperature and diluted with water followed by extraction with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate and concentrated under vacuum. The residue was purified on silica gel column with the eluent of ethyl acetate petroleum ether=l/l (Rf=0.7) to afford the compound, 3-b, (0.36g, 42%). \n\n\nStep C: 4-fbeiizvloxvV2^1H-DVi^l-l-vnDvrimidine-S-carboxvlic acid (3-ci \n\n\nEthyl 4-(benzyloxy)-2-(lH-pyraz»l-l-yl)pyi½^ 3-b, (150g, 0.46mol) in THF (1.5L) was treated with LiOH monohydrate (58g, 1.39mol) in water (60ml) at room temperature for 3 hours. The mixture was concentrated under vacuum and diluted with water (200ml) followed by extraction with ethyl acetate. The aqueous layer was acidified to pH=2 with 10% HC1 and solid crushed out from the solution which was then filtered and washed with water to afford the compound, 3-c. (40g, 29%). \n\n\nSte D; Benzvl 4-H>enCTloxvV2-f lH-pvrazol-l-vnpYrimidin-5-vlcarbamate (3-d¾ To a solution of 4-(benzyloxy)-2-(lH-pyrazol-l-yl)pyrimidin acid, 3-c,\n\n\n(2g, 6.76 mmol) in dry THF (40ml) and toluene (40ml) were added Et\n3\nN (2.04g, 20.3mmol), DPPA (2.04g, 7.43 mmol) and benzyl alcohol (l.lg, 10.1 mmol). The resulting mixture was heated at 60°C for 12 hours. The mixture was concentrated under vacuum and the residue was purified on silica gel column with the eluent of ethyl acetate petroleum ether=l/5 (Rf=0.6) to provide the compound, 3-d (1.96g, 72.6%). Ή NMR (DMSO-d*, 300ΜΗζ,):δ 9.39(br, 1H), 8.73(s, IH), 8.62(s, 1H), 7.83(s, 1 H), 7.56(m, 2H), 7.33(m, 8H), 6.57(m, IH), 5.58(s, 2H), 5.16(s, 2H). \n\n Steo E: S-amino-2 1H-Dvrazol-l-vnDvrimidin-4-ol (3-ei \n\n\nBenzyl 4^benzyloxy 2 lH-pyrazol-l-yl)pyrimidin-5-ylcarbam^ 3-d, (1.96g, 4.9mmol) was hydrogen ated with hydrogen ballon in THF(20ml) and Pd/C (200mg) at room temperature for 12 hours. The mixture was filtered through a celite pad and the filtrate was concentrated under vacuum to provide the compound, 3-e (0.8g, 93%). Ή NMR (DMSO-de, 300ΜΗζ,):δ 8.39(s, 1H), 7.80(s, 1H), 7.20(s, 1H), 6.56(m, 1H), 5.00(br, 2H). \n\n\nExample 3 \n\n\n\n\n\n\n\n\n Step A: Preparation of acid chloride \n\n\n An appropriate carboxylic acid (commercially available, purchased and used as received, 1 mmol) containing the desired R group of compounds 3-f was heated at reflux in excess thionylchloride for 2 hours. The cooled reaction mixture was concentrated under vacuum and the residue was co- evaporated with anhydrous dichloromethane to give the desired acid chloride. \n\n\nStep B: Preparation of amides (Reversed amide 3-f) \n\n\n5-amino-2 lH-pyrazol-l-yl)pyrimidin-4-ol, 3-e, (1 mmol) and Et\n3\nN (2mmols) were dissolved in dichloromethane(5ml) and cooled to 0 °C. The appropriate concentrated acid chloride (1 mmol) made in Step A was further diluted in dichloromethane(5ml) to form a mixture. This acid chloride mixture was then added dropwise to the solution containing 3-e and Et\n3\nN to form a reaction mixture. The reaction mixture was allowed to stir at room temperature for additional 3 hours. The reaction mixture was concentrated under vacuum and the residue was taken into THF (10ml) and treated with 2N lithium hydroxide (10ml) The mixture was stirred at room temperature for 30 min to 12 hours. \n\n For some of the compounds (ca. 20%) a solid precipitated out, thus the solid was collected via filtration to provide the product For compounds that did not precipitate out, the THF layer was separated and concentrated to afford the crude product, which was further purified by recrystallization using a mixed solvent system of petroleum ether/ethyl acetate/methanol (solvent ratio was optimized for each compound to produce the best crystallization conditions). \n\n\nTable 1 discloses compounds 3-1 through 3-55 that were made in accordance to the general procedure outlined in Example 3 and by utilizing the appropriate carboxylic acid. Table 1 \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n General procedure for Compound 4-a \n\n\n5-amino-2-( 1 H-pyrazol- 1 -yl) pyrimidin-4-ol (1.44mmol) (3-e) was dissolved pyridine(5ml) and cooled to 0°C. Sulfonyl chloride (1.58minol) was added dropwise. The resulting \n\n mixture was allowed to stir at room temperature for additional 3 hours. The mixture was concentrated under vacuum and the residue was diluted with formic acid (10ml) and water (10ml). A solid precipitated out of solution. The solid was then filtered out of solution. The crude solid was recrystallized (methanol, ethyl acetate or tetrafuran) to provide the product. \n\n\n Compounds 4-1 through 4-4 were prepared in a manner similar to that described in the general procedure of Example 4-a by substituting the appropriate R group. Table 2 shows compounds 4-1 through 4-4. \n\n\nTable 2 \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nAzido^4-n egzYloxvV2-riH-Dvrazol-l-vnDvrimidin-S-TDmethanone f5-a \n\n\n4-(beiizyloxy}-2-(lH-pyrazol-l-yl)pyrimidm acid (3-c) was synthesized in a manner outlined in Steps A through Step C of the synthesis of Intermediate 3-e. \n\n\nTo a solution of 4-(benzyloxy)-2-(lH-pyrazol-l-yl)pyrimW^ acid, 3-c, (500 mg, 1.69 mmol) in dry dichloromethane (10 ml) was added dropwise oxalyl chloride (0.29 ml, 3.38 mmol) at 0 °C and a catalytic amount of DMF (3-5 drops). The mixture was stirred at room temperature for 3 hours. Then the mixture was concentrated under vacuum and the residue was dissolved in acetone (10 ml). Et\n3\nN (205mg, 2.03 mmol) was added at 0 °C and the mixture was stirred for 5 mins before sodium azide (988 mg, 15.2 mmol) in water (1 ml) was added. The resulting mixture was stirred at room temperature for lh. Subsequently, the mixture was diluted with water and filtered. The solid was washed with water (5-10 ml) and then taken into approximately 20-30 mL of dichloromethane. The organic layer was dried over sodium sulfate and concentrated under vacuum to provide compound 5-a as a solid(130 mg) which was used in Step B without any further purification. (M+H)\n+\n=322. \n\n\nThe yyp f hesfo of fte Carb rnqteftTrea ff-b) \n\n\n \n\n To a solution of aado(4^benzyloxy 2-(lH-pyra^ 5-a, (1 mmol) in anhydrous toluene (10 ml) was added the appropriate amine or alcohol (purchased and used as received, 1.2 mmol). The resulting mixture was heated at reflux under nitrogen 5 hours. The mixture was concentrated under vacuum and the residue was purified on silica gel column with the eluent of ethyl acetate petroleum ether=l 2, v/v, (Rf = 0.2) to provide the desired product. \n\n\nSft Pf?)} Pe-benzvlationfCarbamate/Urea 1\n)\n The desired urea or carbamate obtained in Step B( 1 ) was dissolved in THF( 10ml) and treated with Pd(OH)2(10% amount). The mixture underwent hydrogenation at room temperature and 1 atm (a balloon filled with hydrogen) of hydrogen for 5 hours. The mixture was filtered and the filtrate was concentrated under vacuum. The residue was purified by prep-HPLC to provide the desired product. \n\n\n Table 3 discloses compounds 5-1 through 5-11 that were made in accordance to the general procedure outlined in Example 5 and by utilizing the appropriate urea or carbamate. \n\n\nTable 3 \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n l-benzhvdrvl-3-f4-hvdroiv-2-ilH-Dvra2ol-l-vnDvrimidiD-5-vnthionrea(6-l) \n\n\n 5-amino-2-( 1 H-pyrazol- 1 -yl)pyTimidin-4-ol, 3-e(Sigma-Aldricb), (44mg, 0.25mmol) and isothiocyanatodiphenylmethane (56mg, 0.25mmol) were dissolved in dry THF and the mixture was stirred at reflux for 60 hours. Then the mixture was filtered. The solid was washed with MeOH and purified by pre-HPLC to give the title compound, 6-1. Ή NMR (DMSO-d«, 300MHz,): δ 12.72(br, 1H), 9.2 (br, 3H), 8.50(d, lH), 7.96(s, lH), 7.23(m, lOH), 6.65(m, 2H). (M+H)\n+\n=403.1. \n\n\n Example 7-1 \n\n\n l-(4-hvdroxv-2^1H-Dvrazo l-vnDv^^ \n\n\n 5-amino-2-(lH-pyrazol-l-yl)pyrimidin-4-ol, 3-e, (lOOmg, 0.56mmol) and alpha- methylbenzyl isothiocyanate (Sigma-Aldrich) (92mg, 0.56mmol) were dissolved in dry THF and the mixture was stirred at reflux for 60 hours. Then the mixture was filtered. The solid was washed with MeOH and purified by pre-HPLC to give the title compound, 7-1. Ή NMR (DMSO-d«, 300MHz,): δ 9.21(br, 3H), 8.50(d, 1H), 7.95(s, 1H), 7.22<m, SH), 6.65(s, 2H), 5.41(m, 1H), 1.41(d, 3H). \n\n\n (M+H)\n+\n=341.1. \n\n\n\n\n\n\n\n\n l-f4-hvdroiy-2-aH-Pvi^l-l-vnDvrim^ \n\n\n 2-phenylpropan-2-amine (500mg, 3.7mmol) and Et3 (747mg, 7.4mmol) was dissolved in dry ethyl acetate (10ml), thiophosgene (425mg, 3.7mmol) was added dropwise to the mixture at 0°C.\n\n\nThe reaction mixture was warmed to room temperature and stirred for 2 hours. The mixture was washed with water and brine, dried and concentrated. The residue was dissolved in THF (10ml) and 5-amino-2-\n\n\n(1 H-pyrazol- l-yl)pyrimidin-4-ol, 3-e, (655mg, 3.7mmol) was added. The resulting mixture was reflux ed \n\n for 60 hours. Then it was filtered and the solid was washed with MeOH and purified by pre-HPLC to give the title compound, 8-1. Ή NMR (DMSO-de, 300MHz,): δ I2.62(br, lH), 9.23(br, IH), 8.49(m, lH), 7.93(s, IH), 7.13(m, 5H), 6.64(m, 1H), 1.70(s, 6H). (M+H)\n+\n=355.1. \n\n\n\n\n\n\n\n\nbenzhvdryl 4-hvdroxv-2-ClH-Dvrazol-l-Ynpvrimidine-5-€arboxvlate (9-1) \n\n\n To a solution of 4-(benzyloxy)-2-(lH-pyrazol-l-yl)pyrimidme-5-car^ acid, 2-e, (Ig, 3.38mmol) in dry DCM (20ml) was added dropwise oxalyl chloride (0.44ml, 5.07mmol) at 0°C and catalytic DMF. The reaction mixture was stirred for 3 hours at room temperature. Then it was concentrated under vacuum and the residue was dissolve in DCM (10ml). To the mixture was added dropwise a solution of diphenylmethanol (685mg, 3.72mmol) and E.3N(1.02g, lO.lmmol) in DCM (20ml) at 0°C. The resulting mixture was stirred at room temperature for 3 hours. The resulting mixture was then concentrated and the residue was purified on silica gel (petroleum ether/ethyl acetate=3/l) to give an ester (0.9g, 58%). \n\n\n The ester (200mg, 0.43mmol) was dissolved in dry THF (10ml) and Pd(OHyC (30mg) was added. The reaction mixture was stirred under ¾ balloon at room temperature for S hours. The mixture was filtered and the filtrate was concentrate under vacuum. The residue was purified by pre- HPLC to give the title compound, 9-1. Ή NMR (DMSO-de, 300MHz,): δ 8.76(br, lH), 8.60(d, IH), 7.99(s, IH), 7.27(m, 1 IH), 6.98(s, IH), 6.68(m, IH). (M+Na)\n4\n=395.1. \n\n\n\n\n\n\n\n\n\n\n SSSBLAI Pfco)in¾mjd\n-n\ne hydrochloride flo-b) \n\n\nTo a solution of 2-cyanopyridine (10-a) (Sigma-Aldrich) (lOOg, 0.95mol) in methanol (1.5L) under nitrogen was added sodium methoxide (2.5g, 44mmoJ). The reaction mixture was stirred at room temperature for 24 hours. Ammonium chloride (53.5g, lmol) was added to the reaction mixture. The mixture was stirred at room temperature for 4h and the solvent was removed in vacuo. The residue was washed with ipropanol/ethyl acetate=l/10 and dried in vacuo to provide compound 10-b (lOOg, 66%). \n\n\n Step B: 4-hvdroiY-2 Dvridiji-2-vnDvrimidine-5-carhoxvlic acid (10-c) \n\n\nTo picolinamidine hydrochloride (10-b) (112 g, 0.71mol) in MeOH (1.1L) was added sodium methoxide (39.4g, 0.7 lmol) and diethyl ethoxymethylenemalonate (2-b) (142g, 0.71 mol). The reaction was heated at reflux overnight and then cooled to room temperature. The resulting mixture was filtered and to the filtrate was added potassium hydroxide (71.4 g, 1.37 mol) in water (265 mL). The reaction was heated at reflux for 2h. The reaction mixture was cooled to room temperature before adding cone. HC1 (37 %, 180 mL, 2.35 mol) in portions. The reaction aged for 2 h. The solids were filtered and rinsed with EtOH, Et\n2\n0 and then hexane to provide compound 10-c (HOg, 65%). \n\n Steo C: Benzvl 4-hvdroxY-2-fDvridin-2-vnDvrimidin-5-vlcarfaamate fl0-d¾ \n\n\nTo a solution of 4-hydroxy-2-(pyridin-2-yl)pyrimidine-5-cart)oxylic acid (10-c) (10g, 46mmol) in toluene (150ml) was added DPPA(13.94g, 50.6mmol), Et\n3\nN (9.31, 92.1mmol) and benzyl alcohol (14.93g, 0.14mol). The resulting mixture was heated at reflux overnight Then the mixture was concentrated under vacuum and the residue was purified on silica gel chromatography with the eluent of petroleum ether/ethyl acetate=l/5, v/v, (Rf\n«\n=0.3) to afford the crude compound 10-d (3.2g). The sample delivered was re-purified on prep-HPLC. Ή R (DMSO-d6, 300ΜΗζ,):δ 8.73(m, 1H), 8.40(m, 2H), 8.00(m, 1H), 7.37(m, 6H), 5.19(s, 1H). (M+H)\n+\n=323.1. \n\n\n5-atnino-2-('pvridin-2-vnDvriinldin-4-ol (10-e) \n\n\nBenzyl 4-hydroxy-2-(pyridin-2-yI)pyrimidin-5-ylcarbamate (10-d) (Ig, 3.1mmol) in methanol (20ml) was hydrogenated under 1 atm of hydrogen in the presence of Pd C (500mg) overnight. The mixture was filtered and the filtrate was concentrated to provide the crude product, 10-e (240mg). \n\n\nSteo E; N-f4-hvdroxv-2-fDvridin-2-vnDvr^ To a solution of 5-ammo-2-(pyridin-2-yl)pyrimidin-4-ol (10-e) (120mg, 0.64mmol) in MeCN (5ml) were added HATU (254mg, 0.67mmol), Et\n3\nN (130mg, 1.28mmol) and 2^-dipbenylacetic acid (135mg, 0.64mmol). The resulting mixture was stirred at room temperature for lhour. Then the mixture was diluted with water and followed by extraction with dichloromethane. The organic layer was washed with brine, dried over sodium sulfate and concentrated under vacuum. The residue was purified by prep- HPLC to provide compound 10-1. Ή NMR (DMSO-d*, 300ΜΗζ,):δ 12.50(br, 1H), 9.85(br, 1H), 8.73(m, 2H), 8.10(m, 1H), 8.00(m, 1H), 7.60(m, 1H), 7.35(m, 10H), 5.75 (s, 1H). (M+H)\n+\n-383.2. \n\n\nExample 11 \n\n\n Synthetic route \n\n\n \n\n Table 4 \n\n\n\n\n\n\n\n\n Example 12 \n\n\n\n\n\n\n\n\n Step A Ethvl 2^4^benzvlo¾vV-2-flH-pvimol-l-vnpvrimidin-S-vnacetate (12-b) \n\n\n To a solution of 4-(benzyloxy)-2-(lH-pyrazol-l-yl)pyrim acid, (3- c),(500mg, 1.69mmol) in dry DCM (10ml) was added dropwise oxalyl chloride (0.29ml, 3.38 mmol) at 0°C. Subsequently, one drop of DMF was added. The reaction mixture was stirred for 3 hours at room temperature. The mixture was concentrated under vacuum and the residue was dissolved in DCM (Sml). The resulting solution was added dropwise to a solution of TMSCHN\n2\n(193mg, 8.45mmol) and \n\n\n Et\n3\nN(512mg, 5.07mmol) in DCM(20ml) at 0°C. The mixture was stirred at room temperature overnight. The mixture was then concentrated under vacuum to give the diazo compound as a brown solid (crude product). \n\n To a solution of the diazo compound (397mg, 1.24mmol) in EtOH (5ml) was added Ag\n2\n0 (287mg, 1.24mmol). The mixture was then stirred at room temperature for 2 hours. The mixture was heated to SO °C and stirred for 1 hour. The mixture was filtered and the filtrate was concentrated under vacuum. The residue was purified by silica gel (PE EA=5: 1 ) to give compound 12-b as a yellow oil (90mg, 21.5%). Ή MR (CDCl\n3\n-<¼, 300 MHz,): δ 8.51 (s, 1 H), 8.34 (s, 1 H), 7.81 (s, 1 H), 7.32-7.44 (m, 5H), 6.46 (s, 2H), 5.54 (s, 2H), 4.07-4.14 (q, 2H), 3.58 (s, 2H), 1.15-1.20 (t, 3H). (M+H)\n+\n=339.2. \n\n\nSte B 2^4 beiizyloivV-2^1H-pyrazo---l-vnpyrimidin-S-yl)acetlc acid (12-c \n\n\n To a solution of ethyl 2-(4-(benzyloxy)-2-(lH-pynizol-l-yl)pyrimidin-5-yl)acetate, 12-b, (90mg, 0.27mmol) in THF (6ml) was added LiOH monohydrate (19mg, 0.8mmol) in H\n2\n0(3ml). The mixture was stirred at room temperature for 3 hours. The mixture was concentrated under vacuum and the remaining aqueous solution was extracted with ethyl acetate (5ml). The separated aqueous phase was adjusted to pH=2 with Cone. HC1. The solid crashed out and was filtered to give compound 12-c(40mg, 48.5%). ¾ NMR (DMSO-tfc, 300 MHz,): δ 12.56 (s, 1H), 8.66 (s, 1H), 8.47 (s, 1H), 7.84 (S, 1H),7.32- 7.52 (M, 5H), 6.59 (s, 1H), 5.57 (S, 2H), 3.61 (s, 2H). (M+H)\n+\n=311.1. \n\n\nSiSEjQ 2^4-hvdrory-2-ilH-Dvrazo^l-vnDvrinildin-S-vnacetic acid (12-d \n\n\n To a solution of 2-(4-(benzyloxy)-2-(lH-pyra-a)l-l-yl)pyruOidm-5-yl)acetic acid, 12-c, (1.239g, 4mmol) in THF (40ml) was added PdiOHVC (0.14g). The resulting mixture was hydrogenated at room temperature at 1 atm overnight The mixture was filtered and the filtrate was concentrate under vacuum to give compound 12-d (800mg, 91%). Ή NMR (DMSO-tfi, 300 MHz,): δ 12.59 (s, 2H), 8.53 (s, 1H), 7.89 (s, 2H), 6.61 (s, 1H), 3.37 (s, 2H). (M+H)\n+\n=221.1. \n\n\n ?tep P N-^4-ch oroDhenvl -2-f4-hvdroiv-2-flH-Dvrazo^l-Yr Dvrimidin-5-vn \n\n\n ace^nn^e AH) \n\n\n To a solution of 2-(4-hydroxy-2-( 1 H-pyrazol- 1 -yl)pyrimidin-5-yl)acetic acid, 12-d,\n\n\n(150mg, 0.68mmol) and HOBt (101.2mg, 0.75mmol) in DMF(5ml) was added EDC.HC1 (144mg, 0.75mmol) and DIEPA(264mg, 2.05mmol). The solution was stirred at room temperature for 5 mins before the addition of the chlorophenyl amine (0.75mmol) (Sigma-Aldrich). The mixture was stirred at room temperature for 24 hours. The mixture was then diluted with water and extracted with ethyl acetate. The organic layer was concentrated under vacuum and the residue was purified by silica gel column or Prep-HPLC to give the final compound 12-1. Ή NMR (DMSO-c , 300 MHz,): δ 10.23 (s, 1H), 8.56 (d, 1H), 7.92 (s, 1H), 7.63 (d, 2H), 7.37 (d, 2H), 6.64 (s, 1H), 3.53 (s, 2H). (M+H)\n+\n=330.1. \n\n\nIn addition to compound 12-1, Table 5 discloses compounds 12-2 and 12-3 that were made in accordance to the general procedure outlined in Example 13 and by utilizing the appropriate amine. \n\n Table 5 \n\n\n\n\n\n\n\n\nExample 13 \n\n\n\n\n\n\n\n\n4-hvdroxY-2^Dvridaztn-3-vlVN-tosvlDvrimidine-5-carboiamide Q3-1) \n\n\n 4-hydroxy-2-(pyridazin-3-yl) pyrimidine-5-carboxylic acid, 13-b, (350mg, 1.6 mmol, which was prepared f om compound 1-e via sodium hydroxide hydrolysis in a similar manner as the conversion of 3-b to 3-c) in thionyl chloride (10 ml) was heated at reflux for 4h. The mixture was concentrated under vacuum and the residue was co-evaporated with dichloromethane twice. The remaining oil was dissolved in dichloromethane (10ml). /7-toluenesulfonamide (329mg, 1.93 mmol), triethylamine (486mg, 4.82mmol) and DMAP (390mg, 3.2mmol) were added to the solution at room temperature. The mixture was subsequently stirred at room temperature overnight. The mixture was then concentrated under vacuum and the residue was diluted with water (10ml). The solid crashed out and then filtered out of the solution. The solids were then recrystallization in methanol ethyl acetate to afford compound 13-1 (300mg, 50%). \n]\nH NMR (DMSO^j, 300 MHz,): δ 12.92 (br, 1H), 9.51 (s, 1H), 8.53 (s, 2H), 8.00 (m, 3H), 7.46 (s, 2H), 2.41 (s, 3H). (M+H)\n+\n=372.1. \n\n Biological Away? \n\n\n The exemplified compounds, Examples 1 through 13 of the present invention, have been found to inhibit the interaction between PHD2 and a HIF peptide and exhibit IC50 values ranging between 0.1 nanomolar to 10 micromolar. Non-limiting examples of assays that may be useful to detect favorable activity are disclosed in the following publications: Oehme, F., et al., Anal. Biochem. 330:74- 80 (2004); Hirsilft, M, et al., J. Bio. Chem. 278 (33): 30772-30780 (2005); Hyunju, C, et al., Biochem. Bjophys, Res, Comm. 330 (2005) 275-280; and Hewitson, K. S., et al., Methods in Enzvmologv. (Oxygen Biology and Hypoxia); Elsevier Publisher (2007), pg. 25-42 (ISSN: 0076-6879). \n\n\n The biological activity of the present compounds may be evaluated using assays described herein below: \n\n\n To each well of a 96-well plate was added 1 uL of test compound in DMSO and 20 μΐ of assay buffer (50 mM Tris pH 7.4/0.01% Tween-20/0.1 mg ml bovine serum albumin 10 μΜ ferrous sulfate/1 mM sodium ascorbate/20 μ^πιΐ catalase) containing 0.15 g ml FLAG-tagged full length PHD2 expressed in and purified from baculovirus-infected Sf9 cells. After a 30 min preincubation at room temperature, the enzymatic reactions were initiated by the addition of 4 μΐ, of substrates (final concentrations of 0.2 μΜ 2-oxoglutarate and 0.5 μΜ HIF- la peptide biotinyl- DLDLEMLAPYIPMDDDFQL (SEQ ID NO: 1)). After 2 hr at room temperature, the reactions were terminated and signals were developed by the addition of a 25 μί, quench detection mix to a final concentration of 1 mM ortho-phenanthroline, 0.1 mM EDTA, 0.5 nM anti-{His)6 LANCE reagent (Perkin-Elmer Life Sciences), 100 nM AF647-labeled streptavidin (Invitrogen), and 2 μg/ml (His)6-VHL complex (S. Tan (2001) Protein Expr. Purif. 21, 224-234). The ratio of time resolved fluorescence signals at 665 and 620 nm was determined, and percent inhibition was calculated relative to an uninhibited control sample run in parallel. \n\n\n Inhibition of the catalytic activity of HlP-PHDl and HIF-PHD3 can be determined similarly. \n\n\n Table 6 depicts the inhibition of HIF PHD2 activity expressed as IC50 (nM), for the exemplified compounds, 1-1, 1-2, 2-1, 3-1 to 3-6, 4-1, and 5-1 of the present invention. \n\n\n TABLE 6 \n\n\n PHD2 Inhibition Activity \n\n\n + = 0.5 < IC\n5\no < 20 (nM) \n\n\n ++ = 20 < IC\n5\no < 100 (nM) \n\n\n +++ = 100 <IC\n50\n < ΙΟΟΟΟ(ηΜ)"
  },
  {
    "id": "WO2011132048A1",
    "text": "Heteroaryl compounds as pde10a inhibitors AbstractThe present invention provides heteroaryl compounds as Phosphodiesterase 10A (PDE I OA) inhibitors. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders by inhibiting Phosphodiesterase 10A enzyme. Also provided herein are processes for preparing compounds described herein, Formula (I), intermediates used in their synthesis, pharmaceutical compositions thereof. Claims\n\n\n\n\n\n\n \n\n\nWE CLAIM: \n\n\n A compound of the formula (I): \n\n\n or a pharmaceutically acceptable salt thereof, \n\n\nwherein, \n\n\n G, is \n\n\n\n\n\n is \n\n\n \n7\n ( )p ( )q \n\n\n O R\n7\n \n\n\n -C-N -© or Hg) . \n\n\n with the proviso that \n\n\n\n\n\n\n\n\n ring Ar\n1\n and Ar\n2\n are independently selected from aryl, heteroaryl and heterocyclyl; L is a bond, or is selected from -(CR\n10\nR\nU\n)\nR\n-, -(C=0)- and -(C=0)-NR\n12\n-; \n\n\n A is selected from -(C=0)-, -(C=S)-,\n\n\n\n2\n- and -(C=S)-\n\n\nNR\n12\n-\n\n\nB and D, which may be the same or different, are independently selected from hydrogen, substituted or unsubstituted alkyl, haloalkyl, aryl, heteroaryl and heterocyclyl; with the proviso that when D is phenyl and A is -(C=0)- or -(C=0)-(CH\n2\n)\nr\n- then B is not hydrogen or substituted or unsubstituted alkyl; \n\n\n at each occurrence, R\n1\n, R\n8\n and R\n9\n, which may be the same or different, are independently selected from halogen, nitro, cyano, substituted or unsubstituted alkyl, alkenyl, alkynyl, alkoxyalkyl, haloalkyl, haloalkoxy, cyanoalkyl, cyanoalkyloxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, aryl, aryloxy, aralkyl, arylalkyloxy, heteroaryl, heteroaralkyl, heterocyclyl, heterocyclylalkyl, -OR\na\n, -OC(0)R\na\n, -OC(0)NR\na\nR\nb\n, -C(0)R\na\n, -C(0)OR\na\n, - \n\n C(0)NR\na\nR\nb\n, -CR'^R'R', -NR\na\nR\nb\n, -NR\na\nC(0)NR\nb\nR\nc\n, -NR\na\nC(0)OR\nb\n, -N(R\na\n)S(0)R\nb\n, - N(R\na\n)S0\n2\nR , -NR\na\nC(0)R\nb\n, -NR\na\nC(S)R\nb\n, -NR\na\nC(S)NR\nb\nR\nc\n, -S(0)NR\na\nR\nb\n, -S0\n2\nNR\na\nR\nh\n, -SR\na\n, - S(0)R\na\n, -S0\n2\nR\na\n and -C(S)R\na\n; \n\n\n at each occurrence, R\n2\n, R\n3\n, R\n10\n and R\n1\n ', which may be the same or different, are independently selected from hydrogen, halogen, hydroxyl, cyano, substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, -C(0)OR\na\n and -NR\na\nR\nb\n; or R\n2\n and R\n3\n or R\n10\n and R\", together with the carbon atom to which they are attached may form cyclic ring, which may be monocyclic, bicyclic or tricyclic rings; substituted or unsubstituted; saturated, unsaturated or partially saturated; the cyclic ring may optionally contain one or more heteroatoms selected from O, N or S; \n\n\n R\n4\n, R\n7\n and R\n12\n, which may be the same or different, are independently selected from hydrogen, substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocyclyl, -C(0)R\na\n, -C(0)OR\na\n, -C(0)NR\na\nR\nb\n, -S(0)NR\na\nR\nb\n, -S0\n2\nNR\na\nR\nb\n, - S(0)R\na\n and -S0\n2\nR\na\n; \n\n\n R\n5\n and R\n6\n, which may be the same or different, are independently selected from hydrogen, halogen, haloalkyl, hydroxyl, cyano, nitro, substituted or unsubstituted alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, cyanoalkyl, cyanoalkyloxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocyclyl, -C(0)R\na\n, -C(0)NR\na\nR\nb\n, -C(0)OR\na\n, -CR'R^R'R', -NR\na\nR\nb\n, - NR\na\nCONR\nb\nR\nc\n, -NR\na\nC(0)OR\nb\n, -N(R\na\n)SOR\nb\n, -N(R\na\n)S0\n2\nR\nb\n, -NR\na\nC(0)R\nb\n, -NR\na\nC(S)R\nb\n, - NR\na\nC(S)NR R°, -SONR\na\nR\nb\n, -S0\n2\nNR\na\nR\nb\n, -OC(0)R\na\n, -OC(0)NR\na\nR\nb\n, -SR\na\n, -SOR\na\n, -S0\n2\nR\na\n and -C(S)R\na\n ; \n\n\n or R\n4\n and R\n5\n together with the atoms to which they are attached may form cyclic ring, which may be monocyclic, bicyclic or tricyclic rings; substituted or unsubstituted; saturated, unsaturated or partially saturated; the cyclic ring may optionally include one or more heteroatoms selected from O, N, or S; \n\n\n R\na\n, R and R\nc\n, which may be the same or different, are independently selected from hydrogen, halogen, cyano, substituted or unsubstituted alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; \n\n\n 'm' is an integer ranging from 0 to 4, both inclusive; \n\n\n 'n' is an integer ranging from 1 to 3, both inclusive; \n\n\n 'p' is an integer ranging from 0 to 4, both inclusive; \n\n\n 'q' is an integer ranging from 0 to 4, both inclusive; and \n\n\n V is an integer ranging from 1 to 3, both inclusive. \n\n\n\n\n2. The compound of claim 1 having the formula (II): \n\n\n\n\n\n\n\n\n or a pharmaceutically acceptable salt thereof, \n\n\n wherein, \n\n\n ring Ar\n3\n and Ar\n4\n are independently selected from aryl, heteroaryl and heterocyclyl; A is selected from -(C=0)-, -(C=S)-, -(C=O)-(CR\n,0\nR\nn\n)\nr\n-, -(C=0)-NR\n12\n- and -(C=S)-\n\n\nNR\n12\n-; \n\n\n at each occurrence, R\n1\n , R\n9\n, R\n13\n and R\n14\n, which may be the same or different, are independently selected from halogen, nitro, cyano, substituted or unsubstituted alkyl, alkenyl, alkynyl, alkoxyalkyl, haloalkyl, haloalkoxy, cyanoalkyl, cyanoalkyloxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, aryl, aryloxy, aralkyl, arylalkyloxy, heteroaryl, heteroaralkyl, heterocyclyl, heterocyclylalkyl, -OR\na\n, -OC(0)R\na\n, -OC(0)NR\na\nR\nb\n, -C(0)R\na\n, -C(0)OR\na\n, - C(0)NR\na\nR\nb\n, -CR R\nb\nNR\na\nR\nc\n, -NR\na\nR\nb\n, -NR\na\nC(0)NR\nb\nR\nc\n, -NR\na\nC(0)OR\nb\n, -N(R\na\n)S(0)R\nb\n, - N(R\na\n)S0\n2\nR\nb\n, -NR\na\nC(0)R\nb\n, -NR\na\nC(S)R\nb\n, -NR\na\nC(S)NR\nb\nR\nc\n, -S(0)NR\na\nR\nb\n, -S0\n2\nNR\na\nR\nb\n, -SR\na\n, - S(0)R\na\n, -S0\n2\nR\na\n and -C(S)R\na\n; \n\n\n at each occurrence, R\n10\n and R\n1 1\n , which may be the same or different, are independently selected from hydrogen, halogen, hydroxyl, cyano, substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, -C(0)OR\na\n and -NR\na\nR\nb\n; or R\n10\n and R\nn\n, together with the carbon atom to which they are attached may form cyclic ring, which may be monocyclic, bicyclic or tricyclic rings; substituted or unsubstituted; saturated, unsaturated or partially saturated; the cyclic ring may optionally contain one or more heteroatoms selected from O, N or S; \n\n\n R\n12\n is selected from hydrogen, substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocyclyl, -C(0)R\na\n, -C(0)OR\na\n, -C(0)NR\na\nR\nb\n, - S(0)NR\na\nR\nb\n, -S0\n2\nNR\na\nR\nb\n, -S(0)R\na\n and -S0\n2\nR\na\n; \n\n\n R\na\n, R\nb\n and R\nc\n, which may be the same or different, are independently selected from hydrogen, halogen, cyano, substituted or unsubstituted alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; \n\n 'm' is an integer ranging from 0 to 4, both inclusive; \n\n\n 'q' is an integer ranging from 0 to 4, both inclusive; \n\n\n 'r' is an integer ranging from 1 to 3, both inclusive; \n\n\n 't' is an integer ranging from 0 to 4, both inclusive; and \n\n\n 'u' is an integer ranging from 0 to 4, both inclusive. \n\n\nThe compound of claim 2, wherein ring Ar\n3\n is, \n\n\n\n\n\n The compound of claim 2, wherein R\n1\n is selected from fluorine, methyl and \n\n\nThe compound of claim 2, wherein ring Ar\n4\n is, \n\n\n\n\n\n The compound of claim 2, wherein R\n14\n is fluorine, chlorine, methyl, ethyl, /-butyl, trifluoromethyl, cyclopropyl or -OCH\n3\n \n\n\n The compound of claim 1 having the formula (III): \n\n\n\n\n\n\n\n\n (III) \n\n\nor a pharmaceutically acceptable salt thereof, \n\n\nwherein, \n\n\n A is selected from -(C=0)-, -(C=S)-, -(C=O)-(CR\nL 0\nR\" )\nR\n-, -(C=0)-NR\n1 2\n- and -(C=S)-\n\n\nNR\n12\n-; \n\n\n B is selected from hydrogen, substituted or unsubstituted alkyl, haloalkyl, aryl, heteroaryl and heterocyclyl; \n\n\n at each occurrence, R\n1\n , R\n9\n and R\n1 3\n, which may be the same or different, are independently selected from halogen, nitro, cyano, substituted or unsubstituted alkyl, alkenyl, alkynyl, alkoxyalkyl, haloalkyl, haloalkoxy, cyanoalkyl, cyanoalkyloxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, aryl, aryloxy, aralkyl, arylalkyloxy, heteroaryl, heteroaralkyl, heterocyclyl, heterocyclylalkyl, -OR\nA\n, -OC(0)R\nA\n, -OC(0)NR\nA\nR\nB\n, -C(0)R\nA\n, -C(0)OR\nA\n, - C(0)NR\nA\nR\nB\n, -CR\nA\nR\nB\nNR\nA\nR\nC\n, -NR\nA\nR\nB\n, -NR\nA\nC(0)NR\nB\nR\nC\n, -NR\nA\nC(0)OR\nB\n, -N(R\nA\n)S(0)R\nB\n, - \n\n N(R\na\n)S0\n2\nR\nb\n, -NR\na\nC(0)R\nb\n, -NR\na\nC(S)R\nb\n, -NR\na\nC(S)NR\nb\nR\nc\n, -S(0)NR\na\nR\nb\n, -S0\n2\nNR\na\nR\nb\n, -SR\na\n, - S(0)R\na\n, -S0\n2\nR\na\n and -C(S)R\na\n; \n\n\n at each occurrence, R\nl 0\n and R\nn\n, which may be the same or different, are independently selected from hydrogen, halogen, hydroxyl, cyano, substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, -C(0)OR\na\n and -NR\na\nR\nb\n; or R\n10\n and R\nn\n, together with the carbon atom to which they are attached may form cyclic ring, which may be monocyclic, bicyclic or tricyclic rings; substituted or unsubstituted; saturated, unsaturated or partially saturated; the cyclic ring may optionally contain one or more heteroatoms selected from O, N or S; \n\n\n R\n12\n is selected from hydrogen, substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocyclyl, -C(0)R\na\n, -C(0)OR\na\n, -C(0)NR R , - S(0)NR\na\nR\nb\n, -S0\n2\nNR\na\nR\nb\n, -S(0)R\na\n and -S0\n2\nR\na\n; \n\n\n R\na\n, R\nb\n and R\nc\n, which may be the same or different, are independently selected from hydrogen, halogen, cyano, substituted or unsubstituted alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; \n\n\n 'm' is an integer ranging from 0 to 4, both inclusive; \n\n\n 'q' is an integer ranging from 0 to 4, both inclusive; \n\n\n V is an integer ranging from 1 to 3, both inclusive; and \n\n\n 't' is an integer ranging from 0 to 4, both inclusive. \n\n\n 8. The compound of claim 7, wherein A is -(C=0)-. \n\n\n 9. The compound of claim 7, wherein A is -(C=0)-(CH\n2\n)\nr\n-,. \n\n\n 10. The compound of claim 9, wherein 'r' is 1, 2 or 3. \n\n\n 1 1 . The compound of claim 7, wherein A is -(C=S)-NH-. \n\n\n 12. The compound of claim 7, wherein B is methyl, ethyl, propyl, butyl or trifluoromethyl. \n\n\n 13. The compound of claim 1 hav \n\n\n \n\n or a pharmaceutically acceptable salt thereof, \n\n\n wherein, \n\n D is selected from hydrogen, substituted or unsubstituted alkyl, haloalkyl, aryl, heteroaryl and heterocyclyl; \n\n\n at each occurrence, R\n1\n, R\n9\n and R\n14\n, which may be the same or different, are independently selected from halogen, nitro, cyano, substituted or unsubstituted alkyl, alkenyl, alkynyl, alkoxyalkyl, haloalkyl, haloalkoxy, cyanoalkyl, cyanoalkyloxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, aryl, aryloxy, aralkyl, arylalkyloxy, heteroaryl, heteroaralkyl, heterocyclyl, heterocyclylalkyl, -OR\na\n, -OC(0)R\na\n, -OC(0)NR\na\nR\nb\n, -C(0)R\na\n, -C(0)OR\na\n, - C(0)NR\na\nR\nb\n, -CR^^R^, -NR\na\nR\nb\n, -NR\na\nC(0)NR\nb\nR\nc\n, -NR\na\nC(0)OR\nb\n, -N(R\na\n)S(0)R\nb\n, - N(R\na\n)S0\n2\nR\nb\n, -NR\na\nC(0)R\nb\n, -NR\na\nC(S)R\nb\n, -NR\na\nC(S)NR\nb\nR\nc\n, -S(0)NR\na\nR\nb\n, -S0\n2\nNR\na\nR\nb\n, -SR\na\n, - S(0)R\na\n, -S0\n2\nR\na\n and -C(S)R\na\n; \n\n\n R\na\n, R\nb\n and R\nc\n, which may be the same or different, are independently selected from hydrogen, halogen, cyano, substituted or unsubstituted alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; \n\n\n 'm' is an integer ranging from 0 to 4, both inclusive; \n\n\n 'q' is an integer ranging from 0 to 4, both inclusive; and \n\n\n 'u' is an integer ranging from 0 to 4, both inclusive. \n\n\n 14. The compound of claim 13, wherein R\n1\n is pyridyl. \n\n\n 15. The compound of claim 13, wherein R\n14\n is fluoro. \n\n\n 16. The compound of claim 13, wherein D is hydrogen or methyl. \n\n\n 17. The compound of claim 1 having the formula (V): \n\n\n\n\n\n\n\n\n substituted or unsubstituted alkyl, alkenyl, alkynyl, alkoxyalkyl, haloalkyl, haloalkoxy, cyanoalkyl, cyanoalkyloxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, aryl, aryloxy, aralkyk arylalkyloxy, heteroaryl, heteroaralkyl, heterocyclyl, heterocyclylalkyl, -OR\na\n, -OC(0)R\na\n, - OC(0)NR\na\nR\nb\n, -C(0)R\na\n, -C(0)OR\na\n, -C(0)NR\na\nR\nb\n, -CR\na\nR\nb\nNR\na\nR\nc\n, -NR\na\nR\nb\n, -NR\na\nC(0)NR\nb\nR\nc\n, - \n\n NR\na\nC(0)OR\nb\n, -N(R\na\n)S(0)R , -N(R\na\n)S0\n2\nR\nb\n, -NR\na\nC(0)R\nb\n, -NR\na\nC(S)R\nb\n, -NR\na\nC(S)NR\nb\nR\nc\n, - S(0)NR\na\nR\nb\n, -S0\n2\nNR\na\nR\nb\n, -SR\na\n, -S(0)R\na\n, -S0\n2\nR\na\n and -C(S)R\na\n; \n\n\n R\n6\n is selected from hydrogen, halogen, haloalkyl, hydroxyl, cyano, nitro, substituted or unsubstituted alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, cyanoalkyi, cyanoalkyloxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocyclyl, -C(0)R\na\n, -C(0)NR\na\nR\nb\n, -C(0)OR\na\n, - CR'R^R^, -NR\na\nR\nb\n, -NR\na\nCONR\nb\nR\nc\n, -NR\na\nC(0)OR\nb\n, -N(R\na\n)SOR\nb\n, -N(R\na\n)S0\n2\nR\nb\n, - NR\na\nC(0)R\nb\n, -NR\na\nC(S)R\nb\n, -NR\na\nC(S)NR R\nc\n, -SONR\na\nR , -S0\n2\nNR\na\nR\nb\n, -OC(0)R\na\n, - OC(0)NR\na\nR\nb\n, -SR\na\n, -SOR\na\n, -S0\n2\nR\na\n and -C(S)R\na\n ; \n\n\n R\n7\n is selected from hydrogen, substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocyclyl, -C(0)R\na\n, -C(0)OR\na\n, -C(0)NR\na\nR\nb\n, - S(0)NR\na\nR\nb\n, -S0\n2\nNR\na\nR\nb\n, -S(0)R\na\n and -S0\n2\nR\na\n; \n\n\n R\na\n, R\nb\n and R\nc\n, which may be the same or different, are independently selected from hydrogen, halogen, cyano, substituted or unsubstituted alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; \n\n\n 'm' is an integer ranging from 0 to 4, both inclusive; and \n\n\n 'p' is an integer ranging from 0 to 4, both inclusive. \n\n\n18. The compound of claim 17, wherein Ar\n1\n is \n\n\n\n\n\n 19. The compound of claim 1 7, wherein R is chloro, cyano, methyl or trifluoromethyl. \n\n\n 20. The compound of claim 1 havin \n\n\n\n\n\n\n\n\n (VI) \n\n\n or a pharmaceutically acceptable salt thereof, \n\n\n wherein, \n\n\n A is -S- or -N=CH-; \n\n\n ring Ar\n1\n is selected from aryl, heteroaryl and heterocyclyl; \n\n\n R\n6\n is selected from hydrogen, halogen, haloalkyl, hydroxyl, cyano, nitro, substituted or unsubstituted alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, cyanoalkyi, cyanoalkyloxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocyclyl, -C(0)R\na\n, -C(0)NR\na\nR\nb\n, -C(0)OR\na\n, - \n\n CR^'WR\n0\n, -NR\na\nR\nb\n, -NR\na\nCONR\nb\nR°, -NR\na\nC(0)OR\nb\n, -N(R\na\n)SOR\nb\n, -N(R\na\n)S0\n2\nR\nb\n, - NR\na\nC(0)R\nb\n, -NR\na\nC(S)R\nb\n, -NR\na\nC(S)NR\nb\nR\nc\n, -SONR\na\nR\nb\n, -S0\n2\nNR\na\nR\nb\n, -OC(0)R\na\n, - OC(0)NR\na\nR\nb\n, -SR\na\n, -SOR\na\n, -S0\n2\nR\na\n and -C(S)R\na\n ; \n\n\n R\n7\n is selected from hydrogen, substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocyclyl, -C(0)R\na\n, -C(0)OR\na\n, -C(0)NR\na\nR\nb\n, - S(0)NR\na\nR\nb\n, -S0\n2\nNR\na\nR\nb\n, -S(0)R\na\n and -S0\n2\nR\na\n; \n\n\n at each occurrence, R\n9\n is independently selected from halogen, nitro, cyano, substituted or unsubstituted alkyl, alkenyl, alkynyl, alkoxyalkyl, haloalkyl, haloalkoxy, cyanoalkyl, cyanoalkyloxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, aryl, aryloxy, aralkyl, arylalkyloxy, heteroaryl, heteroaralkyl, heterocyclyl, heterocyclylalkyl, -OR\na\n, -OC(0)R\na\n, - OC(0)NR\na\nR\nb\n, -C(0)R\na\n, -C(0)OR\na\n, -C(0)NR\na\nR\nb\n, -CR'R^R'R^ -NR\na\nR , -NR\na\nC(0)NR R\nc\n, - NR\na\nC(0)OR\nb\n, -N(R\na\n)S(0)R\nb\n, -N(R\na\n)S0\n2\nR\nb\n, -NR\na\nC(0)R\nb\n, -NR\na\nC(S)R\nb\n, -NR\na\nC(S)NR\nb\nR\nc\n, - S(0)N R\na\nR\nb\n, -S0\n2\nNR\na\nR\nb\n, -SR\na\n, -S(0)R\na\n, -S0\n2\nR\na\n and -C(S)R\na\n; \n\n\n R\na\n, R\nb\n and R\nc\n, which may be the same or different, are independently selected from hydrogen, halogen, cyano, substituted or unsubstituted alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; and \n\n\n R\n16\n and R\n17\n, which may be the same or different, are independently selected from hydrogen and substituted or unsubstituted alkyl; and \n\n\n 'q' is an integer ranging from 0 to 4, both inclusive. \n\n\n 21 . The compound of claim 20, wherein A is -S-. \n\n\n 22. The compound of claim 20, wherein A is -N=CH-\n\n\n23. The compound of claim 17 or 20, wherein R\n6\n is substituted aryl. \n\n\n 24. The compound of claim 23, wherein R\n6\n is para-substituted phenyl, in which substitutent is chlorine. \n\n\n 25. The compound of claim 1 7 or 20, wherein R\n7\n is hydrogen, methyl or ethyl. \n\n\n 26. The compound of claim 20, wherein Ar' is phenyl or pyridyl. \n\n\n 27. The compound of claim 20, wherein R\n16\n and R\n17\n are independently hydrogen or methyl .\n\n\n28. The compound selected from : \n\n\n 2-(3-methoxyphenyl)-N-(pyridin-3-ylmethyl)-N-[4-(quinolin-2-ylmethoxy)phenyl] acetamide; \n\n\n 2-(4-fluorophenyl)-N-(pyridin-3-ylmethyl)-N-[4-(quinolin-2-ylmethoxy)phenyl] acetamide; \n\n\n 2-(2-methoxyphenyl)-N-(pyridin-3-ylmethyl)-N-[4-(quinolin-2-ylmethoxy)phenyl] acetamide; \n\n 2-(2-fluorophenyl)-N-(pyridin-3-ylmethyl)-N-[4-(quinolin-2-ylmethoxy)phenyl] acetam ide; \n\n\n 2-(4-chlorophenyl)-N-(pyridin-3-ylmethyl)-N-[4-(quinolin-2-ylmethoxy)phenyl] acetamide; \n\n\n 2-(4-chlorophenyl)-N-(pyridin-3-ylmethyl)-N-[4-(quinolin-2-ylmethoxy)phenyl] acetamide; \n\n\n 2-(2,3-difluorophenyl)-N-(pyridin-3-ylmethyl)-N-[4-(quinolin-2-ylmethoxy) phenyl] acetamide; \n\n\n 2-(3-trifluoromethylphenyl)-N-(pyridin-3-ylmethyl)-N-[4-(quinolin-2-ylmethoxy) phenyl] acetamide; \n\n\n N-benzyl-2-(2-fluorophenyl)-N-[4-(quinolin-2-ylmethoxy)phenyl]acetamide; \n\n\n N-benzyl-2-(2-methoxyphenyl)-N-[4-(quinolin-2-ylmethoxy)pheny]]acetam ide; \n\n\n N-benzyl-2-(4-fluorophenyl)-N-[4-(quinolin-2-ylmethoxy)phenyl]acetam ide; \n\n\n N-benzyl-2-(2,3-difluorophenyl)-N-[4-(quinolin-2-ylmethoxy)phenyl]acetamide; N-benzyl-2-(2-chlorophenyl)-N-[4-(quinol in-2-ylmethoxy)phenyl]acetamide; \n\n\n /V-(4-fluorobenzyl)-2-(4-fluorophenyl)-N-[4-(quinolin-2-ylmethoxy)phenyl] acetam ide; \n\n\n /V-(4-fluorobenzyl-2-(2-fluorophenyl)-N-[4-(quinolin-2-ylmethoxy)phenyl] acetamide; \n\n\n N-benzyl -2-(2,6-difluorophenyl)-N-[4-(quinolin-2-ylmethoxy)phenyl]acetamide; , N-benzyl -2-(3-methoxyphenyl)-N-[4-(quinolin-2-ylmethoxy)phenyl]acetamide; \n\n\n 2-(2,4-difluorophenyl)-N-(4-Pyridylmethyl)-N-[4-(quinolin-2-ylmethoxy)-phenyl] acetamide; \n\n\n 2-(2,4-difluorophenyl)-N-(2-Pyridylmethyl)-N-[4-(quinolin-2-ylmethoxy)-phenyl] acetam ide; \n\n\n N-pyridin-3-ylmethyl-N-[4-(quinolin-2-ylmeth0xy)-phenyl]-2-(2,3,4-trifluoro-phenyl) acetamide; \n\n\n 2-(2,4-difluoro-phenyl)-N-[4-(6-fluoro-quinolin-2-ylmethoxy)-phenyI]-/V-pyridin-3- ylmethylacetamide; \n\n\n /V-pyridin-3-ylmethyl-N-[4-(quinolin-2-ylmethoxy)-phenyl]-2-(2,4,5-trifluoro-phenyl) acetam ide; \n\n\n 2-pyridin-2-yl-N-pyridin-3-ylmethyl-N-[4-(quinolin-2-yimethoxy)-phenyl]acetamide; 2-pyridin-3-yl-N-pyridin-3-ylmethyl-N-[4-(quinolin-2-ylmethoxy)-phenyl]acetamide; 2-pyridin-4-yl-N-pyridin-3-ylmethyl-N-[4-(quinolin-2-ylmethoxy)-phenyl]acetamide; \n\n 2-(3-methyl-isoxazol-5-yl)-N-pyridin-3-ylmethyl-N-[4-(quinolin-2-ylmethoxy)- phenyljacetamide; \n\n\n 2-(2,4-difluoro-p enyl)-N-(4-methyl-thiazol-5-ylmethyl)-N-[4-(quinolin-2- ylmethoxy)-phenyl]acetamide; \n\n\n 1 -phenyl-cyclopropanecarboxylic acid pyridin-3-ylmethyl-[4-(quinolin-2-ylmethoxy) -phenyl]amide; \n\n\n 2-(2,4-difluoro-phenyl)-N-(6-methoxy-pyridin-2-ylmethyl)-N-[4-(quinolin-2- ylmethoxy)-phenyl]acetamide; \n\n\n 2-(2,4-difluoro-phenyl)-N-(3,5-dimethyl-isoxazol-4-ylmethyl)-N-[4-(quinolin-2- ylmethoxy)-phenyl]acetamide; \n\n\n 2- (2,4-difluoro-phenyl)-N-(5-methyl-isoxazol-3-ylmethyl)-N-[4-(quinolin-2- ylmethoxy)-phenyl]acetamide; \n\n\n l -benzyl-3-(5-tertbutyl-l ,3,4-thiadiazol-2-yl)-l -[4-(quinoline-2-ylmethoxy)phenyl] urea; \n\n\n 1 - benzyl-3-(5-tertbutyl-l ,3,4-thiadiazol-2-yl)-l -[4-(quinoline-2-ylmethoxy)phenyl urea; \n\n\n 1 -benzyI-3-(5-ethyl- 1 ,3,4-thiadiazol-2-yl)- 1 -[4-(quinoline-2-ylmethoxy)phenyl]urea; l -benzyl-3-(5-ethyl- l ,3,4-thiazol-2-yl)- l -[4-(quinoline-2-ylmethoxy)phenyl jurea; N-pyridin-3-ylmethyl-N-[4-(quinolin-2-ylrnethoxy)-phenyl]propionarnide; \n\n\n N-pyridin-3-ylrnethyl-N-[4-(quinolin-2-ylrnethoxy)-phenyl]acetamide; \n\n\n 3- butyl-l ^yridin-3-ylrnethyl-l -[4-(quinolin-2-ylmethoxy)-phenyl]thiourea; \n\n\n 4,4,4-trifluoro-N-pyridin-3-ylrnethyl-N-[4-(quinolin-2-ylrnethoxy)-phenyl]- butyramide; \n\n\n 2- (2,4-difluorophenyl)-N-[2-pyridin-4-yl-4-(quinolin-2-ylmethoxy)-phenyl] acetamide; \n\n\n 2-(2,4-difluorophenyl)-N-methyl-N-[2-pyridin-4-yl-4-(quinoIin-2-ylrnethoxy)- phenyl]acetamide; \n\n\n 2-{4-[2-(4-chlorophenyl)irnidazo[2, l -6][l ,3]benzothiazol-3-yl]phenoxy}-N-(5-methyl pyridin-2-yl)acetamide; \n\n\n 2-{4-[2-(4-chlorophenyl)imidazo[2, l -¾][l ,3]benzothiazol-3-yl]phenoxy} -N-(5-chloro pyridin-2-yl)acetamide; \n\n\n 2-{4-[2-(4-chlorophenyl)imidazo[2, l - )][l ,3]benzothiazol-3-yl]phenoxy}-N-(4-methyl pyridin-2-yl)acetamide; \n\n 2-{4-[2-(4-chlorophenyl)imidazo[2, l-0][l ,3]benzothiazol-3-yl]phenoxy}-N-(6- chloropyridin -2-yl)acetamide; \n\n\n 2-{4-[2-(4-chlorophenyl)imidazo[2, l - >][l,3]benzothiazol-3-yl]phenoxy}-N-[3- chloro-5-(trifluoromethyl)pyridin-2-yl]acetamide; \n\n\n 2-{4-[2-(4-chlorophenyl)imidazo[2, l - >][l,3]benzothiazol-3-yl]phenoxy}N-(5-cyano pyridin-2-yl)acetamide; \n\n\n 2-{4-[2-(4-chlorophenyl)imidazo[2, l - >][l ,3]benzothiazol-3-yl]phenoxy}N-pyrazin-2- ylacetamide; \n\n\n 2-{4-[2-(4-chlorophenyl)imidazo[2, l -6][l ,3]benzothiazol-3-yl]phenoxy}-N- pyrimidin-2-yl acetamide; \n\n\n 2-{4-[2-(4-chlorophenyl)imidazo[2, l - )][l ,3]benzothiazol-3-yl]phenoxy}-N-methyl- N-pyridin-2-ylacetamide; \n\n\n 2-{4-[2-(4-chlorophenyl)imidazo[2, l - )][l ,3]benzothiazol-3-yl]phenoxy}-N-methyl- N-phenylacetamide; \n\n\n 2-{4-[2-(4-chlorophenyl)imidazo[2, l-0][l,3]benzothiazol-3-yl]phenoxy}N-pyridin-2- yi acetamide; \n\n\n 2- {4-[2-(4-chlorophenyl)imidazo[2, 1 -b][ 1 ,3]benzothiazol-3-yl]phenoxy } -N-(2- chlorophenyl) acetamide; \n\n\n 2-{4-[2-(4-chlorophenyl)imidazo[2, l- )][l ,3]benzothiazol-3-yl]phenoxy}N- phenylacetamide; \n\n\n 2-{4-[6-(4-(chlorophenyl)-3-methylimidazo[2, l -b][ \\ , 3]thiazol-5-yl)phenoxy}-N- methyl-N-phenylacetamide; \n\n\n 2-{4-[2-(4-(chlorophenyl)-imidazo[ l ,2-a]pyrimidin-3-yl])phenoxy} -iV-methyl-N- pyridin-2-ylacetamide; \n\n\n 2-{4-[6-(4-(chlorophenyl)-2,3-dimethylimidazo[2, l -6]tl ,3]thiazol-5-yl)phenoxy}-N- methyl-N-pyridin-2-ylacetamide; and \n\n\n 2-{4-[6-(4-(chlorophenyl)-3-methylimidazo[2, l - >][l ,3]thiazol-5-yl)phenoxy}-N- ethyl-N-pyridin-2-ylacetamide; \n\n\n or pharmaceutically acceptable salts thereof. \n\n\n29. The compound selected from: \n\n\n 2-(2,6-difluorophenyl)-N-(pyridin-3-ylmethyl)-N-[4-(quinolin-2-ylmethoxy)phenyl] acetamide; \n\n\n 2-(phenyl)-N-(pyridin-3-ylmethyl)-N-[4-(quinolin-2-ylmethoxy)phenyl]acetamide; \n\n 2-(2,4-difluorophenyl)-N-(pyridin-3-ylmethyl)-N-[4-(quino!in-2-ylmethoxy acetamide; \n\n\n N-pyridin-3-ylmethyl-N-[4-(quinolin-2-ylmethoxy)-phenyl]-2-(2,4,6-trifluoro-phenyl) acetamide; \n\n\n 2-(4-chloro-2-fluoro-phenyl)-N-pyridin-3-ylmethyl-N-[4-(quinolin-2-ylmethoxy)- phenyl] acetamide; \n\n\n 2-(4-chloro-2,6-difluoro-phenyl)-N-pyridin-3-yImethyl-N-[4-(quinolin-2-ylmethoxy)- phenyljacetamide; \n\n\n N-pyridin-3-ylmethyl-N-[4-(quinolin-2-ylmethoxy)-phenyl]-butyramide; pentanoic acid pyridin-3-ylmethyl-[4-(quinolin-2-ylmethoxy)-phenyl]amide; heptanoic acid pyridin-3-ylmethyl-[4-(quinolin-2-ylmethoxy)-phenyl]amide; hexanoic acid pyridin-3-ylmethyl-[4-(quinolin-2-ylmethoxy)-phenyl]amide;\n\n\n2-{4-[6-(4-(chlorophenyl)-3-methylimidazo[2, l -0][ l ,3]thiazol-5-yl)phenoxy}-N- methyl-N-pyridin-2-ylacetamide; \n\n\n 2-{4-[6-(4-(chlorophenyl)-2-methylimidazo[2, l -0][l ,3]thiazol-5-yl)phenoxy}-N- methyl-N-pyridin-2-ylacetamide; and \n\n\n 2-{4-[6-(4-(chlorophenyl)-imidazo[2, l -¾][l,3]thiazol-5-yl)phenoxy} -N-methyl-N- pyridin-2-ylacetamide; \n\n\n or pharmaceutically acceptable salts thereof. \n\n\n 30. A pharmaceutical composition comprising a compound according to claims 1 to 29 either as a free base or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients, carriers, diluents or mixture thereof. \n\n\n 31 . A method for preventing, ameliorating or treating a disease, disorder or syndrome modulated by PDE 10A in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound according to any one of claims 1 to 29.\n\n\n32. A method of treating schizophrenia in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound according to any one of claims 1 to 29. Description\n\n\n\n\n HETEROARYL COMPOUNDS AS PDE10A INHIBITORS \n\n\nRelated applications \n\n\n This application claims the benefit of Indian Provisional Application Nos. 1274/MUM/2010 filed on April 19, 2010; 2447/MUM/2010 filed on September 3, 2010; and US Provisional Application Nos. 61/329,305 filed on April 29, 2010 and all of which are hereby incorporated by reference. \n\n\nTechnical Field \n\n\n The present invention relates to heteroaryl compounds and their use in treating or preventing diseases, conditions and/or disorders by inhibiting phosphodiesterase 10A (PDE 10 A) enzyme. \n\n\n Background of the Invention \n\n\n Phosphodiesterases (PDEs) are a class of intracellular enzymes involved in the hydrolysis of the nucleotides cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphates (cGMP) into their respective nucleotide monophosphates. The cyclic nucleotides cAMP and cGMP are synthesized by adenylyl and guanylyl cyclases, respectively and serve as secondary messengers in several cellular pathways. \n\n\n In tissues of vertebrates, various PDE subtypes have been found that hydrolyze cyclic nucleotides [Trend. Pharmacol. Sci. vol. 1 1 , p.150, (1990), Physiol. Rev. vol. 75, p.725, (1 995), Arch. Biochem. Biophys. vol. 322, p. l , (1995) and Kidney International, vol. 55, p.29, ( 1999)]. These have been classified into 1 1 families (PDE1 to PDE 1 1 ) according to biochemical characteristics, enzymological characteristics, homology of amino acid sequences by cloning of corresponding cDNAs, sensitivity to inhibitors and the like. \n\n\n A principal mechanism for regulating cyclic nucleotide signaling is by phosphodiesterase-catalyzed cyclic nucleotide catabolism. There are 1 1 known families of PDE's encoded by 21 different genes. Each gene typically yields multiple splice variants that further contribute to the isozyme diversity. The PDE families are distinguished functionally based on cyclic nucleotide substrate specificity, mechanism(s) of regulation and sensitivity to inhibitors. Furthermore, PDE's are differentially expressed throughout the body, including in the central nervous system. As a result of these distinct enzymatic activities and localization, different PDE's isozymes can serve distinct physiological functions. \n\n Human PDEI O was identified by identification of cDNA fragments published in the National Center for Biotechnology Information (NCBI) Expressed Sequence Tags (EST) database (Loughney et al., W099/42596). While PDE 10 was found to share homology with known PDE's, no function could be identified for PDE10. PDE10 has been identified as a unique family based on primary amino acid sequence and distinct enzymatic activity. Homology screening of EST databases revealed mouse PDEI OA as the first member of the PDE10 family of PDE's [Fujishige et al., J. Biol. Chem. vol. 274, p. l 8438-18445, (1999); Loughney, K. et al., Gene vol. 234, p. 109-1 17, ( 1999)]. The murine homologue has also been cloned [Soderling, S. et al., Proc. Natl. Acad. Sci. USA vol. 96 p. 7071 -7076, ( 1999)] and N-terminal splice variants of both the rat and human genes have been identified [ otera, J. et al., Biochem. Biophys. Res. Comm. vol. 261 , p. 551 -557, (1999); Fujishige, K. et al., Eur. J. Biochem. vol. 266, p. 1 1 1 8- 1 127, ( 1 999)]. There is a high degree of homology across species. The mouse PDE 10A 1 is a 779 amino acid protein that hydrolyzes both cAMP and cGMP to AMP and GMP, respectively. The affinity of PDE10 for cAMP is higher than for cGMP. However, approximately 5-fold greater Vmax for cGMP over cAMP has lead to the suggestion that PDE10 is a unique cAMP-inhibited cGMPase [Fujishige et al., J. Biol. Chem. vol. 274, p. 18438-18445, (1999)]. \n\n\n The PDE10 family of polypeptides shows a lower degree of sequence homology to previously identified PDE families. These low degrees of sequence homology of PDE10 family of polypeptide make them insensitive to certain inhibitors that are known to be specific for other known PDE families (US 6,350,603, incorporated herein by reference). \n\n\n Regarding PDEI OA which is one of the PDE subtypes, the expression of its mRNA has been identified in many tissues and organs such as striatum, testis, kidney, thyroid gland, pituitary gland, thalamus, cerebellum, heart, lungs and placenta, cells such as aortic smooth muscle cells and aortic endothelial cells, cells of cancers such as lung small cell carcinoma, breast cancer and large bowel cancer. Accordingly, the possibility that PDEI OA is involved in diseases related to these cells, tissues and organs has been demonstrated [J. Biol. Chem. vol. 274, p. 1 8438 ( 1999); Gene, vol. 234, p. 109 ( 1999) and WO 01 /29199]. \n\n\n From the view points of strong expression of mRNA of PDEI OA and its enzymatic activity in the striatum, this enzyme is suggested to be involved in, for example, onset or progression of Parkinson's disease, Huntington disease and dyskinesia caused by long-term administration of L-DOPA (L-3,4-dihydroxyphenylalanine). It has been reported that PDEI OA mRNA expression in the striatum of Huntington disease mouse model is different from that in the striatum of normal mice (WO 01/24781). \n\n There are very few effective treatments for neurological disorders characterized by progressive cell loss, known as neurodegenerative diseases, as well as those involving acute cell loss, such as stroke and trauma. In addition, few effective treatments exist for neurological disorders such as psychosis which has been linked to altered striatal function relating to changes in expression of the enzyme PDEI OA [J. A. Siuciak, et al. Neuropharmacology, vol. 51 , p. 374-385, (2006)]. Striatal dysfunction is implicated in a number of CNS disorders including psychosis, schizophrenia, obsessive-compulsive disorders, Parkinson's disease and Huntington's disease. The results with PDEI OA knock-out mice provide evidence that PDEI OA functions to inhibit striatal output by reducing spiny medium neuron excitability. PDEI OA is selectively expressed in dopamine receptive medium spiny neurons, and considerable data suggests that cAMP and cGMP signalling pathways play significant roles in the regulation of medium spiny neuron excitability. Additional studies with papaverine, a potent inhibitor of PDEI OA, confirm that PDEI OA regulates both cAMP and cGMP in vivo in rats [J. A. Siuciak, et al. Neuropharmacology, vol. 5 1 , p. 386- 396, (2006)]. \n\n\n In view of the foregoing, PDE I OA inhibitors are useful for treating and/or preventing various diseases caused by enhanced activity of PDEI OA, possibly with reduced side effects (for example, a neural disease such as Parkinson's disease, Huntington disease or Alzheimer's disease, dyskinesia, hypogonadism, diabetes, an ischemic heart disease, hypertension, an inflammatory disease, a disease of the digestive system, an allergic disease, osteoporosis, pain or a malignant tumor). \n\n\n WO 2003/000269, WO 2003/0141 15, WO 2003/0141 16, WO 2003/0141 17, WO 2003/051877, WO 2006/034491 and WO 2006/034512 describe PDE10 inhibitors for treatment of neurodegenerative diseases, cancer, diabetes and its related disorders. WO 2006/072828, WO 2008/084299, WO 2003/093499, WO 2005/082883, WO 2005/120514, WO 2006/01 1040, WO 2006/070284, WO 2007/077490, WO 2007/085954, WO 2007/096743, WO 2007/129183, WO 2008/001 182, WO 2008/0041 17, WO 2008/020302, WO 2009/070584, WO 2009/068320, WO 2009/068246 and WO 2009/036766 describe PDE10 inhibitors for treatment of obesity, diabetes, certain central nervous system disorders, neurodegenerative and psychiatric disorders. WO 2009/029214, WO 2009/025839 and WO 2009/025823 describe PDE 10 inhibitors for treatment of obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder and obsessive-compulsive disorder. WO 2009/1431 78, WO 2009/152825, WO 2009/158393, WO 2009/158467, WO 2009/158473, WO 2010/006130, WO 2010/017236, WO 2010/027097 and WO 2010/030027 describe \n\n PDE 10 inhibitors for treatment of anxiety, schizophrenia, drug addiction, movement disorder, certain central nervous system disorders, neurodegenerative and psychiatric disorders. \n\n\nSummary of the Invention \n\n\nThe present invention relates to compounds of formula (1): \n\n\n\n\n\n (I) \n\n\nor a pharmaceutically acceptable salt thereof, \n\n\nwherein, \n\n\n G] is \n\n\n\n\n\n\n\n with the proviso that \n\n\n\n\n\n\n\n\n ring Ar\n1\n and Ar\n2\n are independently selected from aryl, heteroaryl and heterocyclyi; L is a bond, or is selected from -(CR\nl0\nR\nn\n)\nr\n-, -(C=0)- and -(C=0)-NR\n12\n-; \n\n\n A is selected from -(C=0)-, -(C=S)-, -(C=O)-(CR\nl0\nR\nn\n) , -(C=0)-NR\n12\n- and -(C=S)-\n\n\nNR' \n2\n-\n\n\nB and D, which may be the same or different, are independently selected from hydrogen, substituted or unsubstituted alkyl, haloalkyl, aryl, heteroaryl and heterocyclyi; with the proviso that when D is phenyl and A is -(C=0)- or -(C=0)-(CH\n2\n)\nr\n- then B is not hydrogen or substituted or unsubstituted alkyl; \n\n\n at each occurrence, R \n1\n , R\n8\n and R\n9\n, which may be the same or different, are independently selected from halogen, nitro, cyano, substituted or unsubstituted alkyl, alkenyl, \n\n alkynyl, alkoxyalkyl, haloalkyl, haloalkoxy, cyanoalkyl, cyanoalky!oxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, aryl, aryloxy, aralkyl, arylalkyloxy, heteroaryl, heteroaralkyl, heterocyclyl, heterocyclylalkyl, -OR\na\n, -OC(0)R\na\n, -OC(0)NR\na\nR\nb\n, -C(0)R\na\n, -C(0)OR\na\n, - C(0)NR\na\nR\nb\n, -CR\na\nR\nb\nNR\na\nR\nc\n, -NR\na\nR\nb\n, -NR\na\nC(0)NR\nb\nR\nc\n, -NR\na\nC(0)OR\nb\n, -N(R\na\n)S(0)R\nb\n, - N(R\na\n)S0\n2\nR\nb\n, -NR\na\nC(0)R\nb\n, -NR\na\nC(S)R\nb\n, -NR\na\nC(S)NR\nb\nR\nc\n, -S(0)NR\na\nR\nb\n, -S0\n2\nNR\na\nR\nb\n, -SR\na\n, - S(0)R\na\n, -S0\n2\nR\na\n and -C(S)R\na\n; \n\n\n at each occurrence, R\n2\n, R\n3\n, R\n10\n and R\n1 1\n, which may be the same or different, are independently selected from hydrogen, halogen, hydroxyl, cyano, substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, -C(0)OR\na\n and -NR\na\nR\nb\n; or R\n2\n and R\n3\n or R\n10\n and R\nn\n, together with the carbon atom to which they are attached may form cyclic ring, which may be monocyclic, bicyclic or tricyclic rings; substituted or unsubstituted; saturated, unsaturated or partially saturated; the cyclic ring may optionally contain one or more heteroatoms selected from O, N or S; \n\n\n R\n4\n, R\n7\n and R\n12\n, which may be the same or different, are independently selected from hydrogen, substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocyclyl, -C(0)R\na\n, -C(0)OR\na\n, -C(0)NR\na\nR\nb\n, -S(0)NR\na\nR\nb\n, -S0\n2\nNR\na\nR\nb\n, - S(0)R\na\n and -S0\n2\nR\na\n; \n\n\n R\n3\n and R\n6\n, which may be the same or different, are independently selected from hydrogen, halogen, haloalkyl, hydroxyl, cyano, nitro, substituted or unsubstituted alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, cyanoalkyl, cyanoalkyloxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocyclyl, -C(0)R , -C(0)NR\na\nR\nb\n, -C(0)OR\na\n, -CR'R'WR', -NR\na\nR\nb\n, - NR\na\nCONR\nb\nR\nc\n, -NR\na\nC(0)OR\nb\n, -N(R\na\n)SOR\nb\n, -N(R\na\n)S0\n2\nR\nb\n, -NR\na\nC(0)R\nb\n, -NR\na\nC(S)R\nb\n, - NR\na\nC(S)NR\nb\nR\nc\n, -SONR\na\nR\nb\n, -S0\n2\nNR\na\nR\nb\n, -OC(0)R\na\n, -OC(0)NR\na\nR\nb\n, -SR\na\n, -SOR\na\n, -S0\n2\nR\na\n and -C(S)R\na\n ; \n\n\n or R\n4\n and R\n5\n together with the atoms to which they are attached may form cyclic ring, which may be monocyclic, bicyclic or tricyclic rings; substituted or unsubstituted; saturated, unsaturated or partially saturated; the cyclic ring may optionally include one or more heteroatoms selected from O, N, or S; \n\n\n R\na\n, R\nb\n and R\nc\n, which may be the same or different, are independently selected from hydrogen, halogen, cyano, substituted or unsubstituted alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; \n\n\n 'm' is an integer ranging from 0 to 4, both inclusive; \n\n\n 'n' is an integer ranging from 1 to 3, both inclusive; \n\n\n 'p' is an integer ranging from 0 to 4, both inclusive; \n\n 'q' is an integer ranging from 0 to 4, both inclusive; and \n\n\n 'r is an integer ranging from 1 to 3, both inclusive. \n\n\n The compounds of formula (I) may involve one or more embodiments. It is to be understood that the embodiments below are illustrative of the present invention and are not intended to limit the claims to the specific embodiments exemplified. \n\n\nAccording to one e ula (II): \n\n\n \n\n or a pharmaceutically acceptable salt thereof, \n\n\nwherein, \n\n\n ring Ar\n3\n and Ar\n4\n are independently selected from aryl, heteroaryl and heterocyclyl; A is selected from -(C=0)-, -(C=S)-, -(C=O)-(CR\nl 0\nR\")\nr\n-, -(C=0)-NR\n12\n- and -(C=S)-\n\n\nNR\n1 2\n-; \n\n\n at each occurrence, R\n1\n , R\n9\n, R\n13\n and R\n14\n, which may be the same or different, are independently selected from halogen, nitro, cyano, substituted or unsubstituted alkyl, alkenyl, alkynyl, alkoxyalkyl, haloalkyl, haloalkoxy, cyanoalkyl, cyanoalkyloxy, cycloalkyl, cycloalkylalkyi, cycloalkenyl, aryl, aryloxy, aralkyl, arylalkyloxy, heteroaryl, heteroaralkyl, heterocyclyl, heterocyclylalkyl, -OR\na\n, -OC(0)R\na\n, -OC(0)NR\na\nR\nb\n, -C(0)R\\ -C(0)OR\na\n, - C(0)NR\na\nR , -CR'R'WR\n0\n, -NR\na\nR\nb\n, -NR\na\nC(0)NR\nb\nR\nc\n, -NR\na\nC(0)OR\nb\n, -N(R\na\n)S(0)R\nb\n, - N(R\na\n)S0\n2\nR\nb\n, -NR\na\nC(0)R\nb\n, -NR\na\nC(S)R\nb\n, -NR\na\nC(S)NR\nb\nR\nc\n, -S(0)NR\na\nR\nb\n, -S0\n2\nNR\na\nR , -SR\na\n, - S(0)R\na\n, -S0\n2\nR\na\n and -C(S)R\na\n; \n\n\n at each occurrence, R\n10\n and R\" , which may be the same or different, are independently selected from hydrogen, halogen, hydroxyl, cyano, substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, -C(0)OR\na\n and -NR\na\nR\nb\n; or R\n10\n and R\n1 1\n , together with the carbon atom to which they are attached may form cyclic ring, which may be monocyclic, bicyclic or tricyclic rings; substituted or unsubstituted; saturated, unsaturated or partially saturated; the cyclic ring may optionally contain one or more heteroatoms selected from O, N or S; \n\n R\n12\n is selected from hydrogen, substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloa!kyl, aryl, arylalkyl, heteroaryl, heterocyclyl, -C(0)R\na\n, -C(0)OR\na\n, -C(0)NR\na\nR\nb\n, - S(0)NR\na\nR\nb\n, -S0\n2\nNR\na\nR\nb\n, -S(0)R\na\n and -S0\n2\nR\na\n; \n\n\n R\na\n, R\nb\n and R\nc\n, which may be the same or different, are independently selected from hydrogen, halogen, cyano, substituted or unsubstituted alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; \n\n\n \n:\nm ' is an integer ranging from 0 to 4, both inclusive; \n\n\n 'q' is an integer ranging from 0 to 4, both inclusive; \n\n\n 'r' is an integer ranging from 1 to 3, both inclusive; \n\n\n 't' is an integer ranging from 0 to 4, both inclusive; and \n\n\n 'u' is an integer ranging from 0 to 4, both inclusive. \n\n\n The embodiments below are illustrative of the present invention and are not intended to limit the claims to the specific embodiments exemplified. \n\n\n According to one embodiment, specifically provided are compounds of the formula (II) in which R\n9\n is halogen (e.g., fluorine) and 'q' is 1. \n\n\n According to another embodiment, specifically provided are compounds of the formula (II) in which 'q' is 0. \n\n\n According to yet another embodiment, specifically provided are compounds of the formula (II) in which 'm' is 0. \n\n\n According to yet another embodiment, specifically provided are compounds of the formula (II) in which ring Ar\n3\n is aryl, preferably phenyl. \n\n\n According to yet another embodiment, specifically provided are compounds of the formula (II) in which ring Ar\n3\n is heteroaryl, referabl\n\n\n\n\n\n\n\n\nAccording to yet another embodiment, specifically provided are compounds of the formula (II) in which 't' is 0. \n\n\n According to yet another embodiment, specifically provided are compounds of the formula (II) in which R\n13\n is halogen (e.g., fluorine), substituted or unsubstituted alkyl (preferably unsubstituted alkyl, more preferably methyl) or OR\na\n; wherein R\na\n is substituted or unsubstituted alkyl, preferably unsubstituted alkyl, more preferably methyl. In this embodiment 't' is 1 or 2. \n\n According to yet another embodiment, specifically provided are compounds of the formula (II) in which A is -(C=O)-(CR\nl 0\nR\")\nr\n-, wherein both R\n10\n and R\nn\n are hydrogen and 'r' is 1. \n\n\n According to yet another embodiment, specifically provided are compounds of the formula (II) in which A is -(C=O)-(CR\n10\nR\")\nr\n-, wherein R\n!0\n and R\n1 1\n combine together with the carbon atom to which they are attached to form cyclopropyl ring and 'r' is 1. \n\n\n According to yet another embodiment, specifically provided are compounds of the formula (Π) in which A is -(C=0)-NR\n12\n-, wherein R\n12\n is hydrogen. \n\n\n According to yet another embodiment, specifically provided are compounds of the formula (II) in which ring Ar\n4\n is aryl, preferably phenyl. \n\n\n According to yet another embodiment, specifically provided are compounds of the formula (11) in which ring Ar\n4\n is heteroaryl, preferably \n\n\n\n\n\n According to yet another embodiment, specifically provided are compounds of the formula (II) in which 'u' is 0. \n\n\n According to yet another embodiment, specifically provided are compounds of the formula (II) in which R\n14\n is halogen (e.g., fluorine or chlorine), substituted or unsubstituted alkyl (preferably unsubstituted alkyl, more preferably methyl, ethyl or r-butyl), haloalkyl (e.g., trifluoromethyl), cycloalkyl (e.g., cyclopropyl) or OR\na\n; wherein R\na\n is substituted or unsubstituted alkyl, preferably unsubstituted alkyl, more preferably methyl. In this embodiment 'u' is 1 , 2 or 3. \n\n\nAccording to one embodiment, there is provided a compound of formula (111): \n\n\n\n\n\n\n\n\n (III) \n\n\nor a pharmaceutically acceptable salt thereof, \n\n\nwherein, \n\n A is selected from -(CO)-, -(C=S)-, -(C=O)-(CR\nl 0\nR\")\nr\n-, -(CO)-NR\n12\n- and -(C=S)-\n\n\nNR\n12\n-; \n\n\n B is selected from hydrogen, substituted or unsubstituted alkyl, haloalkyl, aryl, heteroaryl and heterocyclyl; \n\n\n at each occurrence, R\n1\n , R\n9\n and R\n13\n, which may be the same or different, are independently selected from halogen, nitro, cyano, substituted or unsubstituted alkyl, alkenyl, alkynyl, alkoxyalkyl, haloalkyl, haloalkoxy, cyanoalkyl, cyanoalkyloxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, aryl, aryloxy, aralkyi, arylalkyloxy, heteroaryl, heteroaralkyi, heterocyclyl, heterocyclylalkyl, -OR\na\n, -OC(0)R\na\n, -OC(0)NR\na\nR\nb\n, -C(0)R\na\n, -C(0)OR\na\n, - C(0)NR\na\nR\nb\n, -CR\na\nR\nb\nNR\na\nR\nc\n, -NR\na\nR\nb\n, -NR\na\nC(0)NR\nb\nR\nc\n, -NR\na\nC(0)OR\nb\n, -N(R\na\n)S(0)R\nb\n, - N(R\na\n)S0\n2\nR\nb\n, -NR\na\nC(0)R\nb\n, -NR\na\nC(S)R\nb\n, -NR\na\nC(S)NR\nb\nR\nc\n, -S(0)NR\na\nR\nb\n, -S0\n2\nNR\na\nR\nb\n, -SR\na\n, - S(0)R\na\n, -S0\n2\nR\na\n and -C(S)R\na\n; \n\n\n at each occurrence, R\nl 0\n and R\n1\n ' , which may be the same or different, are independently selected from hydrogen, halogen, hydroxyl, cyano, substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl, -C(0)OR\na\n and -NR\na\nR\nb\n; or R\n10\n and R\nn\n , together with the carbon atom to which they are attached may form cyclic ring, which may be monocyclic, bicyclic or tricyclic rings; substituted or unsubstituted; saturated, unsaturated or partially saturated; the cyclic ring may optionally contain one or more heteroatoms selected from O, N or S; \n\n\n R\n12\n is selected from hydrogen, substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocyclyl, -C(0)R\na\n, -C(0)OR\na\n, -C(0)NR\na\nR\nb\n, - S(0)NR\na\nR , -S0\n2\nNR\na\nR\nb\n, -S(0)R\na\n and -S0\n2\nR\na\n; \n\n\n R\na\n, R\nb\n and R\nc\n, which may be the same or different, are independently selected from hydrogen, halogen, cyano, substituted or unsubstituted alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; \n\n\n 'm' is an integer ranging from 0 to 4, both inclusive; \n\n\n 'q' is an integer ranging from 0 to 4, both inclusive; \n\n\n 'r' is an integer ranging from 1 to 3, both inclusive; and \n\n\n 't' is an integer ranging from 0 to 4, both inclusive. \n\n\n The embodiments below are illustrative of the present invention and are not intended to limit the claims to the specific embodiments exemplified. \n\n\n According to one embodiment, specifically provided are compounds of the formula (III) in which A is -(CO)-. \n\n According to another embodiment, specifically provided are compounds of the formula (III) in which A is -(C=0)-(CH\n2\n) , wherein 'r' is 1 , 2 or 3. \n\n\n According to yet another embodiment, specifically provided are compounds of the formula (III) in which A is -(OS)-NH-. \n\n\n According to yet another embodiment, specifically provided are compounds of the formula (111) in which B is substituted or unsubstituted alkyl (preferably unsubstituted alkyl, more preferably methyl, ethyl, propyl or butyl) or substituted or unsubstituted haloalkyl (preferably trifluoromethyl). \n\n\n According to yet another embodiment, specifically provided are compounds of the formula (III) in which 'm' is 0. \n\n\n According to yet another embodiment, specifically provided are compounds of the formula (III) in which 'q' is 0. \n\n\n According to yet another embodiment, specifically provided are compounds of the formula (III) in which 't' is 0. \n\n\nAccording to one embodiment, there is provided a compound of formula (IV): \n\n\n\n\n\n\n\n\n (IV) \n\n\nor a pharmaceutically acceptable salt thereof, \n\n\nwherein, \n\n\n D is selected from hydrogen, substituted or unsubstituted alkyl, haloalkyl, aryl, heteroaryl and heterocyclyl; \n\n\n at each occurrence, R\n1\n, R\n9\n and R\n14\n, which may be the same or different, are independently selected from halogen, nitro, cyano, substituted or unsubstituted alkyl, alkenyl, alkynyl, alkoxyalkyl, haloalkyl, haloalkoxy, cyanoalkyl, cyanoalkyloxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, aryl, aryloxy, aralkyi, arylalkyloxy, heteroaryl, heteroaralkyi, heterocyclyl, heterocyclylalkyl, -OR\na\n, -OC(0)R\na\n, -OC(0)NR\na\nR\nb\n, -C(0)R\na\n, -C(0)OR\na\n, - C(0)NR\na\nR , -CR\na\nR\nb\nNR\na\nR\nc\n, -NR\na\nR\nb\n, -NR\na\nC(0)NR\nb\nR\nc\n, -NR\na\nC(0)OR\nb\n, -N(R\na\n)S(0)R\nb\n, - N(R\na\n)S0\n2\nR\nb\n, -NR\na\nC(0)R\nb\n, -NR\na\nC(S)R , -NR\na\nC(S)NR\nb\nR\nc\n, -S(0)NR\na\nR\nb\n, -S0\n2\nNR\na\nR , -SR\na\n, - S(0)R\na\n, -S0\n2\nR\na\n and -C(S)R\na\n; \n\n R\nA\n, R\nB\n and R\nC\n, which may be the same or different, are independently selected from hydrogen, halogen, cyano, substituted or unsubstituted alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; \n\n\n 'm' is an integer ranging from 0 to 4, both inclusive; \n\n\n 'q' is an integer ranging from 0 to 4, both inclusive; and \n\n\n 'u' is an integer ranging from 0 to 4, both inclusive. \n\n\n The embodiments below are illustrative of the present invention and are not intended to limit the claims to the specific embodiments exemplified. \n\n\n According to one embodiment, specifically provided are compounds of the formula (IV) in which R\n1\n is r unsubstituted heteroaryl, preferably unsubstituted heteroaryl, more prefera\n\n\n and 'm' is 1. \n\n\n According to another embodiment, specifically provided are compounds of the formula (IV) in which R\n14\n is halogen, preferably fluorine and 'u' is 2. \n\n\n According to yet another embodiment, specifically provided are compounds of the formula (IV) in which D is hydrogen or substituted or unsubstituted alkyl (preferably unsubstituted alkyl, more preferably methyl). \n\n\n According to yet another embodiment, specifically provided are compounds of the formula (IV) in which 'q' is 0. \n\n\nAccording to one embodiment, there is provided a compound of formula (V): \n\n\n\n\n\n\n\n\n (V) \n\n\nor a pharmaceutically acceptable salt thereof, \n\n\nwherein, \n\n\n ring Ar\n1\n is selected from aryl, heteroaryl and heterocyclyl; \n\n\n at each occurrence, R\n1\n and R\n8\n are independently selected from halogen, nitro, cyano, substituted or unsubstituted alkyl, alkenyl, alkynyl, alkoxyalkyl, haloalkyl, haloalkoxy, cyanoalkyl, cyanoalkyloxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, aryl, aryloxy, aralkyl, arylalkyloxy, heteroaryl, heteroaralkyl, heterocyclyl, heterocyclylalkyl, -OR\nA\n, -OC(0)R\nA\n, -\n\n\nOC(0)NR\nA\nR\nB\n, -C(0)R\nA\n, -C(0)OR\nA\n, -C(0)NR\nA\nR\nB\n, -CRVWR', -NR\nA\nR\nB\n, -NR\nA\nC(0)NR\nB\nR\nC\n, - \n\n NR\na\nC(0)OR\nb\n, -N(R\na\n)S(0)R\nb\n, -N(R\na\n)S0\n2\nR\nb\n, -NR\na\nC(0)R\nb\n, -NR\na\nC(S)R\nb\n, -NR\na\nC(S)NR\nb\nR\nc\n, - S(0)NR\na\nR\nb\n, -S0\n2\nNR\na\nR\nb\n, -SR\na\n, -S(0)R\na\n, -S0\n2\nR\na\n and -C(S)R\na\n; \n\n\n R\n6\n is selected from hydrogen, halogen, haloalkyl, hydroxyl, cyano, nitro, substituted or unsubstituted alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, cyanoalkyl, cyanoalkyloxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocyclyl, -C(0)R\na\n, -C(0)NR\na\nR\nb\n, -C(0)OR\na\n, - CR^'WR\n0\n, -NR\na\nR\nb\n, -NR\na\nCONR\nb\nR\nc\n, -NR\na\nC(0)OR\nb\n, -N(R\na\n)SOR\nb\n, -N(R\na\n)S0\n2\nR\nb\n, - NR\na\nC(0)R\nb\n, -NR\na\nC(S)R\nb\n, -NR\na\nC(S)NR\nb\nR\nc\n, -SONR\na\nR\nb\n, -S0\n2\nNR\na\nR\nb\n, -OC(0)R\na\n, - OC(0)NR\na\nR\nb\n, -SR\na\n, -SOR\na\n, -S0\n2\nR\na\n and -C(S)R\na\n ; \n\n\n R\n7\n is selected from hydrogen, substituted or unsubstituted alkyl, alkenyl. alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocyclyl, -C(0)R\na\n, -C(0)OR\na\n, -C(0)NR\na\nR\\ - S(0)NR\na\nR\nb\n, -S0\n2\nNR\na\nR\nb\n, -S(0)R\na\n and -S0\n2\nR\na\n; \n\n\n R\na\n, R\nb\n and R\nc\n, which may be the same or different, are independently selected from hydrogen, halogen, cyano, substituted or unsubstituted alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; \n\n\n 'm' is an integer ranging from 0 to 4, both inclusive; and \n\n\n 'p' is an integer ranging from 0 to 4, both inclusive. \n\n\n The embodiments below are illustrative of the present invention and are not intended to limit the claims to the specific embodiments exemplified. \n\n\n According to one embodiment, specifically provided are compounds of the formula (V) in which R\n6\n is substituted or unsubstituted aryl, preferably substituted aryl, more preferably substituted phenyl; wherein the substituent is halogen preferably chlorine. \n\n\n According to another embodiment, specifically provided are compounds of the formula (V) in which R\n7\n is hydrogen or substituted or unsubstituted alkyl (preferably unsubstituted alkyl, more preferably methyl). \n\n\n According to yet another embodiment, specifically provided are compounds of the formula (V) in which ring Ar' is aryl, preferably phenyl. \n\n\n According to yet another embodiment, specifically provided are compounds of the formula (V) in which ring Ar' is heteroaryl, preferably \n\n\n\n\n\n According to yet another embodiment, specifically provided are compounds of the formula (V) in which 'p' is 0. \n\n According to yet another embodiment, specifically provided are compounds of the formula (V) in which R\n8\n is halogen (e.g., chlorine), cyano, substituted or unsubstituted alkyl (e.g.. methyl) or haloalkyl (e.g., trifluoromethyl); and 'p' is 1 or 2. \n\n\n According to yet another embodiment, specifically provided are compounds of the formula (V) in which 'm' is 0. \n\n\nAccording to one embodiment, there is provided a compound of formula (VI): \n\n\n\n\n\n\n\n\n (VI) \n\n\nor a pharmaceutically acceptable salt thereof, \n\n\nwherein, \n\n\n A is -S- or -N=CH-; \n\n\n ring Ar\n1\n is selected from aryl, heteroaryl and heterocyclyl; \n\n\n R\n6\n is selected from hydrogen, halogen, haloalkyl, hydroxyl, cyano, nitro, substituted or unsubstituted alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, cyanoalkyl, cyanoalkyloxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocyclyl, -C(0)R\nA\n, -C(0)NR\nA\nR\nB\n, -C(0)OR\nA\n, - CR WR\n0\n, -NR\nA\nR\nB\n, -NR\nA\nCONR\nB\nR°, -NR\nA\nC(0)OR\nB\n, -N(R\nA\n)SOR\nB\n, -N(R\na\n)S0\n2\nR\nB\n, - NR\nA\nC(0)R\nB\n, -NR\nA\nC(S)R\nB\n, -NR\nA\nC(S)NR\nB\nR\nC\n, -SONR\nA\nR\nB\n, -S0\n2\nNR\nA\nR\nB\n, -OC(0)R\nA\n, - OC(0)NR\nA\nR , -SR\nA\n, -SOR , -S0\n2\nR\nA\n and -C(S)R\nA\n ; \n\n\n R\n7\n is selected from hydrogen, substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocyclyl, -C(0)R , -C(0)OR\nA\n, -C(0)NR\nA\nR\nB\n, - S(0)NR\nA\nR\nB\n, -S0\n2\nNR\nA\nR , -S(0)R\nA\n and -S0\n2\nR\nA\n; \n\n\n at each occurrence, R\n9\n is independently selected from halogen, nitro, cyano, substituted or unsubstituted alkyl, alkenyl, alkynyl, alkoxyalkyl, haloalkyl, haloalkoxy, cyanoalkyl, cyanoalkyloxy, cycloalkyl, cycloalkylalkyl, cycloalkenyl, aryl, aryloxy, aralkyl, arylalkyloxy, heteroaryl, heteroaralkyl, heterocyclyl, heterocyclylalkyl, -OR\nA\n, -OC(0)R\nA\n, - OC(0)N R\nA\nR\nB\n, -C(0)R\nA\n, -C(0)OR\nA\n, -C(0)NR\nA\nR\nB\n, -CR'R'WR\", -NR\nA\nR\nB\n, -NR\nA\nC(0)NR\nB\nR\nC\n, - NR\nA\nC(0)OR\nB\n, -N(R\nA\n)S(0)R\nB\n, -N(R\na\n)S0\n2\nR , -NR\nA\nC(0)R\nB\n, -NR\nA\nC(S)R\nB\n, -NR\nA\nC(S)NR\nB\nR\nC\n, - S(0)NR\nA\nR\nB\n, -S0\n2\nNR\nA\nR\nB\n, -SR\nA\n, -S(0)R\nA\n, -S0\n2\nR\nA\n and -C(S)R\nA\n; \n\n R\na\n, R\nb\n and R\nc\n, which may be the same or different, are independently selected from hydrogen, halogen, cyano, substituted or unsubstituted alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl; and \n\n\n R\n16\n and R\n1 7\n, which may be the same or different, are independently selected from hydrogen and substituted or unsubstituted alkyl; and \n\n\n 'q' is an integer ranging from 0 to 4, both inclusive. \n\n\n The embodiments below are illustrative of the present invention and are not intended to limit the claims to the specific embodiments exemplified. \n\n\n According to one embodiment, specifically provided are compounds of the formula (VI) in which R\n6\n is substituted or unsubstituted aryl, preferably substituted aryl, more preferably substituted phenyl; wherein the substituent is halogen preferably chlorine. \n\n\n According to another embodiment, specifically provided are compounds of the formula (VI) in which R\n7\n is substituted or unsubstituted alkyl, preferably unsubstituted alkyl, more preferably methyl or ethyl. \n\n\n According to yet another embodiment, specifically provided are compounds of the formula (VI) in which ring Ar\n1\n is aryl, preferably phenyl. \n\n\n According to yet another embodiment, specifically provided are compounds of the formula (VI) in which ring Ar' is heteroaryl, preferably\n\n\n , \n\n\n According to yet another embodiment, specifically provided are compounds of the formula (VI) in which A is -S-. \n\n\n According to yet another embodiment, specifically provided are compounds of the formula (VI) in which A is -N=CH-\n\n\nAccording to yet another embodiment, specifically provided are compounds of the formula (VI) in which R\n16\n is hydrogen or substituted or unsubstituted alkyl (preferably unsubstituted alkyl, more preferably methyl). \n\n\n According to yet another embodiment, specifically provided are compounds of the formula (VI) in which R\n17\n is hydrogen or substituted or unsubstituted alkyl (preferably unsubstituted alkyl, more preferably methyl). \n\n\n According to yet another embodiment, specifically provided are compounds of the formula (VI) in which 'q' is 0. \n\n\n It should be understood that the formula (I-VI) structurally encompasses all stereoisomer, including enantiomer and diastereomer, N-oxide, deuterated compound, and \n\n pharmaceutically acceptable salt that may be contemplated from the chemical structure of the genus described herein. \n\n\n The present invention also provides a pharmaceutical composition that includes at least one compound described herein and at least one pharmaceutically acceptable excipient, such as a pharmaceutically acceptable carrier or diluent. Preferably, the pharmaceutical composition comprises a therapeutically effective amount of at least one compound described herein. The compounds described in the present patent application may be associated with a pharmaceutically acceptable excipient, such as a carrier or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper or other container. \n\n\n The compounds and pharmaceutical compositions of the present invention are useful for inhibiting PDE10A, which is related to a variety of disease states. \n\n\n The present invention further provides a method of inhibiting PDE 10A in a subject in need thereof by administering to the subject one or more compounds described herein in an amount effective to cause inhibition of such receptor. \n\n\nDetailed Description of the Invention \n\n\n Definitions \n\n\n The terms \"halogen\" or \"halo\" means fluorine, chlorine, bromine or iodine. \n\n\n The term \"alkyl\" refers to a hydrocarbon chain radical that includes solely carbon and hydrogen atoms in the backbone, containing no unsaturation, having from one to eight carbon atoms, and which is attached to the rest of the molecule by a single bond, e.g., methyl, ethyl, n-propyl, 1 -methylethyl (isopropyl), n-butyl, n-pentyl and 1 , 1 -dimethylethyl (t-butyl). Unless set forth or recited to the contrary, all alkyl groups described herein may be straight chain or branched, substituted or unsubstituted. \n\n\n The term \"alkenyl\" refers to a hydrocarbon chain containing from 2 to 10 carbon atoms and including at least one carbon-carbon double bond. Examples of such alkenyl moiety include, but are not limited to, ethenyl, 1 -propenyl, 2-propenyl (allyl), wo-propenyl, \n'\n 2-methyl- l -propenyl, 1 -butenyl and 2-butenyl. Unless set forth or recited to the contrary, all alkenyl groups described herein may be straight chain or branched, substituted or unsubstituted. \n\n\n The term \"alkynyl\" refers to a hydrocarbyl radical having at least one carbon-carbon triple bond, and having 2 to about 12 carbon atoms (with radicals having 2 to about 10 carbon atoms being preferred). Examples of such alkynyl moiety include, but are not limited to, \n\n ethynyl, propynyl and butynyl. Unless set forth or recited to the contrary, al l alkynyl groups described herein may be straight chain or branched, substituted or unsubstituted. \n\n\n The term \"alkoxy\" refers an alkyl group attached via an oxygen linkage to the rest of the molecule. Examples of such alkoxy moiety include, but are not limited to, -OCH\n3\n and - OC\n2\nH\n5\n. Unless set forth or recited to the contrary, all alkoxy groups described herein may be straight chain or branched, substituted or unsubstituted. \n\n\n The term \"alkoxyalkyl\" or \"alkyloxyalkyl\" refers to an alkoxy or alkyloxy group as defined above directly bonded to an alkyl group as defined above. Example of such alkoxyalkyl moiety includes, but are not limited to, -CH\n2\nOCH\n3\n and -CH\n2\nOC\n2\nH\n5\n. Unless set forth or recited to the contrary, all alkoxyalkyl groups described herein may be straight chain or branched, substituted or unsubstituted. \n\n\n The term \"haloalkyl\" refers to at least one halo group (selected from F, CI. Br or I), linked to an alkyl group as defined above. Examples of such haloalkyl moiety include, but are not l im ited to, trifluoromethyl, difluoromethyl and fluoromethyl groups. Unless set forth or recited to the contrary, all haloalkyl groups described herein may be straight chain or branched, substituted or unsubstituted. \n\n\n The term \"haloalkoxy\" refers to an alkoxy group substituted with one or more halogen atoms. Examples of \"haloalkoxy\" include but are not limited to fluoromethoxy, difluoromethoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, pentafluoroethoxy, pentachloroethoxy, chloromethoxy, dichlorormethoxy, trichloromethoxy and 1 -bromoethoxy. Unless set forth or recited to the contrary, all haloalkoxy groups described herein may be straight chain or branched, substituted or unsubstituted. \n\n\n The term \"hydroxyalkyl\" refers to an alkyl group as defined above wherein one to three hydrogen atoms on different carbon atoms is/are replaced by hydroxyl groups. Examples of hydroxyalkyl moiety include, but are not limited to -CH2OH and -C2H\n4\nOH . \n\n\n The term \"cycloalkyl\" denotes a non-aromatic mono or multicyclic ring system of 3 to about 12 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. Examples of multicyclic cycloalkyl groups include, but are not limited to, perhydronapththyl, adamantyl and norbornyl groups, bridged cyclic groups or sprirobicyclic groups, e.g., sprio(4,4)non-2-yl, spiro[3,3]heptanyl, spiro[3,4]octanyl and spiro[4,4]heptanyl. Unless set forth or recited to the contrary, all cycloalkyl groups described herein may be substituted or unsubstituted. \n\n\n The term \"cycloalkylalkyl\" refers to a cyclic ring-containing radical having 3 to about 8 carbon atoms directly attached to an alkyl group. The cycloalkylalkyl group may be \n\n attached to the main structure at any carbon atom in the alkyl group that results in the creation of a stable structure. Examples of cycloalkylalkyl moiety include, but are not limited to cyclopropylmethyl, cyclobutylethyl, and cyclopentylethyl. Unless set forth or recited to the contrary, all cycloalkylalkyl groups described or claimed herein may be substituted or unsubstituted. \n\n\n The term \"cycloalkenyl\" refers to a cyclic ring-containing radical having 3 to about 8 carbon atoms with at least one carbon-carbon double bond, such as cyclopropenyl, cyclobutenyl, and cyclopentenyl. Unless set forth or recited to the contrary, all cycloalkenyl groups described or claimed herein may be substituted or unsubstituted. \n\n\n The term \"aryl\" refers to an aromatic radical having 6 to 14 carbon atoms, including monocyclic, bicyclic and tricyclic aromatic systems, such as phenyl, naphthyl, tetrahydronapthyl, indanyl and biphenyl. Unless set forth or recited to the contrary, all aryl groups described herein may be substituted or unsubstituted. \n\n\n The term \"aryloxy\" refers to an aryl group as defined above attached via an oxygen linkage to the rest of the molecule. Examples of aryloxy moiety include, but are not limited to phenoxy and naphthoxy. Unless set forth or recited to the contrary, all aryloxy groups described herein may be substituted or unsubstituted. \n\n\n The term \"arylalkyl\" refers to an aryl group as defined above directly bonded to an alkyl group as defined above. Examples of arylalkyl moiety include, but are not limited to - CH\n2\nC6H\n5\n and -C2H4C6H5. Unless set forth or recited to the contrary, all arylalkyl groups described herein may be substituted or unsubstituted. \n\n\n The term \"arylalkyloxy\" refers to an arylalkyl group attached via an oxygen linkage to the rest of the molecule. Examples of arylalkyloxy moiety include, but are not limited to - OCH2C6H5 and -OC2H4C6H5. Unless set forth or recited to the contrary, all arylalkyloxy groups described herein may be substituted or unsubstituted. \n\n\n The term \"heterocyclic ring\" or \"heterocyclyl\" unless otherwise specified refers to substituted or unsubstituted non-aromatic 3 to 15 membered ring radical which consists of carbon atoms and from one to five heteroatoms selected from nitrogen, phosphorus, oxygen and sulfur. The heterocyclic ring radical may be a mono-, bi- or tricyclic ring system, which may include fused, bridged or spiro ring systems, and the nitrogen, phosphorus, carbon, oxygen or sulfur atoms in the heterocyclic ring radical may be optionally oxidized to various oxidation states. In addition, the nitrogen atom may be optionally quaternized; also, unless otherwise constrained by the definition the heterocyclic ring or heterocyclyl may optionally contain one or more olefinic bond(s). Examples of such heterocyclic ring radicals include, but \n\n are not limited to azepinyl, azetidinyl, benzodioxolyl, benzodioxanyl, chromanyl, dioxolanyl, dioxaphospholanyl, decahydroisoquinolyl, indanyl, indolinyl, isoindolinyl, isochromanyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, oxazolinyl, oxazolidinyl, oxadiazolyl, 2- oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxoazepinyl, octahydroindolyl, octahydroisoindolyl, perhydroazepinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, piperidinyl, phenothiazinyl, phenoxazinyl, quinuclidinyl, tetrahydroisquinolyl, tetrahydrofuryl, tetrahydropyranyl, thiazolinyl, thiazolidinyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, 7-aza-spiro[3,3]heptanyl, 7-spiro[3,4]octanyl, and 7-aza- spiro[3,4]octanyI. The heterocyclic ring radical may be attached to the main structure at any heteroatom or carbon atom that results in the creation of a stable structure. Unless set forth or recited to the contrary, all heterocyclyl groups described herein may be substituted or unsubstituted. \n\n\n The term \"heterocyclylalkyl\" refers to a heterocyclic ring radical directly bonded to an alkyl group. The heterocyclylalkyl radical may be attached to the main structure at any carbon atom in the alkyl group that results in the creation of a stable structure. Unless set forth or recited to the contrary, all heterocyclylalkyl groups described herein may be substituted or unsubstituted. \n\n\n The term \"heteroaryl\" unless otherwise specified refers to substituted or unsubstituted 5 to 14 membered aromatic heterocyclic ring radical with one or more heteroatom(s) independently selected from N, O or S. The heteroaryl may be a mono-, bi- or tricyclic ring system. The heteroaryl ring radical may be attached to the main structure at any heteroatom or carbon atom that results in the creation of a stable structure. Examples of such heteroaryl ring radicals include, but are not limited to oxazolyl, isoxazolyl, imidazolyl, furyl, indolyl, isoindolyl, pyrrolyl, triazolyl, triazinyl, tetrazoyl, thienyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, benzofuranyl, benzothiazolyl, benzoxazolyl, benzimidazolyl, benzothienyl, benzopyranyl, carbazolyl, quinolinyl, isoquinolinyl, quinazolinyl, cinnolinyl, naphthyridinyl, pteridinyl, purinyl, quinoxalinyl, quinolyl, isoquinolyl, thiadiazolyl, indolizinyl, acridinyl, phenazinyl and phthalazinyl. Unless set forth or recited to the contrary, all heteroaryl groups described herein may be substituted or unsubstituted. \n\n\n The term \"heteroarylalkyl\" refers to a heteroaryl ring radical directly bonded to an alkyl group. The heteroarylalkyl radical may be attached to the main structure at any carbon atom in the alkyl group that results in the creation of a stable structure. Unless set forth or \n\n recited to the contrary, all heteroarylalkyi groups described herein may be substituted or unsubstituted. \n\n\n Unless otherwise specified, the term \"substituted\" as used herein refers to a group or moiety having one or more of the substituents attached to the structural skeleton of the group or moiety, including, but not limited to such substituents as hydroxy, halogen, carboxyl, cyano, nitro, oxo (=0), thio (=S), substituted or unsubstituted alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted haloalkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkeny!, substituted or unsubstituted amino, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclylalkyl ring, substituted or unsubstituted heteroarylalkyi, substituted or unsubstituted heterocyclic ring, substituted or unsubstiuted guanidine, -COOR\nx\n, -C(0)R\nx\n, -C(S)R\nX\n, -C(0)NR\nx\nR\ny\n, - C(0)ONR\nx\nR\nv\n, -NR CONR\ny\nR\nz\n, -N(R\nx\n)SOR\ny\n, -N(R\nx\n)S0\n2\nR\ny\n, -(=N-N(R\nx\n)R\ny\n), -NR\nx\nC(0)OR\ny\n, - NR R\ny\n, -NR\nx\nC(0)R\ny\n, -NR\nx\nC(S)R\ny\n, -NR\nx\nC(S)NR\ny\nR\n7\n, -SONR\nx\nR\ny\n, -S0\n2\nNR\nx\nR\ny\n, -OR\nx\n, - OC(0)R\nx\n, -OC(0)NR\nx\nR\ny\n, -SR\nX\n, -SOR\nx\n, -S0\n2\nR\nx\n, and -ON0\n2\n, wherein R\nx\n, R\ny\n and R\nz\n are independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted amino, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted heterocyclylalkyl ring, substituted or unsubstituted heteroarylalkyi, or substituted or unsubstituted heterocyclic ring. The substituents in the aforementioned \"substituted\" groups cannot be further substituted. For example, when the substituent on \"substituted alkyl\" is \"substituted aryl\", the substituent on \"substituted aryl\" cannot be \"substituted alkenyl\". \n\n\n The term \"treating\" or \"treatment\" of a state, disorder or condition includes: (a) preventing or delaying the appearance of clinical symptoms of the state, disorder or condition developing in a subject that may be afflicted with or predisposed to the state, disorder or condition but does not yet experience or display clinical or subclinical symptoms of the state, disorder or condition; (b) inhibiting the state, disorder or condition, i.e., arresting or reducing the development of the disease or at least one clinical or subclinical symptom thereof; or (c) relieving the disease, i.e., causing regression of the state, disorder or condition or at least one of its clinical or subclinical symptoms. \n\n The term \"subject\" includes mammals (especially humans). Other mammals include domestic animals (e.g., household pets including cats and dogs) and non-domestic animals (such as wildlife). \n\n\n A \"therapeutically effective amount\" means the amount of a compound that, when administered to a subject for treating a state, disorder or condition, is sufficient to effect such treatment. The \"therapeutically effective amount\" will vary depending on the compound, the disease and its severity and the age, weight, physical condition and responsiveness of the subject to be treated. \n\n\n Pharmaceutically acceptable salts forming part of this patent application include salts derived from inorganic bases (such as Li, Na, K, Ca, Mg, Fe, Cu, Zn, and Mn), salts of organic bases (such as N,N'-diacetylethylenediamine, glucamine, triethylamine, choline, hydroxide, dicyclohexylamine, metformin, benzylamine, trialkylamine, and thiamine), salts of chiral bases (such as alkylphenylamine, glycinol, and phenyl glycinol), salts of natural amino acids (such as glycine, alanine, valine, leucine, isoleucine, norleucine. tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, and serine), salts of non-natural amino acids (such as D-isomers or substituted amino acids), salts of guanidine, salts of substituted guanidine (wherein the substituents are selected from nitro, amino, alkyl, alkenyl or alkynyl), ammonium salts, substituted ammonium salts and aluminum salts. Other pharmaceutically acceptable salts include acid addition salts (where appropriate) such as sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates (such as trifluoroacetate), tartrates, maleates, citrates, fumarates, succinates, palmoates, methanesulphonates, benzoates, salicylates, benzenesulfonates, ascorbates, glycerophosphates and ketoglutarates. Yet other pharmaceutically acceptable salts include, but are not limited to, quaternary ammonium salts of the compounds of invention with alkyl halides or alkyl sulphates (such as Mel or Me\n2\nS0\n4\n). \n\n\n Compounds described herein can comprise one or more asymmetric carbon atoms and thus can occur as racemic mixtures, enantiomers and diastereomers. These compounds can also exist as conformers/rotamers. All such isomeric forms of these compounds are expressly included in the present patent application. Although the specific compounds exemplified in this application may be depicted in a particular stereochemical configuration, compounds having either the opposite stereochemistry at any given chiral centre are envisioned as a part thereof. In addition, compounds of Formula I can exist in different geometrical isomeric forms. Unless otherwise stated a reference to a particular compound includes all such isomeric forms, including racemic and other mixtures thereof. The various isomeric forms of \n\n the compounds of the present invention may be separated from one another by methods known in the art or a given isomer may be obtained by stereospecific or asymmetric synthesis. Tautomeric forms and mixtures of compounds described herein are also contemplated. \n\n\nPharmaceutical Compositions \n\n\n The pharmaceutical composition of the present patent application comprises one or more compounds described herein and one or more pharmaceutically acceptable excipients, carriers, diluents or mixture thereof. The compounds described herein may be associated with one or more pharmaceutically acceptable excipients, carriers, diluents or mixture thereof in the form of capsule, sachet, paper or other container. \n\n\n Examples of suitable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, peanut oil, olive oil, gelatin, lactose, terra alba, sucrose, dextrin, magnesium carbonate, sugar, cyclodextrin, amylose, magnesium stearate, talc, gelatin, agar, pectin, acacia, stearic acid or lower alkyl ethers of cellulose, silicic acid, fatty acids, fatty acid amines, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, polyoxyethylene, hydroxymethyl cellulose and polyvinylpyrrolidone. \n\n\n The carrier or diluent may include a sustained release material, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax. \n\n\n The pharmaceutical composition may also include one or more pharmaceutically acceptable auxiliary agents, wetting agents, emulsifying agents, suspending agents, preserving agents, salts for influencing osmetic pressure, buffers, sweetening agents, flavoring agents, colorants or any combination of the foregoing. The pharmaceutical composition of the patent application may be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the subject by employing methods known in the art. \n\n\n The pharmaceutical compositions of the present patent application may be prepared by conventional techniques, e.g., as described in Remington: The Science and Practice of Pharmacy, 20\nth\n Ed., 2003 (Lippincott Williams & Wilkins). For example, the active compound is mixed with a carrier, or diluted by a carrier, or enclosed within a carrier, which may be in the form of an ampoule, capsule, sachet, paper or other container. When the carrier serves as a diluent, it may be a solid, semi-solid or liquid material that acts as a vehicle, \n\n excipient or medium for the active compound. The active compound is adsorbed on a granular solid container, for example, in a sachet. \n\n\n The pharmaceutical compositions may be in conventional forms, for example, capsules, tablets, aerosols, solutions, suspensions or products for topical application. \n\n\n The route of administration may be any route which effectively transports the active compound of the patent application to the appropriate or desired site of action. Suitable routes of administration include, but are not limited to, oral, nasal, pulmonary, buccal, subdermal, intradermal, transdermal, parenteral, rectal, depot, subcutaneous, intravenous, intraurethral, intramuscular, intranasal, ophthalmic (such as with an ophthalmic solution) or topical (such as with a topical ointment). The oral route is preferred. \n\n\n Solid oral formulations include, but are not limited to, tablets, capsules (soft or hard gelatin), dragees (containing the active ingredient in powder or pellet form), troches and lozenges. Tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or the like are particularly suitable for oral application. Preferable carriers for tablets, dragees, or capsules include lactose, cornstarch and/or potato starch. A syrup or elixir is used in cases where a sweetened vehicle is employed. \n\n\n Liquid formulations include, but are not limited to, syrups, emulsions, soft gelatin and sterile injectable liquids, such as aqueous or non-aqueous liquid suspensions or solutions. \n\n\n For parenteral application, particularly suitable are injectable solutions or suspensions, preferably aqueous solutions with the active compound dissolved in polyhydroxylated castor oil. \n\n\n Suitable doses of the compounds for use in treating the diseases and disorders described herein can be determined by those skilled in the relevant art. Therapeutic doses are generally identified through a dose ranging study in humans based on preliminary evidence derived from the animal studies. Doses must be sufficient to result in a desired therapeutic benefit without causing unwanted side effects. For example, the daily dosage of the PDEI OA inhibitors can range from about 0.1 to about 30.0 mg/Kg. Mode of administration, dosage forms, suitable pharmaceutical excipients, diluents or carriers can also be well used and adjusted by those skilled in the art. All changes and modifications are envisioned within the scope of the present patent application. \n\n\nMethods of Treatment \n\n\n The present patent application provides a method of treating a disease, condition or disorder modulated by a PDEI OA, in a subject by administering to the subject in need thereof \n\n a therapeutically effective amount of a compound or a pharmaceutical composition described herein. \n\n\n The present patent application further provides a method of treating diseases, disorders or conditions, modulated by a PDE10A in mammals including human, of neuropsychiatric, neurodegenerative, neurological, neuroendocrinological nature such as, but not limiting to, schizophrenia, psychoses, schizoaffective disorders, positive symptoms of schizophrenia including delusions, disordered thoughts and speech, and tactile, auditory, visual, olfactory and gustatory hallucinations, paranoia, paranormal behaviors, negative symptoms of schizophrenia like deficits of normal emotional responses or of other thought processes including flat or blunted affect and emotion, poverty of speech (alogia), inability to experience pleasure (anhedonia), lack of desire to form relationships (asociality), and lack of motivation (avolition) leading to poor quality of life, functional disabilities typically regarded as manifestations of psychosis and other comorbidities like cognitive, executive, attention, learning, memory, spatial memory and social cognitive functions, Tic disorders like Tourette's syndrome, autism, autism spectrum disorders, attention deficit hyperactivity disorders (ADHD), pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS), mood disorders, anxiety, depression, major depressive disorders, bipolar disorders, manias, aggression, obsessive compulsive disorders, Huntington's disease, Alzheimer's disease, Parkinsons disease, rest-less leg syndrome, various other neurological disorders consisting of movement disorders, ataxias, sensation disorders, cognitive disorders related to multiple sclerosis, amyotrophic lateral sclerosis, abnormalities of brain, spinal cord, nerves leading to symptoms such as paralysis, seizures, catatonias, catalepsies, muscle rigidities, muscle weakness, poor coordination, loss of sensation, confusion, mental suffering, pain and altered levels of consciousness and various other diseases, disorders or conditions related to neuroendocrinological and metabolic manifestations like change of circardian rhythms, sleep disorders, insomnia, jet lags, eating disorders like anorexia nervosa, bulimia nervosa, exercise bulimia or binge eating disorder, aggressive behaviours, obsessive compulsive personality disorders, narcissistic personality disorders, sexual and gender identity disorders and diseases related to brain, spinal cord regions, glands and hormones located in the central and peripheral nervous systems related to basal ganglia, limbic system, neostriatum, caudate putamen, striatum, striatal medium spiny neurons, globus pallidus, thalamus, prefrontal cortex, cortex, nucleus accumbens, ventral tegmental area, corpus striatum, substantia nigra, optic chiasm, vomeronasal organ, suprachiasmatic nucleus, hippocampus, amygdala, cerebellum, pineal gland, pituitary gland, \n\n hypothalamus, hypothalamo-pituitary-adrenal axis, thyroid, gonads and trinucleotide repeat expansion diseases of polyglutamine and non-polyglutamine nature. \n\n\n This patent application also provides a method of treating a disorder or condition comprising as a symptom a deficiency in attention and/or cognition in a mammal, including a human, which method comprises administering to said mammal an amount of a compound of formula I effective in treating said disorder or condition. The phrase \"deficiency in attention and/or cognition\" as used in the phrase \"disorder comprising as a symptom a deficiency in attention and/or cognition\" refers to a subnormal functioning in one or more cognitive aspects such as memory, intellect, or learning and logic ability, in a particular individual relative to other individuals within the same general age population. \"Deficiency in attention and/or cognition\" also refers to a reduction in any particular individual's functioning in one or more cognitive aspects, for example as occur in age-related cognitive decline. \n\n\n Examples of disorders that comprise as a symptom a deficiency in attention and/or cognition that can be treated according to the present patent application are dementia, for example, Alzheimer's disease, multi-infarct dementia, alcoholic dementia or other drug- related dementia, dementia associated with intracranial tumors or cerebral trauma, dementia associated with Huntington's disease or Parkinson's disease, Multiple sclerosis, Amyotrophic lateral sclerosis, Down's syndrome or AIDS-related dementia; delirium, amnestic disorder, post-traumatic stress disorder, mental retardation, a learning disorder, for example reading disorder, mathematics disorder, or a disorder of written expression, attention- deficit/hyperactivity disorder and age-related cognitive decline. This patent application also provides a method of treating a mood disorder or mood episode in a mammal, including a human, comprising administering to said mammal an amount of a compound of formula I effective in treating said disorder or episode. This patent application also provides a method of treating a mood disorder or mood episode in a mammal, including a human, comprising administering to said mammal a therapeutically effective amount of a compound of formula I in inhibiting PDE1 OA. \n\n\n Examples of mood disorders and mood episodes that can be treated according to the present patent application include, but are not limited to, major depressive episode of the mild, moderate or severe type, a manic or mixed mood episode, a hypomanic mood episode; a depressive episode with atypical features; a depressive episode with melancholic features; a depressive episode with catatonic features; a mood episode with postpartum onset; post- stroke depression; major depressive disorder; dysthymic disorder; minor depressive disorder; premenstrual dysphoric disorder; post-psychotic depressive disorder of schizophrenia; a \n\n major depressive disorder superimposed on a psychotic disorder such as delusional disorder or schizophrenia; a bipolar disorder, for example bipolar ] disorder, bipolar 11 disorder and cyclothymic disorder. \n\n\n This patent application further provides a method of treating a neurodegenerative disorder or condition in a mammal, including a human, which method comprises administering to said mammal a therapeutically effective amount of a compound of the present invention in treating said disorder or condition. \n\n\n This patent application further provides a method of treating a neurodegenerative disorder or condition in a mammal, including a human, which method comprises administering to said mammal a therapeutically effective amount of a compound of formula (1) in inhibiting PDE 10A. As used herein and unless otherwise indicated, a \"neurodegenerative disorder or condition\" refers to a disorder or condition that is caused by the dysfunction and/or death of neurons in the central nervous system. The treatment of these disorders and conditions can be facilitated by administration of an agent which prevents the dysfunction or death of neurons at risk in these disorders or conditions and/or enhances the function of damaged or healthy neurons in such a way as to compensate for the loss of function caused by the dysfunction or death of at-risk neurons. The term \"neurotrophic agent\" as used herein refers to a substance or agent that has some or all of these properties. \n\n\n Examples of neurodegenerative disorders and conditions that can be treated according to the present patent application include, but are not limited to, Parkinson's disease; Huntington's disease; dementia, for example Alzheimer's disease, multi-infarct dementia, AIDS-related dementia, and Fronto temperal Dementia; neurodegeneration associated with cerebral trauma; neurodegeneration associated with stroke, neurodegeneration associated with cerebral infarct; hypoglycemia-induced neurodegeneration; neurodegeneration associated with epileptic seizure; neurodegeneration associated with neurotoxin poisoning; and multi-system atrophy. \n\n\n In one aspect of the present patent application, the neurodegenerative disorder or condition comprises neurodegeneration of striatal medium spiny neurons in a mammal, including a human. \n\n\n In another aspect, this patent application provides a pharmaceutical composition for treating psychotic disorders, delusional disorders and drug induced psychosis, anxiety disorders, movement disorders, mood disorders, neurodegenerative disorders or drug addiction, comprising a therapeutically effective amount of a compound of the present invention in treating said disorder or condition. \n\n In another aspect, this patent application provides a method of treating a disorder selected from psychotic disorders, delusional disorders and drug induced psychosis, anxiety disorders, movement disorders, mood disorders, and neurodegenerative disorders, which method comprises administering a therapeutically effective amount of a compound of the present invention in treating said disorder. \n\n\n In another aspect, this patent application provides a method of treating the disorders above, where the disorders are selected from the group consisting of: dementia, Alzheimer's disease, multi-infarct dementia, alcoholic dementia or other drug-related dementia, dementia associated with intracranial tumors or cerebral trauma, dementia associated with Huntington's disease or Parkinson's disease, or AIDS-related dementia; delirium; amnestic disorder; posttraumatic stress disorder; mental retardation; a learning disorder, for example reading disorder, mathematics disorder, or a disorder of written expression; attention- deficit/hyperactivity disorder; age-related cognitive decline, major depressive episode of the mild, moderate or severe type; a manic or mixed mood episode; a hypomanic mood episode; a depressive episode with atypical features; a depressive episode with melancholic features; a depressive episode with catatonic features; a mood episode with postpartum onset; post- stroke depression; major depressive disorder; dysthymic disorder; minor depressive disorder; premenstrual dysphoric disorder; post-psychotic depressive disorder of schizophrenia; a major depressive disorder superimposed on a psychotic disorder comprising a delusional disorder or schizophrenia; a bipolar disorder comprising bipolar I disorder, bipolar II disorder, cyclothymic disorder, Parkinson's disease; Huntington's disease; dementia, Alzheimer's disease, multi-infarct dementia, AIDS-related dementia, Fronto temperal Dementia; neurodegeneration associated with cerebral trauma; neurodegeneration associated with stroke; neurodegeneration associated with cerebral infarct; hypoglycemia-induced neurodegeneration; neurodegeneration associated with epileptic seizure; neurodegeneration associated with neurotoxin poisoning; multi-system atrophy, paranoid, disorganized, catatonic, undifferentiated or residual type; schizophreniform disorder; schizoaffective disorder of the delusional type or the depressive type; delusional disorder; substance-induced psychotic disorder, psychosis induced by alcohol, amphetamine, cannabis, cocaine, hallucinogens, inhalants, opioids, or phencyciidine; personality disorder of the paranoid type; personality disorder of the schizoid type. \n\n\n In another aspect, there is provided a method for preventing, ameliorating or treating a disease or condition selected from obesity or related diseases, conditions; diabetes (including Type I and Type II diabetes); diabetic complications; glucose tolerance; hyperinsulinemia; \n\n insulin sensitivity or resistance; metabolic syndromes; cardiovascular diseases including, for example, atherosclerosis, lipidemia, dyslipidemia, elevated blood pressure, microalbuminemia, hyperuricaemia, hypercholesterolemia, hyperlipidemias, hypertriglyceridemias, arteriosclerosis or combination thereof; respiratory diseases or disorders including, for example, sinusitis, asthma, bronchitis or combination thereof; or any combination these diseases, disorders, conditions and/or syndromes thereof; the disease or condition related to serum levels of triglyceride, LDL, HDL, VLDL, total chlolesterol, which method comprises administering to said mammal a therapeutically effective amount of a compound of formula (1) in treating said disorder or condition. \n\n\nGeneral Methods of Preparation \n\n\n The compounds described herein, including compounds of general formula (l)-(VI) and specific examples are prepared using techniques known to one skilled in the art through the reaction sequences depicted in Schemes 1 -5 as well as by other methods. Furthermore, in the following schemes, where specific acids, bases, reagents, coupling agents, solvents, etc. are mentioned, it is understood that other suitable acids, bases, reagents, coupling agents etc. may be used and are included within the scope of the present invention. Modifications to reaction conditions, for example, temperature, duration of the reaction or combinations thereof, are envisioned as part of the present invention. The compounds obtained by using the general reaction sequences may be of insufficient purity. These compounds can be purified by using any of the methods for purification of organic compounds known to persons skilled in the art, for example, crystallization or silica gel or alumina column chromatography using different solvents in suitable ratios. All possible stereoisomers are envisioned within the scope of this invention. \n\n\n The starting materials for the below reaction schemes are commercially available or can be prepared according to methods known to one skilled in the art or by methods disclosed herein. In general, the compounds according to the present invention may be prepared through the reaction scheme as follows. \n\n\n Synthetic scheme 1 \n\n\n\n\n\n\n\n\n\n\n(ΙΑ) \n\n\n A general approach for the synthesis of compounds of the general formula (IA), wherein R , R\n2\n, R\n3\n, R\n9\n, A, B, D, L, Ar\n2\n, ' m', 'n' and 'q' are as defined in the description is described in Synthetic scheme 1 . \n\n\n The compound of formula (l a) is converted into compound of formula (2) by reacting with a substituted alkyl halide at a temperature range of 0-100°C using a suitable solvent (for e.g., acetonitrile, dimethylformamide, dimethylsulphoxide, tetrahydrofuran etc.) in the presence of suitable base such as alkali metal carbonate (for e.g., potassium carbonate etc.), alkali metal hydride (for e.g., sodium hydride etc.) or alkali metal hydroxide (for e.g., sodium hydroxide etc.) and the like following procedures known in the art of organic synthesis. Alternatively a compound of formula (2) can also be prepared by the reaction of a compound of formula (l a) with a substituted hydroxy compound under Mitsunobu conditions. Compound of formula (2) can also be prepared by the reaction of a compound of formula ( l b) with an appropriately substituted hydroxy compound in the presence of a base such as alkali metal carbonate (for e.g., potassium carbonate etc.), alkali metal hydride (for e.g., sodium hydride etc.) or alkali metal hydroxide (for e.g., sodium hydroxide etc.) and the like using a suitable solvent (for e.g., acetonitrile, dimethylformamide, dimethyl sulfoxide, tetrahydrofuran etc.). Compound of formula (2) is converted into compound of formula (3) \n\n under reductive conditions utilizing iron or tin metal in a mineral acid like hydrochloric acid or catalytic reduction condition utilizing palladium or platinum on carbon in presence of hydrogen gas and the like. Compound of formula (3) can be converted to a compound of formula (4) by reacting with a substituted halide compound at a temperature (0-100°C) using an appropriate solvent (for e.g., acetonitrile, dimethylformamide, dimethylsulphoxide, tetrahydrofuran etc.) in the presence of suitable base such as alkali metal carbonate (for e.g., potassium carbonate etc.), alkali metal hydride (for e.g., sodium hydride etc.) or alkali metal hydroxide (for e.g., sodium hydroxide etc.) and the like following procedures known in the art of organic synthesis. Alternatively compound of formula (4) can be prepared by reacting the compound of formula (3) with an aldehyde under reductive amination conditions utilizing sodium borohydride, sodium triacetoxyborohydride and the like in an appropriate solvent (for e.g., dichloromethane, dichloroethane etc.) at a temperature range of 0-50°C. Compound of formula (4) can also be prepared by reacting compound of formula (3) with an acid chloride or substituted carbamate derivative in the presence of a base (for e.g. triethylamine, diisopropylethylamine etc.) in an appropriate solvent (for e.g., dichloromethane, tetrahydrofuran, dimethylformamide, dimethyl sulfoxide etc.) under standard coupling conditions. Compound of formula (4) can be converted to a compound of formula (IA) by reacting with a carboxylic acid derivative under standard amidation conditions utilizing a coupling agent (for e.g., carbodiimide, benzotriazol-l -yloxytris(dimethylamino) phosphoniumhexafluorophosphate (BOP reagent) etc.) in the presence of a base (for e.g., triethylamine, diisopropylethylamine etc.) in an appropriate solvent (for e.g., dichloromethane, tetrahydrofuran, dimethylformamide etc.). Alternatively, compound of formula (1A) can also be prepared by reacting a compound of formula (4) with an acid chloride, substituted isothiocyanate derivative or substituted carbamate derivative in the presence of a base (for e.g., triethylamine, diisopropylethylamine etc.) in an appropriate solvent (for e.g., dichloromethane, tetrahydrofuran, dimethylformamide, dimethylsulphoxide etc.). Alternatively, Compound of formula (3) can be converted to a compound of formula (5) by reacting with carboxylic acid compounds under standard amidation conditions utilizing a coupling agent (for e.g., carbodiimide, BOP reagent etc.) in the presence of a base (for e.g., triethylamine, diisopropylethylamine etc.) in an appropriate solvent (for e.g., dichloromethane, tetrahydrofuran, dimethylformamide etc.). Alternatively, compound of formula (5) can also be prepared by reacting a compound of formula (3) with an acid chloride, substituted isothiocyanate derivative or substituted carbamate derivative in the presence of a base (for e.g., triethylamine, diisopropylethylamine etc.) in an appropriate \n\n solvent (for e.g., dichloromethane, tetrahydrofuran, dimethylformamide etc.). Compound of formula (5) can be converted to a compound of formula (IA) by reacting with a substituted alkyl halide or acyl halide at 0-100°C using an appropriate solvent (for e.g., acetonitrile, dimethylformamide, dimethylsulphoxide, tetrahydrofuran etc.) in the presence of suitable base such as alkali metal carbonate (for e.g., potassium carbonate etc.), alkali metal hydride (for e.g., sodium hydride etc.) or alkali metal hydroxide (for e.g., sodium hydroxide etc.) and the like. Compound of formula (IA) can also be prepared by reacting compound of formula (5) with an acid chloride or substituted carbamate derivative in a presence of a suitable base (for e.g. triethylamine, diisopropylethylamine etc.) in an appropriate solvent (for e.g., dichloromethane, tetrahydrofuran, dimethylformam ide, dimethyl sulfoxide etc.). \n\n\nSynthetic scheme 2 \n\n\n\n\n\n\n\n\n X is O or S \n\n\n Y is -(CR\n10\nR\n1 1\n)\nr\n- or -NR\n12\n-\n\n\nA general approach for the synthesis of compounds of the general formula (I I A), wherein R \n1\n . R\n9\n, R \n1 0\n, R \" , R \n1 2\n, R \n1 3\n, B, Ar\n3\n, 'm\\ 'q ', V and 't' are as defined in description is descri bed in Synthetic scheme 2. \n\n\n Compound of formula ( l a) is converted into compound of formula (6) by reacting with a substituted 2-chloromethylquinoline at a temperature range of 0- 100°C using an appropriate solvent (for e.g., acetonitrile, dimethylformamide, dimethylsulphoxide, tetrahydrofuran etc.) in the presence of suitable base such as alkali metal carbonate (for e.g., potassium carbonate etc.), alkali metal hydride (for e.g., sodium hydride etc.) or alkali metal hydroxide (for e.g., sodium hydroxide etc.). Alternatively compound of formula (6) can also be prepared by reacting compound of formula ( l a) with a substituted hydroxy 1 compound of quinoline derivative under Mitsunobu conditions. Compound of formula (6) is converted to a compound of formula (7) under reductive conditions utilizing iron or tin metal in a mineral \n\n acid like hydrochloric acid or catalytic reduction condition utilizing palladium or platinum on carbon in presence of hydrogen gas and the like. Compound of formula (7) can be converted to a compound of formula (8) by reacting with an substituted alkyl halide at 0-100°C using an appropriate solvent (for e.g. acetonitrile, dimethylformamide, dimethylsulphoxide, tetrahydrofuran etc.) in the presence of suitable base such as alkali metal carbonate (for e.g. potassium carbonate etc.), alkali metal hydride (for e.g., sodium hydride etc.) or alkali metal hydroxide (for e.g., sodium hydroxide etc.) and the like following procedure known in the art of organic synthesis. Alternatively formula (8) could also be prepared by reacting a compound of formula (7) with an aldehyde compound under reductive amination conditions utilizing sodium borohydride, sodium triacetoxyborohydride and the like in an appropriate solvent (for e.g., dichloromethane, dichloroethane etc.) at a temperature range of 0-50°C. Compound of formula (8) can be converted to a compound of formula (IIA) by reacting with a carboxylic acid derivative under standard amidation conditions utilizing a coupling agent (for e.g., carbodiimide, benzotriazol-l -yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP reagent) etc.) in the presence of suitable base (for e.g., triethylamine, diisopropylethylamine etc.) in an appropriate solvent (for e.g., dichloromethane, tetrahydrofuran, dimethylformamide etc.). Alternatively formula (IIA) can also be prepared by reacting a compound of formula (8) with an acid chloride, substituted carbamate derivative or substituted isothiocyanate derivative in the presence of a base (for e.g., triethylamine, diisopropylethylamine etc.) in an appropriate solvent (for e.g., dichloromethane. tetrahydrofuran, dimethylformamide, dimethyl sulfoxide etc.). \n\n\nSynthetic scheme 3 \n\n\n\n\n\n\n\n\n (9) (10) (1 1 ) (7) \n\n\nA general approach for the synthesis of compound of formula (7) wherein R\n1\n, R\n9\n, 'm' and 'q' are as defined in the description is described in Synthetic scheme 3. In this scheme, a compound of formula (9) is converted into compound of formula ( 10) (wherein, PG is protecting group) by reacting with a suitable protecting group (for e.g., BOC anhydride) in the presence of suitable base (for e.g., triethylamine, diisopropylethylamine, sodium \n\n hydroxide etc.) and the like in a appropriate solvent (for e.g., dichloromethane, dichloroethane, tetrahydrofuran, acetonitrile, DMSO, water etc.) and the like at a temperature range of 0-80°C following procedures known in the art of organic synthesis. A compound of formula ( 10) is converted to a compound of formula (1 1) by reacting with a substituted 2- chloromethylquinoline at a temperature range of 0-100°C using an appropriate solvent (for e.g., acetonitrile, dimethylformamide, dimethyl sulfoxide, tetrahydrofuran etc.) in the presence of a suitable base such as alkali metal carbonate (for e.g., potassium carbonate), alkali metal hydride (for e.g., sodium hydride) or alkali metal hydroxide (for e.g., sodium hydroxide) and the like by following procedure known in the art of organic synthesis. Compound of formula (1 1 ) is converted to a compound of formula (7) under deprotection conditions utilizing a deprotecting reagent (for e.g., Cone. HCI, saturated ethyl acetate in HCI gas, methanol saturated with HCI gas, p-toluenesulphonic acid etc.) and the like by following procedure known in the art of organic synthesis. \n\n\nSynthetic scheme 4 \n\n\n\n\n\n\n\n\n A general approach for the synthesis of compounds of the general formula (IB), wherein R\n1\n , R\n2\n, R\n3\n, R\n4\n, R\n5\n, R\n6\n, R\n7\n, R\n8\n, Ar\n1\n, 'm', 'n' and 'p' are as defined above in the description is illustrated in Synthetic scheme 4. \n\n In this synthetic scheme, compound of formula (12) is converted to a compound of formula (13), by reacting it with an appropriate substituted or unsubstituted acyl halide at elevated temperature (60°C to 120°C) in a suitable solvent (for e.g., acetonitrile, dimethylformamide, ethanol, dimethoxyethane, dioxane, dimethylsulphoxide etc.) by following procedures known in the art. Compound of formula (13) is converted to a compound of formula (14) where Hal is halogen, by reacting it with halogenating agents such as N-bromosuccinimide or N-iodosuccinimide at -20°C to 100°C, in a suitable solvent such as diethylether, acetonitrile, tetrahydrofuran, dimethylformamide, dimethylsulphoxide or the like by following procedure known in the art. Compound of formula (14) is converted to a compound of formula (15) by reacting with 4-hydroxyphenylboronic acid in presence of palladium metal or palladium complex such as dichlorobis(triphenylphosphine)palladium(ll), tetrakis(triphenylphosphine) palladium(O), dichlorobis(diphenylphosphinopropane)palladium, tris(dibenzylideneacetone) dipalladium or the like as a catalyst, in a suitable solvent such as dioxane, toluene, ethanol, dimethylformamide, dimethylsulphoxide or water or a mixture of them in the temperature range of 25°C to 100°C. Compound of formula (15) is converted to a compound of formula (16) by reacting with an a-haloester derivative in presence of a base such as alkali metal carbonate, alkali metal hydroxide or alkali metal hydride in a solvent such as acetonitrile, dimethylformamide or dimethylsulphoxide in the temperature range of 25°C to 100°C. Compound of formula (16) is converted to a compound of formula (17) in presence of a base such as alkali metal carbonate or alkali metal hydroxide in a solvent such as acetonitrile, methanol, ethanol, tetrahydrofuran or the like in presence of water in the temperature range of 25°C to 100°C. Compound of formula (17) is converted to a compound of formula ( 18) (where Ar is aryl, heteroaryl or heterocyclyl ring), by reacting it with a phenol containing an electron withdrawing group especially a nitro group, by activating the acid, as acidchloride by reacting it with thionyl chloride or oxalyl chloride, using EDCI .HCI or \nt\nBOP reagent, in the presence of a base such as triethylamine, diisopropylethylamine or the like in a solvent such as dichloromethane, dimethylformamide, tetrahydrofuran or the like in the temperature range of 25°C to 100°C. Compound of formula (18) is converted to a compound of formula (IB) by reacting with a compound of formula (19) in the presence of a base such as triethylamine, diisopropeylethylamine or an alkalimetal hydride in a solvent such as tetrahydrofuran, dimethylformamide or the like in the temperature range of 25°C to 100°C. Alternatively compound of formula (17) can also be converted to a compound of formula (IB) by activating it as an acidchloride and reacting it with the compound of formula (19) in the presence of a suitable base such as triethylamine, diisopropeylethylamine or an \n\n alkalimetal hydride in a appropriate solvent such as dichloromethane, tetrahydrofuran, dimethylformamide or the like in the temperature range of 25°C to 100°C. Compound of formula ( 17) can also be converted to a compound of formula (IB) by activating it in the presence of a substituted carbodiimide or BOP reagent and reacting it with a compound of formula (19) in the presence of a suitable base such as triethylamine, diisopropeylethylamine or an alkalimetal hydride in a suitable solvent such as dichloromethane, tetrahydrofuran, dimethylformamide or the like in the temperature range of 25°C to 100°C. \n\n\nSynthetic scheme 5 \n\n\n\n\n\n\n\n\n (IB) \n\n\n An alternative approach for the synthesis of compounds of the general formula (IB), wherein R\n1\n, R\n2\n, R\n3\n, R\n4\n, R\n5\n, R\n6\n, R\n7\n, R\n8\n, Ar\n1\n , 'm', 'n' and 'p' are as defined above in the description is described in Synthetic Scheme 5. \n\n\n In this synthetic scheme, compound of formula (19a) can optionally be converted to a compound of formula (19) (where R is alkyl), by reacting with an alkyl halide in the presence of a base such as triethylamine, diisopropylethylamine or an alkali metal hydride in a solvent such as tetrahydrofuran, dimethylformamide, dimethylsulphoxide etc., at 0°C to 100°C. Compound of formula (19) and (19a) are converted to compound of formula (20) (where Hal is halogen), by reacting with a substituted a-halo acylhalide derivatives in the presence of a suitable base such as triethylamine, diisopropylethylamine or alkalimetal hydride in an appropriate solvent such as dichloromethane, acetonitrile, tetrahydrofuran, dimethylformamide, dimethylsulphoxide etc., at 0°C to 100°C. Compound of formula (20) is further reacted with compound of formula- (15) in presence of a suitable base such as alkali metal carbonate, alkali metal hydroxide or alkali metal hydride in a solvent such as \n\n acetonitrile, dimethylformamide, tetrahydrofuran or dimethylsulphoxide at 25°C to 100°C to obtain a compound of the general formula (IB). \n\n\nExperimental \n\n\n Unless otherwise stated, work-up includes distribution of the reaction mixture between the organic and aqueous phase indicated within parentheses, separation of layers and drying the organic layer over sodium sulphate, filtration and evaporation of the solvent. Purification, unless otherwise mentioned, includes purification by silica gel chromatographic techniques, in suitable solvents of a suitable polarity as the mobile phase. The following abbreviations are used in the text: DMSO-efc: hexadeuterodimethyl sulfoxide; CDCI\n3\n- deuterated chloroform; J: coupling constant in units of Hz; RT or rt: room temperature (22- 26°C). aq.: aqueous; equiv. or eq.: equivalents. \n\n\nPreparation of Intermediates \n\n\n Intermediate 1 \n\n\n 2-[(4-Nitrophenoxy)methyl]quinoline \n\n\n\n\n\n To a solution of 2-chloromethyl quinoline (0.5 g, 2.33 mmol) in NN-dimethylformamide (5 mL) was added potassium carbonate (0.97 g, 7.00 mmol) and p-nitro phenol (0.357 g, 2.5 mmol). The reaction mixture was heated at 80°C for 1 hour. The reaction mixture was poured in ice water; a product precipitated. The precipitate was filtered off and dried under vacuum to afford 0.700 g of the product; Ή NMR (300 MHz, DMSO-<¾: δ 8.40 (d, J = 8.4 Hz, 1 H), 8. 1 8 (d, J = 9.3 Hz, 2H), 7.97 (m, 2H), 7.74 (t, J= 15.0 Hz, IH), 7.67-7.58 (m, 2H), 7.25 (d, J = 9.3 Hz, 2H), 5.52 (s, 2H). \n\n\n Intermediate 2 \n\n\n 4-(Quinolin-2-ylmethoxy)anilin \n\n\n\n\n\n To a solution of 2-[(4-nitrophenoxy)methyl]quinoline (Intermediate 1 , 0.7 g, 2.8 mmol) in methanol ( 1 0 mL) was added iron powder (0.40 g) followed by cone. HC1 ( 1 .0 mL). The \n\n reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was filtered through celite bed. The filtrate was concentrated, diluted with water, neutralized with Na\n2\nC0\n3\n and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulphate and concentrated to afford 0.33 g of the desired product; Ή NMR (300 MHz,\n\n\nDMSC s): δ 8.34 (d, J = 8.4 Hz, 1 H), 7.94 (d, J = 14.1 Hz, 2H), 7.72 (t, J = 15.0 Hz, 2H), 7.63-7.55 (m, 2H), 6.73 (d, J = 6.3 Hz, 2H), 6.46 (d, J = 6.9 Hz, 2H), 5.19 (s, 2H), 4.66 (br s,\n\n\n2H). \n\n\n Intermediate 3 \n\n\n N-Benzyl-4-(quinolin-2-ylmethoxy)aniline \n\n\n\n\n\n\n\n\n To a solution of 4-(quinolin-2-ylmethoxy)aniline (Intermediate 2, 0.15 g, 0.6 mmol) in 1 ,2- dichloroethane (10 mL) was added benzaldehyde (0.074 g, 0.66 mmol) followed by sodium triacetoxyborohydride (0.25 g, 1.18 mmol) and the reaction mixture was stirred for 30 min. To this mixture was added acetic acid and stirred at room temperature for 4 hours. The reaction mixture was poured in water and extracted with 1 ,2-dichloroethane. The organic layer was dried over anhydrous Na\n2\nS0\n4\n, concentrated and purified by column chromatography to afford 0.100 g of the desired product; Ή NMR (300 MHz, DMSO-i¾: δ 8.34 (d, J = 8.4 Hz, 1 H), 7.97-7.95 (m, 2H), 7.71 (t, J = 1 5.6 Hz, 2H), 7.59-7.54 (m, 2H), 7.32-7.1 7 (m, 5H), 6.76 (d, J = 9.0 Hz, 2H), 6.47 (d, J = 8.7 Hz, 2H), 5.86 (m, 1 H), 5.1 8 (s, l H), 4.16 (d, J = 5.4 Hz, 2H); MS (m/z): 341 .16 (M+H)\n+\n. \n\n\nIntermediates 4 to 9 mentioned in Table 1 below were prepared using Intermediate 2 and appropriate starting material, by following the procedure as described for the preparation of Intermediate 3. \n\n\n\n\n\n\n\n\n Table 1 : Structure, starting material and characterization data for Intermediates 4-9 \n\n\n\n\n\n\n\n carbaldehyde \n\n\nIntermediate 10 \n\n\n 4-(6-Fluoro-quinolin-2-ylmethoxy)-pheny!]-pyridin-3-ylmethylamine \n\n\n\n\n\n\n\n\n Step 1 : Preparation of 6-fluoro-quinoline-2-carbaldehyde \n\n To a freshly prepared solution of Se0\n2\n (0.690 g, 6.21 mmol) in 10% water in dioxane (20 mL) at 40-45°C was added 2-methyl-6-fluoro quinoline (0.500 g, 3.1 0 mmol) and the reaction mixture was stirred at 40-45°C for 3-4 hours. The reaction mass was fi ltered through celite bed, filtrate was di luted with water and extracted with dichloromethane. The organic layer was dried and concentrated to afford 0.550 g of the desired product; Ή NMR (300 MHz, DMSO-iVe): δ 10.07 (s, 1 H), 8.56 (d, J - 8.4 Hz, 1 H), 8.3 1 -8.26 (m, 1 H), 7.86-7.79 (m, 3H); MS (m/z): 1 76.30 (M+H)\n+\n. \n\n\n Step 2: Preparation of (6-fluoro-quinolin-2-yl)-methanol \n\n\n To a solution of 6-fluoro-quinoline-2-carbaldehyde, obtained in Step 1 (0.540 g, 3.08 mmol) in tetrahydrofuran was added NaBRi at 10-15°C and the reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was quenched with water, extracted with ethyl acetate. The organic layer was dried and concentrated to afford 0.500 g of the desired product. \n\n\n Step 3 : Preparation of 2-chloromethyl-6-fluoro-quinoline \n\n\n To a solution of (6-fluoro-quinolin-2-yl)-methanol, obtained in Step 2 (0.550 g, 3. 10 mmol) in dichloromethane was added thionyl chloride (0.739 g, 6.21 mmol) and the reaction mixture was refluxed for 2 hours. The reaction mass was quenched with water, basified with Na\n2\nC03 and extracted with dichloromethane. The organic layer was dried and concentrated to afford 0.220 g of the desired product; Ή NMR (300 MHz, DMSO-i/\n6\n): δ 8.43 (d, J = 8. 1 Hz, 1 H), 8.08 (m, I H), 7.83 (d, ./ = 9.3 Hz, 1 H), 7.72 (d, J = 8. 1 Hz, 2H), 4.95 (s, 2H); MS (m/z): 1 96.23 (M+H)\n+\n. \n\n\n Step 4: Preparation of tert-butyl {4-[(6-fluoroquinolin-2-yl)methoxyl]phenyl}carbamate To a suspension of ter/-butyl (4-hydroxyphenyl)carbamate (0.282 g, 1 .35 mmol) and potassium carbonate (0.3 10 g, 2.24 mmol) in tetrahydrofuran at 80-90°C was added 2- chloromethyl-6-fluoro-quinoline, obtained in Step 3 (0.220 g, 1 .12 mmol) and the reaction mixture was stirred at 90- 100°C for 2-3 hours. The reaction mixture was cooled to room temperature and was added aq 10% NaOH solution; a product precipitated. The precipitate was filtered off and dried under vacuum to afford 0.210 g of the desired product; Ή NMR (300 MHz, DMSO-fl¾): 5 9.1 7 (s, 1 H), 8.41 (d, J= 8.7 Hz, I H), 8.07 (t, J = 9.3 Hz. 1 H), 8.81 (d, J = 9.3 Hz, I H), 7.70 (d, J = 7.8 Hz, 2H), 7.35 (d, J = 8.4 Hz, 2H), 6.97 (d, J = 8.7 Hz, 2H), 5.29 (s, 2H), 1 .45 (s, 9H). \n\n\n Step 5 : Preparation of 4-(6-fluoro-quinolin-2-ylmethoxy)-phenyl amine \n\n\n A saturated solution of ethyl acetate with HC1 was added in the stirred solution of tert-butyl\n\n\n{4-[(6-fluoroquinol in-2-yl)methoxyl]phenyl}carbamate, obtained in Step 4 and m ixture was \n\n stirred at room temperature for 2-3 hours. The reaction mass was quenched with water, basified with Na\n2\nC0\n3\n and extracted with dichloromethane. The organic layer was dried and concentrated to afford 0.200 g of the desired product. \n\n\n Step 6: Preparation of [4-(6-fluoro-quinolin-2-ylmethoxy)-phenyl]-pyridin-3-ylmethylamine To a solution of 4-(6-fluoro-quinolin-2-ylmethoxy)-phenyl amine, obtained in Step 5 (0.1 50 g. 0.559 mmol) in ethylene dichloride (5 mL) was added 3-pyridine carbaldehyde (0.071 g, 0.663 mmol) and the reaction mixture was stirred for 30 mins. To this mixture was added acetic acid (0.033 g, 0.550 mmol) followed by sodium triacetoxyborohydride (0.235 g, 1 .1 1 mmol) and stirred for 1 8 hours at room temperature. The reaction mass was neutralized with Na\n2\nC0\n3i\n extracted with dichloromethane and the resultant organic layer was concentrated to afford 0.100 g of the desired product; Ή NMR (300 MHz, DMSO-i/\n6\n): δ 8.71 (s, 1 H), 8.55- 8.37 (m, 2H), 8.06 (m, 1 H), 7.81-7.66 (m, 4H), 7.32 (br s, 1H), 6.81 (d, J = 7.5 Hz, 2H), 6.53 (d, ,/ = 7.8 Hz, 2H), 5.93 (br s, 1H), 5.19 (s, 2H), 4.21 (br s, 2H). \n\n\nIntermediate 1 1 \n\n\n (4-Methyl-thiazol-5-ylmethyl)- -(quinolin-2-ylmethoxy)-phenyl]amine \n\n\n\n\n\n\n\n\n Step 1 : Preparation of 4-methyl-thiazole-5-carbaldehyde \n\n\n To a solution of 2-(4-methyl-thiazol-5-yl)ethanol (0.500 g, 3.496 mmol) in ethylene dichloride (8.0 mL) was added pyridinium chlorochromate (PCC) (1.127 g, 5.244 mmol) and the reaction mixture was stirred at room temperature for 2 hours. Ether was added to the reaction mass, filtered off and resultant organic layer was concentrated to afford 0.150 g of the desired product; Ή NMR (300 MHz, DMSO-a¾: δ 10.14 (s, 1H), 9.39 (s, 1H), 2.72 (s,\n\n\n3H). \n\n\n Step 2: Preparation of (4-methyl-thiazol-5-ylmethyl)-[4-(quinolin-2-ylmethoxy)-phenyl]- amine \n\n\n The title compound was prepared following the procedure described for Intermediate 3, but starting from 4-(quinolin-2-ylmethoxy)aniIine (0.300 g, 1.195 mmol), 4-methyl-thiazole-5- carbaldehyde, obtained in Step 1 (0.1 1 g, 1.195 mmol) and sodium triacetoxyborohydride (0.378 g, 1 .79 mmol) in ethylene dichloride (15 mL) to afford 0.160 g of the desired product: Ή NMR (300 MHz, OMSO-d\n6\n): δ 8.80 (s, 1 H), 8.39 (d, J = 8.1 Hz, -I H), 8.01 -7.97 (m, 2H), \n\n 7.77 (t, J = 7.2 Hz, 1 H), 7.66-7.58 (m, 2H), 6.85 (d, ,/ = 8.7 Hz, 2H), 6.55 (d, J = 8.7 Hz, 2H), 5.76 (s, 1 H), 5.22 (s, 2H), 4.31 (s, 2H), 2.37 (s, 3H). \n\n\nIntermediate 12 \n\n\n 3-Iodomethyl-5-methyl-isoxazole \n\n\n\n\n\n Step 1 : Preparation of (5-methyl-isoxazol-3-yl)-methanol \n\n\n To a solution of 5-methyl-isoxazole-3-carboxylic acid (0.700 g, 5.51 1 mmol) in tetrahydrofuran ( 10 mL) was added lithium aluminium hydride (LAH) (0.203 g, 5.5 1 1 mmol) at 0°C and the reaction mixture stirred for 2 hours at room temperature. The reaction mixture was quenched with brine solution and acidified with acetic acid. The resultant residue was filtered off, washed with chloroform and methanol, and dried to afford 0. 140 g of the desired product; Ή NMR (300 MHz, DMSO-<fc): δ 6.19 (s, 1 H), 5.43 (br s, 1 H), 4.43 (s, 2H), 2.38 (s,\n\n\n3H). \n\n\n Step 2: Preparation of 3-iodomethyl-5-methyl-isoxazole \n\n\n To a solution of triphenyl phosphine (2.216 g, 8.460 mmol) and imidazole (0.575 g, 8.460 mmol) was added iodine (2.247 g, 8.883 mmol) and the reaction mass was stirred for 10 mins followed by the addition of (5-methyl-isoxazol-3-yl)-methanol, obtained in step I (0.478 g, 4.230 mmol). The reaction mixture was stirred for 2 ½ hours at room temperature, quenched the reaction mass with water and extracted with dichloromethane. The organic layer was washed with 5% sodium sulphite solution and concentrated to afford 0.375 g of the desired product; Ή NMR (300 MHz, DMSO-<¾: δ 6.26 (s, 1 H), 4.37 (s, 2H), 2.36 (s, 3H). \n\n\nIntermediate 13 \n\n\n (5-Methyl-isoxazol-3-ylmeth -[4-(quinolin-2-ylmethoxy)-phenyl]amine \n\n\n\n\n\n To a solution of 4-(quinolin-2-ylmethoxy)aniline (Intermediate 2, 0.150 g, 0.597 mmol) in N,N-dimethylformamide (10 mL) was added potassium carbonate (0.164 g, 1.194 mmol) and 3-iodomethyl-5-methyl-isoxazole (Intermediate 12, 0.132 g, 0.597 mmol) and the reaction mixture was stirred at room temperature for 5 hours. The reaction mixture was poured in ice \n\n water, extracted with ethyl acetate and concentrated the organic layer to afford 0.1 16 g of the desired product; Ή NMR (300 MHz, OMSO-d\n6\n): δ 8.39 (d, J = 8.4 Hz, 1 H), 7.99 (m, 2H), 7.77-7.75 (br t, 1 H), 7.66-7.60 (m, 2H), 6.84 (d, J = 8.7 Hz, 2H), 6.55 (d, J = 8.4 Hz, 2H), 6. 10 (s, l H), 5.81 (br s, 1 H), 5.21 (s, 2H), 4.17 (d, J = 5.7 Hz, 2H), 2.33 (s, 3H). \n\n\nIntermediate 14 \n\n\n Phenyl (5-ter?-butyl-l ,3,4-thi \n\n\n\n\n\n To a solution of 5-ier/-butyl-l ,3,4-thiadiazol-2 -amine (1 g) in dichloromethane (20 mL) was added triethylamine (3 eq) followed by phenylchloroformate ( 1 eq) and the reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was diluted with dichloromethane and water. The organic layer was washed with water, dried over Na\n2\nS0\n4\n, concentrated and purified by column chromatography to afford 1 .3 g of the desired product;\n\n\nΉ NMR (DMSO-4s): δ 12.60 (br s, 1 H), 7.42 (t, J = 15.6 Hz, 3H), 7.28 (d, J = 7.2 Hz, 1 H), 7.22 (d, .7 = 7.8 Hz, 1 H), 1.38 (s, 9H). \n\n\nIntermediates 15 to 1 7 mentioned in Table 2 below were prepared using phenylchloroformate and appropriate starting material, by following the procedure as described for the preparation of Intermediate 14. \n\n\n\n\n\n Table 2: Structure, starting material and characterization data for Intermediates 15-17 \n\n\n\n\n\n\n\n\n\n\nIntermediate 18 \n\n\n 2-Pyridin-4-yl-4-(quinolin-2-ylm \n\n\n\n\n\n\n\n\n Step 1 : Preparation of 3-iodo-4-nitrophenol \n\n\n To a solution of 3-iodophenol (1 .5 g) in acetic acid (10 mL) was added cone, nitric acid (0.03 mL) and the reaction mixture was stirred at room temperature for ½ hour. The reaction mixture was diluted with water, filtered off the reaction mass and the filtrate was extracted with ethyl acetate. The organic layer was concentrated to afford 1 .37 g of the desired product; Ή NMR (300 MHz, DMSO-<¾): δ 1 1 .07 (br s, 1 H), 7.96 (d, J = 9.3 Hz, 1 H), 7.46 (s, 1 H), 7.93 (d, J = 8.7 Hz, 1 H). \n\n\n Step 2: Preparation of 4-nitro-3-pyridin-4-yl-phenol \n\n\n To a solution of 3-iodo-4-nitrophenol, obtained in Step 1 ( 1 .36 g, 5.15 mmol) in dimethyl sulfoxide ( 10 mL) was added 4-pyridineboronic acid (0.63 g, 5.15 mmol) followed by potassium carbonate (2.13 g, 15.44 mmol) and tetrakis(triphenylphosphine)palladium (0) (0.178 g, 0.154 mmol) and the reaction mixture was stirred at 80°C for 4 hours. Water was added to the reaction mixture, extracted with ethyl acetate and the organic layer was concentrated to afford 1.0 g of the desired product; Ή NMR (300 MHz, DMSO-i¾: δ 8.61 - 8.60 (br d, 2H), 8.05 (d, J = 9.3 Hz, 1H), 7.34-7.033 (br d, 2H), 6.93 (d, J= 8.7 Hz, 1 H), 6.70 (s, 1 H); MS (m/z): 215.41(M-H)\\ \n\n\n Step 3: Preparation of 2-[(4-nitro-3-pyridin-4-ylphenoxy)methyl]quinoline \n\n\n The title compound was prepared following the procedure described for Intermediate 1 , but starting from 4-nitro-3-pyridin-4-yl-phenol, obtained in Step 2 (1 .0 g, 4.629 mmol), potassium carbonate ( 1 .27 g, 9.20 mmol) and 2-chloromethyl quinoline hydrochloride ( 1 .08 g. 5.04 mmol) to afford 0.90 g of the desired product; Ή NMR (300 MHz, DMSO-i \n6\n): δ 8.63 \n\n (br s, 2H), 8.45 (d, J = 7.8 Hz, 1 H), 8.17 (d, J = 9.3 Hz, 1H), 8.03-7.95 (br d, 2H), 7.80-7.54 (m, 4H), 7.39-7.33 (m, 2H), 7.24 (s, 1H), 5.57 (s, 2H). \n\n\n Step 4: Preparation of 2-pyridin-4-yl-4-(quinolin-2-ylmethoxy)-phenyl amine \n\n\nTo a solution of 2-[(4-nitro-3-pyridin-4-ylphenoxy)methyl]quinoline, obtained in Step 3 (0.900 g, 2.520 mmol) in methanol (3 mL) was added iron powder (2.0 g) and HCl (3 mL) and the reaction mixture was stirred at room temperature for 1 hour. The reaction mass was filtered off, removed methanol under vacuum and water was added to the residue. The aqueous layer was neutralized with potassium carbonate\n,\n extracted with ethyl acetate and concentrated to afford 0.400 g of the desired product; Ή NMR (300 MHz, DMSO-</\n6\n): δ 8.60-8.58 (br d, 2H), 8.41 (d, J = 8.1 Hz, 1 H), 7.99 (m, 2H), 7.80-7.61 (m, 5H), 6.91 -6.86 (m, 2H), 6.75 (d, J = 8.7 Hz, 1 H), 5.28 (s, 2H), 4.68 (br s, 2H). \n\n\nIntermediate 19 \n\n\n 4,4,4-Trifluoro-N-[4-(quinolin-2-ylmethoxy)-phenyl]-butyramide \n\n\n\n\n\n To a solution of 4,4,4-trifluoro butyric acid (0.100 g, 0.704 mmol) in tetrahydrofuran (10 mL) was added l -(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDCI) (0.204 g, 1 .067 mmol), followed by hydroxybenzotriazole (HOBT) (0.142 g, 1 .05 mmol), N,N-diisopropyIethylamine (DIPEA) (0.1 83 g, 1 .41 mmol) and 4-(quinolin-2-ylmethoxy)anil ine (Intermediate 2. 0.300 g. 1 .2 mmol). The reaction mixture was stirred at 80°C for 12 hours. The reaction mixture was cooled to room temperature, quenched in water, extracted with ethyl acetate and concentrated the organic layer to afford 0.075 g of the desired product; Ή NMR (300 MHz, OMSO-d\n6\n): δ 9.96 (s, 1 H), 8.41 (d, J = 8.4 Hz, 1 H), 8.03-7.93 (m, 2H), 7.78 (d, J = 7.5 Hz, 1 H), 7.67-7.59 (m, 2H), 7.49 (d, J = 8.7 Hz, 2H), 7.02 (d, J= 8.7 Hz, 2H), 5.32 (s, 2H), 2.57-2.55 (m, 4H). \n\n\nIntermediate 20 \n\n\n 2-(4-Chlorophenyl)-3-(4-hydroxyphenyl)benzo[i/|imidazo[2, l - >][l ,3]thiazole \n\n\n \n\n Step 1 : Preparation of 2-(4-chlorophenyl)imidazo[2, 1 -b][ 1 ,3]benzothiazole To a solution of 2-aminobenzothiazole (2.000 g, 13.33 mmol) in dry DMF (15 mL) was added 4-chlorophenacyl bromide (3.4 g, 14.66 mmol) and the reaction mixture was stirred at 90°C for 5 hours. The reaction mixture was allowed to cool to room temperature, poured into ice water and extracted with ethyl acetate. The organic layer was washed with water, dried over anhydrous Na\n2\nSC>4, concentrated and purified by column chromatography to afford 2.5 g of the desired product; Ή NMR (300 MHz, DMSO-flfe): δ 8.82 (s, 1H), 8.02 (d, J = 8.1 Hz, 1 H), 7.95 (d, J = 7.8 Hz, 1 H), 7.85 (d, J = 8.4 Hz, 2H), 7.56 (t, J = 7.5 Hz, 1 H), 7.48 (d, J = 9.0 Hz, 2H), 7.44-7.40 (m, 1 H); MS (m/z): 285.52 (M+H)\n+\n. \n\n\nStep 2: Preparation of 2-(4-chlorophenyl)-3-iodoimidazo[2, l -6][l ,3]benzothiazole \n\n\n To a solution of 2-(4-chlorophenyl)imidazo[2, l -6][ l ,3]benzothiazole (1 .39 g, 4.90 mmol.) in dry THF (25 mL) was added N-iodosuccinimide (1.10 g, 4.90 mmol) and the reaction mixture was stirred at room temperature for 12 hours. The solvent was evaporated from the reaction mixture on rotavapor and obtained residue was diluted with water. The precipitated solid was filtered. Stirred the solid in diethyl ether and filtered followed by drying under vacuum to afford 1 .7 g of the desired product; Ή NMR (300 MHz, DMSO-d\n6\n): δ 8.66 (d, J = 7.8 Hz, 1 H), 8.07 (d, ./ = 7.8 Hz, 1 H), 7.94 (d, J = 8.4 Hz, 2H), 7.63-7.58 (br t, 1 H), 7.54 (d, J = 9.0 Hz, 2H), 7.54-7.48 (m, 1 H); MS (m/z): 41 1 .12 (M+H)\n+\n. \n\n\n Step 3: Preparation of 2-(4-chlorophenyl)-3-(4-hydroxyphenyl)benzo[i ]imidazo[2, l-Z>][l ,3] thiazole \n\n\n To a solution of 2-(4-chlorophenyl)-3-iodoimidazo[2,l-6][l ,3]benzothiazole (1.400 g, 3.41 mmol) and 4-hydroxyphenylboronic acid (0.941 g, 6.82 mmol) in DMSO (15 mL) was added K2CO\n3\n (1 .41 g, 7.52 mmol) followed by tetrakistriphenylphosphine palladium (0.1 1 8 g, 0.102 mmol.) and the reaction mixture was stirred at 90°C for 3 hours under nitrogen atmosphere. The reaction mixture was quenched in water, neutralized with dilute HC1 and the obtained solid was filtered and purified by column chromatography to afford 1 .1 g of the desired product; Ή NMR (300 MHz, OMSO-d\n6\n): δ 10.02 (s, 1 H), 8.66 (d, ./ = 8.1 Hz, 1 H), 8.07 (d, J = 6.0 Hz, 1 H), 7.95 (d, J = 8.4 Hz, 2H), 7.61 (t, J = 7.5 Hz, 1 H), 7.60-7.45 (m, 5H), 7.32 (d, J = 8.7 Hz, 2H); MS (m/z): 377.54 (M+H)\n+\n. \n\n\nIntermediates 21 to 24 mentioned in Table 3 below were prepared in three steps using appropriate amino thiazole compounds, 4-chlorophenacyl bromide and 4- hydroxyphenylboronic acid, by following the procedure as described for the preparation of Intermediate 20. \n\n Table 3: Structure, starting material and characterization data for Intermediates 21-24 \n\n\n\n\n\n\n\n\nIntermediate 25 \n\n\n {4-[2-(4-Chlorophenyl)imidazo[2,l-¾][l,3]benzothiazol-3-yl]phenoxy}acetic acid \n\n\n\n\n\n\n\n\n Step 1 : Preparation of ethyl {4-[2-(4-Chlorophenyl)imidazo[2,l-»][l,3]benzothiazol-3-yl] phenoxy} acetate \n\n To a solution of 2-(4-chlorophenyl)-3-(4-hydroxyphenyl)benzo[i ]imidazo[2, l - >][ l ,3] thiazole (Intermediate 20) (0.150 g, 0.398 mmol) in dry DMF (3.0 mL) was added ethylbromoacetate (0.080 g, 0.479 mmol) followed by K\n2\nC0\n3\n (0.166 g, 1.200 mmol) and the reaction mixture was stirred at room temperature for 12 hours. The reaction mixture was poured in water and extracted with ethyl acetate. The organic layer was washed with water and concentrated. The obtained residue was washed with «-pentane and purified by column chromatography to afford 0.190 g of the desired product; Ή NMR (300 MHz, DMSO-c¾: δ 8.00 (d, J = 7.8 Hz, 1 H), 7.54 (dd, ,/ = 8.4 Hz & 8.4 Hz, 4H), 7.32-7.23 (m, 4H), 7. 16 (d, J = 9.0 Hz, 2H), 6.68 (d, J = 6.0 Hz, 1 H), 4.92 (s, 2H), 4.19 (q, .7 = 34.8 Hz, 2H), 1 .23 (t, J = 14.1 Hz, 3H); MS (m/z): 463.49 (M+H)\n+\n. \n\n\n Step 2: Preparation of {4-[2-(4-chlorophenyl)imidazo[2, l -&][l ,3]benzothiazole-3-yl] phenoxy} acetic acid \n\n\n To a solution of ethyl {4-[2-(4-chlorophenyl)imidazo[2, l-0][l,3]benzothiazol-3-yl]phenoxy} acetate (0.180 g, 0.389 mmol) in THF (4 mL) was added aqeous LiOH.H\n2\n0 (0.033 g, 0.786 mmol) and MeOH and it was stirred at room temperature for 3 hours. The solvent was evaporated from the reaction mixture and cold water was added and neutralized with acetic acid. The precipitated solid was filtered, washed with diethyl ether and dried to afford 0.140 g of the desired product; Ή NMR (300 MHz, DMSO-i¾: δ 13.00 (br s, 1 H), 8.00 (d, J = 6.9 Hz, 1 H), 7.54-7.47 (m, 4H), 7.36-7.24 (m, 3H), 7.14 (d, J = 7.8 Hz, 3H), 6.70 (d, J = 8.4 Hz, l H), 4.80 (s, 2H); MS (m/z): 435.60(M+H)\n+\n. \n\n\nIntermediate 26 \n\n\n 4-Nitrophenyl {4-[2-(4-chlorophenylimidazo[2, l -0][ l ,3]benzothiazol-3-yl]phenoxy I } acetate \n\n\n\n\n\n\n\n\n Step 1 : Preparation of {4-[2-(4-chlorophenyl)imidazo[2, l - >][ l ,3]benzothiazol-3-yl]phenoxy} acetyl chloride \n\n\n To the solution of {4-[2-(4-chlorophenyl)imidazo[2, l- >][l ,3]benzothiazol-3-yl]phenoxy} acetic acid (Intermediate 25, 0.480 g, 1.10 mmol) in DCM (10 mL) was added thionyl chloride (0.262 g, 2.2 mmol) and catalytic amount of DMF at room temperature. The reaction \n\n mixture was stirred for 2 hours. The reaction mixture was concentrated under vacuum to remove excess of thionyl chloride and taken for next step. \n\n\n Step 2: Preparation of 4-nitrophenyl {4-[2-(4-chlorophenylimidazo[2, l -6][l ,3]benzothiazoI- 3-yl]phenoxyl}acetate \n\n\n To the solution of {4-[2-(4-chlorophenyl)imidazo[2, l -6][l ,3]benzothiazol-3-yl]phenoxy} acetyl chloride in DCM was added 7-nitro phenol (0.183 g, 1 .31 mmol) and the reaction mixture was cooled at 10-1 5°C. Triethylamine (0.0337 g, 3.33 mmol) was added into stirring mixture and resultant mixtrure was stirred for 3 hours. The reaction mixture was quenched in ice water, filtered the solid and purified by column chromatography to afford 0.540 g of the desired product; Ή NMR (300 MHz, OMSO-d\n6\n): δ 8.37 (d, J = 9.0 Hz, 2H), 8.13 (d, J = 9.0 Hz, 3H), 8.04 (d, J = 7.8 \n'\nHz, 1 H), 7.62-7.33 (m, 2H), 7.31 -7.17 (m, 2H), 6.94 (d, J = 9.0 Hz, 4H), 6.73 (d, J = 7.5 Hz, 2H), 5.31 (s, 2H); MS (m/z): 556.99 (M+H)\n+\n. \n\n\nIntermediate 27 \n\n\n2-Chloro-N-(4-methylpyridin-2-yl)acetamide \n\n\n\n\n\n To the solution of 2-amino-4-methylpyridine (0.500 g, 4.629 mmol) and Ν,Ν- diisopropylethylamine (DIPEA) (0.587 g, 4.629 mmol) in DCM was added chloroacetyl chloride (0.209 g, 1 .849 mmol) at 0-5°C and the reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated and purified the crude \n•\nproduct by column chromatography to afford 0.255 g of the desired product; Ή NMR (300 MHz, DMSO-flfe): δ 10.73 (s, 1 H), 8.18 (d, J = 4.8 Hz, 1 H), 7.90 (s, 1 H), 6.98 (d, J = 4.5 Hz, 1 H), 4.33 (s, 2H), 2.34 (s, 3H); MS (m/z): 185.62 (M+H)\n+\n. \n\n\nIntermediates 28-30 mentioned in Table 4 below were prepared using appropriate starting material and chloroacetyl chloride, by following the procedure as described for the preparation of Intermediate 27. \n\n\n Table 4: Structure, starting material and characterization data for Intermediates 28-30\n\n\nIntermediate Molecular Structure and Starting material Spectral data \n\n\n No. chemical name \n\n\n\n\n\n\n\nIntermediate 31 \n\n\n 4-[2-(4-Chlorophenyl)imidazo[l ,2-a]pyrimidin-3-yl]phenol \n\n\n\n\n\n\n\n\n Step 1 : Preparation of 2-(4-chlorophenyl)imidazo[l,2- ]pyrimidine \n\n\n The title compound was prepared following the procedure described for Step 1 of Intermediate 20, but starting from 2-amino pyrimidine (1 .0 g, 10.5 mmol) and 4- chorophenacyl bromide (2.47 g, 10.5 mmol) to afford 1 .55 g of the desired product; Ή NMR (300 MHz, DMSO-</\n6\n): δ 8.96 (d, ./ = 6.0 Hz, 1 H), 8.55 (br s, 1 H), 8.42 (s, 1 H), 8.01 (d, ./ = 8.1 Hz, 2H), 7.52 (d, J = 8.1 Hz, 2H), 7.08 (br s, 1 H); MS (m/z): 230.49 (M+H)\n+\n. \n\n\n Step 2: Preparation of 3-bromo-2-(4-chIorophenyl)imidazo[ l ,2-a]pyrimidine \n\n\n The title compound was prepared following the procedure described for Step 2 of Intermediate 20, but starting from 2-(4-chlorophenyl)imidazo[ l ,2-o]pyrimidine ( 1 .5 g, 6.7 mmol) and N-bromosuccinimide (1.29 g, 7.3 mmol) to afford 1.9 g of the desired product; Ή \n\n NMR (300 MHz, DMSO-<¾): δ 8.83 (d, J = 6.6 Hz, 1 H), 8.62 (m, 1 H), 8. 13 (d, J = 8.1 Hz, 2H), 7.59 (d, J = 8.4 Hz, 2H), 7.22-7.20 (m, 1 H); MS (m/z): 309.20 (M+H)\n+\n. \n\n\nStep 3: Preparation of 4-[2-(4-chlorophenyl)imidazo[l ,2-o]pyrimidin-3-yl]phenol \n\n\nTo a solution of 3-bromo-2-(4-chlorophenyl)imidazo[l ,2-a]pyrimidine (0.490 g, 1 .588 mmol) in degassed 1 ,4-dioxane (5 mL) was added 4-hydroxyphenylboronic acid (0.219 g, 1 .588 mmol) followed by 3M aqueous Na\n2\nC0\n3\n solution (0.505 g, 4.76 mmol) and PdCl\n2\n(PPh\n3\n)\n2\n (0.055 g, 0.079 mmol) and the reaction mixture was refluxed for 3 hours. The solvent was evaporated from the reaction mixture on rotavapor, the residue was diluted with ethyl acetate and was washed with water. The organic layer was dried over anhydrous Na\n2\nSC>4, concentrated and purified by column chromatography to afford 0.32 g of the desired product; Ή NMR (300 MHz, DMSO-<¾): δ 9.94 (s, 1H), 8.55 (br s, 1 H), 8.40 (d, J = 6.9 Hz, 1 H), 7.70-7.65 (br d, 2H), 7.39 (d, J = 6.9 Hz, 2H), 7.30 (d, J = 7.2 Hz, 2H), 7.00-6.90 (m, 3H); MS (m/z): 322.47 (M+H)\n+\n. \n\n\nIntermediate 32 \n\n\n2-Chloro-N-ethyl-N-pyridin-2-ylacetamide \n\n\n\n\n\n Step 1 : Preparation of N-ethylpyridin-2-amine \n\n\n To the solution of 2-aminopyridine (1.0 g, 10.06 mmol) in DMF was added NaH (0.386 g) at room temperature followed by ethyl iodide (1.570 g, 10.06 mmol). The reaction mixture was stirred at room temperature for 10 hours. The reaction mixture was quenched in water and extracted with ethyl acetate. The organic layer was washed with water, dried over anhydrous sodium sulphate and concentrated. The residue was purified by column chromatography to afford 0.42 g of the desired product; Ή NMR (300 MHz, DMSO-<¾): δ 7.95 (s, 1H), 7.33 (t, J = 6.9 Hz, 1 H), 6.40 (d, J= 8.4 Hz, 3H), 3.24-3.17 (q, J= 6.9 Hz & 6.6 Hz, 2H), 1 .10 (t, J = 6.9 Hz, 3H); MS (m/z): 123.14 (M+H)\n+\n. \n\n\n Step 2: Preparation of 2-chloro-N-ethyl-N-pyridin-2-ylacetamide \n\n\n The title compound was prepared following the procedure described for Intermediate 27, but starting from 2-ethylamino pyridine (0.4 g, 3.27 mmol) and chloroacetyl chloride (0.37 g, 3.27 mmol) to afford 0.25 g of the desired product; Ή NMR (300 MHz, DMSO-i \n6\n): δ 9.82 (d, .7 = 6.3 Hz, l H), 7.88 (t, J = 8.4 Hz, 1 H), 7.73 (d, J = 8.1 Hz, 1 H), 7.37 (t, J = 6.9 Hz, 1 H), \n\n 4.79 (s, 2H), 4.02-4.00 (q, J = 6.9 Hz & 6.6 Hz, 2H), 1.21 (t, J = 6.9 Hz, 3H); MS (m/z): 199.14 (M+H)\n+\n. \n\n\nExamples \n\n\n Example 1 \n\n\n 2-(3-Methoxyphenyl)-N-(py lmethoxy)phenyl]acetami \n\n\n\n\n\n\n\n\n To the solution of N-(pyridin-3-yImethyl)-4-(quinolin-2-ylmethoxy)aniline (Intermediate 4, 0.1 g, 0.294 mmol) in dichioromethane (5 mL) was added 3-methoxyphenylacetic acid (0.049 g, 0.294 mmol) followed by diisopropylethylamine (2 eq) and bezotriazol-l -yloxy tris(dimethylamino)phosphonium hexafluorophosphate (0.39 g, 0.88 mmol) and reaction mixture was refluxed for 12 hours. The reaction mixture was poured in water and extracted with dichioromethane. The organic layer was dried over anhydrous Na\n2\nS0\n4\n, concentrated and purified by column chromatography to afford 0.036 g of the product as a pale yellow sticky solid; Ή NMR (300 MHz,\n\n\n δ 8.44 (d, J = 7.8 Hz, 2H), 8.32 (d, 2H), 7.99 (m, 2H), 7.77 (t, 1 H), 7.69-7.50 (m, 3H), 7.18 (m, I H), 7.01 (m, 4H), 6.70 (d, 1 H), 6.57 (m, 2H), 5.35 (s, 2H), 4.84 (s, 2H), 3.67 (s, 3H), 3.41 (s, 2H); MS (m/z): 490.24(M+H)\n\"\n\\ \n\n\nExamples 2-45 mentioned in Table 5 below were prepared using appropriate starting material and phenylacetic acid derivatives, by following the procedure as described for the preparation of Example 1 . \n\n\n Table 5: Structure, starting material and characterization data for Examples 2-45 \n\n\n Exam. Molecular structure and Chemical Starting Spectral data No. name material \n\n\n 2 Intermediate 4 Ή NMR (300 MHz, and \n\n\n DMSO-i¾: δ 8.44 (d, J =\n\n\n4-Fluorophenyl \n\n\n 7.8 Hz, 2H), 8.34 (s, 1 H), acetic acid \n\n\n 7.99 (m, 2H), 7.60-7.80 (m, 4H), 7.12 (m, 1 H), 7.02 (m,\n\n\n2-(4-Fluorophenyl)-N-(pyridin-3-yl 8H), 5.36 (s, 2H), 4.84 (s, methyl)-N-[4-(quinolin-2-yl 2H), 3.42 (s, 2H). \n\n\n methoxy)phenyl]acetamide \n\n\n\n\n\n\n\n acetamide \n\n Exam. Molecular structure and Chemical Starting Spectral data No. name material \n\n\n 8 Intermediate 3 Ή NMR (300 MHz, and DMSO-i¾: δ 8.32 (d, J =\n\n\n4-Fluorophenyl 8.10 Hz, 1 H), 8.00 (m, 2H), acetic acid 7.76 (t, J = 7.8 Hz, 1 H), 7.62 \n\n\n (m, 2H), 7.27-6.96 (m, 13H), 5.35 (s, 2H), 4.81 (s, 2H),\n\n\nN-Benzyl-2-(4-fluorophenyl)-N-[4- 3.42 (s, 2H). \n\n\n (quinolin-2-ylmethoxy)phenyl] \n\n\n acetamide \n\n\n 9 a, Intermediate 3 Ή NMR (300 MHz, and DMSO-<¾: δ 8.41 (d, J = 2,3- 8.40 Hz, 1 H), 7.99 (m, 2H), Difluorophenyl 7.78 (t, 1 H), 7.62 (m, 2H), acetic acid 7.29-7.09 (m, 12H), 5.34 (s, \n\n\n 2H), 4.83 (s, 2H), 3.52 (s, 2H). \n\n\n N-Benzyl-2-(2,3-difluorophenyl)- N-[4-(quinolin-2- ylmethoxy)phenyl] acetamide \n\n\n 10 Intermediate 3 Ή NMR (300 MHz, and DMSO-i/\n6\n): δ 8.41 (d, J = 4- 8.70 Hz, 1 H), 7.99 (m, 2H),\n\n\nChlorophenyl 7.76 (t, 1 H), 7.68 (m, 2H), acetic acid 7.27-7.05 (m, 13H), 5.35 (s, \n\n\n 2H), 4.81 (s, 2H), 3.42 (s,\n\n\nN-Benzyl-2-(4-chlorophenyl)-N-[4- 2H). \n\n\n (quinolin-2-ylmethoxy)phenyl] \n\n\n acetamide \n\n\n 1 1 Intermediate 5 Ή NMR (300 MHz, and DMSO-i¾: δ 8.42 (d, J =\n\n\n4-Fluorophenyl 8.10 Hz, 1H), 7.99 (m, 2H), acetic acid 7.79 (t, 1H), 7.62 (m, 2H), \n\n\n 7.18-7.02 (m, 12H), 5.35 (s, 2H), 4.78 (s, 2H), 3.40 (s,\n\n\nN-(4-FIuorobenzyl)-2-(4- 2H). \n\n\n fluorophenyl)-N-[4-(quinolin-2- ylmethoxy)phenyl]acetamide \n\n\n 12 Intermediate 5 Ή NMR (300 MHz, and DMSC s): δ 8.41 (d, J =\n\n\n2-Fluorophenyl 8.1 Hz, 1 H), 8.00 (m, 2H), acetic acid 7.79 (t, 1 H), 7.62-7.66 (m, \n\n\n 2H), 7.20-7.09 (m, 12H), 5.35 (s, 2H), 4.80 (s, 2H), 3.44 (s, 2H); MS (m/z):\n\n\nN-(4-Fluorobenzyl-2-(2- 495.27(M+H)\n+\n. \n\n\n fluorophenyl)-N-[4-(quinolin-2- ylmethoxy)phenyl]acetamide \n\n\n\n\n\n\n \n\n Exam. Molecular structure and Chemical Starting Spectral data No. name material \n\n\n 22 Intermediate 7 Ή NMR (300 MHz, \n\n\n a, and DMSO-i/\n6\n): δ 8.50-8.35 (m, \n\n\n 2,4- 2H), 8.05-7.90 (m, 2H), Difluorophenyl 7.80-7.55 (m, 4H), 7.40-7.15 acetic acid (m, 5H), 7.15-6.95 (m, 4H), \n\n\n 5.36 (s, 2H), 4.90 (s, 2H),\n\n\n2-(2,4-Difluorophenyl)-N-(2- 3.48 (s, 2H). \n\n\n pyridylmethyl)-N-[4-(quinolin-2- ylmethoxy)-phenyl]acetamide \n\n\n 23 Intermediate 4 Ή NMR (300 MHz, and DMSO-<¾: δ 8.44-8.42 (m,\n\n\n2,4,6-Trifluoro 2H), 8.36 (s, 1 H), 8.00 (m, phenylacetic 3H), 7.79 (t, J = 7.2 Hz, l H), acid 7.70-7.62 (m, 3H), 7.33 (t, J \n\n\n = 6.9 Hz, l H), 7.23-7.1 3 (m,\n\n\nN-Pyridin-3-ylmethyl-N-[4- 5H), 5.36 (s, 2H), 4.85 (s, (quinolin-2-ylmethoxy)-phenyl]-2- 2H), 3.42 (s, 2H). \n\n\n (2,4,6-trifluoro-phenyl) acetamide \n\n\n 24 Intermediate 4 Ή NMR (300 MHz, and CDC1\n3\n): δ 8.44-8.41 (br d,\n\n\n2,3,4-Trifluoro 2H), 8.36 (s, 1 H), 8.01 -8.00 phenylacetic (br d, 2H), 7.79 (t, J = 7.2 acid Hz, 1H), 7.69-7.62 (m, 3H), \n\n\n 7.35-7.33 (m, 2H), 7.19 (d, J\n\n\nN-Pyridin-3-ylmethyl-N-[4- = 8.7 Hz, 2H), 7.1 1 (d, J = (quinolin-2-ylmethoxy)-phenyl]-2- 8.4 Hz, 3H), 5.36 (s, 2H), (2,3,4-trifluoro-phenyl) acetamide 4.85 (s, 2H), 3.51 (s, 2H).\n\n\n25 Intermediate 4 Ή NMR (300 MHz, and CDCI3): δ 8.44-8.42 (br d, 2-Fluoro-4- 2H), 8.36 (s, 1 H), 8.00 (m, chloro 2H), 7.79-7.76 (br t, 1 H), phenylacetic 7.69-7.62 (m, 3H), 7.33-7.21 acid (m, 3H), 7.18-7.1 1 (m, 4H),\n\n\n2-(4-Chloro-2-fluoro-phenyl)-N- 6.96 (s, 1 H), 5.36 (s, 2H), pyridin-3-ylmethyl-N-[4-(quinolin- 4.85 (s, 2H), 3.46 (s, 2H). 2-ylmethoxy)-phenyl] acetamide \n\n\n 26 Intermediate 4 Ή NMR (300 MHz, and DMSO- i): δ 8.44-8.36 (m,\n\n\n2,4,5-Trifluoro 2H), 8.00 (m, 2H), 7.79 (m, phenylacetic 1 H), 7.69-7.61 (m, 3H), acid 7.44-7.35 (m, 4H), 7.16-7.12 \n\n\n (m, 4H), 5.35 (s, 2H), 4.85\n\n\nN-Pyridin-3-ylmethyl-N-[4- (s, 2H), 3.44 (s, 2H). \n\n\n (quinolin-2-ylmethoxy)-phenyl]-2- (2,4,5-trifluoro-phenyl) acetamide \n\n\n\n\n \n\n Exam. Molecular structure and Chemical Starting Spectral data No. name material \n\n\n pyridin-3-ylmethyl-N-[4-(quinolin- 3H). \n\n\n 2-ylmethoxy)-phenyl] acetamide \n\n\n 32 Intermediate Ή NMR (300 MHz, \n\n\n 11 DMSO-<¾: δ 8.86 (s, 1H), and 8.43 (d, ./ = 8.4 Hz, ΓΗ), 2,4- 8.02-8.00 (m, 2H), 7.97 (t, ./ Difluorophenyl = 7.2 Hz, 1H), 7.70-7.60 (m, acetic acid 2H), 7.28-7.20 (m, 1H),\n\n\n2-(2,4-Difluoro-phenyl)-N-(4- 7.10-7.06 (m, 5H), 7.01-6.96 methyl-thiazol-5-ylmethyl)-N-[4- (m, 1H), 5.39 (s, 2H), 4.94\n\n\n(quinolin-2- (s, 2H), 3.37 (s, 2H), 1.97 (s, ylmethoxy)-phenyl]acetamide 3H). \n\n\n 33 Intermediate 4 Ή NMR (300 MHz, and DMSO- e): δ 8.46-8.41 (m, 1-Phenyl- 2H), 8.27 (s, 1H), 8.02 (d, J cyclopropane = 8.4 Hz, 2H), 7.79 (t, J = carboxylic acid 7.8 Hz, 1H), 7.61 (d, J= 8.1 \n\n\n Hz, 2H), 7.54 (m, 1H), 7.28 (m, 2H), 6.91 (m, 3H), 6.69\n\n\n1 -Phenyl-cyclopropanecarboxylic (m, 3H), 6.54 (m, 2H), 5.27 acid pyridin-3-ylmethyl-[4- (s, 2H), 4.79 (s, 2H), 3.09 (quinolin-2-ylmethoxy)-phenyl] (m, 1H), 1.17-1.06 (m, 4H). amide \n\n\n 34 ocH\n3\n Intermediate 8 Ή NMR (300 MHz, and DMSO-45): δ 8.42 (d, J =\n\n\n2,4- 8.4 Hz, 1H), 8.00-7.79 (m, Difluorophenyl 2H), 7.76-7.68 (br t, 1H), acetic acid 7.65-7.63 (m, 3H), 7.35-7.28 \n\n\n (m, 3H), 7.10 (d, J = 7.8 Hz, 2H), 6.98-6.90 (m, 2H), 6.64\n\n\n2-(2,4-Difluoro-phenyl)-N-(6- (d, J= 7.8 Hz, 2H), 5.37 (s, methoxy-pyridin-2-ylmethyl)-N-[4- 2H), 4.81 (s, 2H), 3.76 (s, (quinolin-2-ylmethoxy)-phenyl] 3H), 3.47 (s, 2H). \n\n\n acetamide \n\n\n 35 Intermediate 9 Ή NMR (300 MHz, and DMSO-£¾: δ 8.42 (d, J = ja\nH\nro-> 2,4- 8.4 Hz, 1H), 8.01-7.99 (br d, \n\n\n Difluorophenyl 2H), 7.79 (t,J=6.9Hz, 1H), acetic acid 7.68-7.62 (m, 2H), 7.25-7.10 \n\n\n (m, 1H), 7.08-6.98 (m, 5H),\n\n\n2-(2,4-Difluoro-phenyl)-N-(3,5- 7.00-6.90 (m, 1H), 5.39 (s, dimethyI-isoxazol-4-ylmethyl)-N- 2H), 4.63 (s, 2H), 3.33 (s, \n\n\n [4-(quinolin-2-ylmethoxy)-phenyl] 2H), 1.91-1.88 (brs, 6H). acetamide \n\n\n\n\n\n\n\n\n\n\n\nExample 46 \n\n\n 2-(2,4-Difluorophenyl)-N-(pyridin-3-ylmethyl)-N-[4-(quinolin-2-ylmethoxy) \n\n\n phenyl]acetamide succinate salt \n\n\n\n\n\n\n\n\n To a solution of 2-(2,4-difluorophenyl)-N-(pyridin-3-ylmethyl)-N-[4-(quinolin-2- ylmethoxy)phenyl]acetamide (Example 15, 0.1 10 g, 0.222 mmol) in acetonitrile (5 ttiL) was added succinic acid (0.026 g, 0.222 mmol) and the reaction mass was stirred for 12 hours at room temperature. The excess of solvent was removed under vacuum and resultant residue was washed with pentane to afford 0.07 g of the desired product; Ή NMR (300 MHz, DMSO-i \n6\n): δ 12.17 (br s, 2H), 8.44-8.36 (m, 3H), 8.00 (m 2H), 7.81 -7.76 (br t, I H), 7.81 - 7.62 (m, 3H), 7.32 (m, I H), 7.14-7.1 1 (m, 6H), 7.01 -6.99 (m, I H), 5.36 (s, 2H), 4.85 (s, 21 1), 3.44 (s, 2H), 2.41 (s, 4H). \n\n\nExample 47 \n\n N-Pyridin-3-ylmethyl-N-[4-(quinolin-2-ylmethoxy)-phenyl]-acetamide \n\n\n\n\n\n\n\n\n To the solution of N-(pyridin-3-ylmethyl)-4-(quinolin-2-ylmethoxy) aniline (Intermediate 4, 0.050 g, 0.147 mmol) in tetrahydrofuran was added sodium hydride (0.010 g, 0. 141 mmol) at 10- 1 5°C followed by addition of acetyl chloride and the reaction mixture was stirred at room temperature for 1 8 hours. The reaction mixture was quenched in water, extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulphate, concentrated to afford 0.025 g of the desired product; Ή NMR (300 MHz, OMSO-d\n6\n): δ 1.80 (s, 3H), 4.83 (s, 2H), 5.34 (s, 2H), 7.06 (d, J = 8.4 Hz, 2H), 7.14 (d, J = 9.0 Hz, 2H), 7.31 (m, 1 H), 7.59-7.69 (m, 3H), 7.79 (t, J= 7.2 Hz, 1H), 7.99-8.01 (m, 2H), 8.41-8.43 (m, 3H). \n\n\nExample 48 \n\n\n 3-Butyl- l -pyridin-3-ylmeth - l -[4-(quinolin-2-ylmethoxy)-phenyl]thiourea \n\n\n\n\n\n\n\n\n To a solution of N-(pyridin-3-ylmethyl)-4-(quinolin-2-ylmethoxy) aniline (Intermediate 4, 0.050 g, 0.147 mmol) in dimethyl sulfoxide (5 mL) was added triethylamine (1 mL) followed by n-butyl isothiocyanate (0.016 g, 0.140 mmol) and was stirred at room temperature for 6 hours. The reaction mixture was diluted with water and extracted with dichloromethane. The organic layer was dried over anhydrous a\n2\nS0\n4\n, concentrated and purified by column chromatography to afford 0.030 g of the desired product; Ή NMR (300 MHz, DMSO-i/\n6\n): δ\n\n\n0.83 (t, J = 7.2 Hz, 3H), 1.15-1.21 (m, 4H), 1.41-1.49 (m, 2H), 5.33 (s, 2H), 5.41 (s, 2H), 6.94 (s, 1H), 7.01 (d, J = 8.7 Hz, 2H), 7.09 (d, J = 8.7 Hz, 2H), 7.31 -7.32 (m, 1H), 7.62-7.71 (m, 3H), 7.79 (t, J = 7.8 Hz, 1 H), 8.01 (d, J = 8.1 Hz, 2H), 8.39-8.44 (m, 3H). \n\n\nExample 49 \n\n\nl -Benzyl-3-(5-tertbutyl- l ,3,4-thiadiazol-2-yl)-l -[4-(quinoline-2-ylmethoxy)phenyl]urea \n\n \n\n\n\n\n\n To a solution of N-benzyl-4-(quinolin-2-ylmethoxy)aniline (Intermediate 3, 0.080 g, 0.235 mmol)) in dimethyl sulfoxide (2 mL) was added triethylamine (1 mL) and phenyl (5-tert butyl- l ,3,4-thiadiazol-2-yl)carbamate (Intermediate 14, 0.071 g, 0.256 mmol) and the reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was poured in water and extracted with ethyl acetate. The organic layer was dried over Na\n2\nS0\n4\n, concentrated and purified by column chromatography to afford 0.030 g of the desired product; Ή NMR (300 MHz, DMSO-i¾: δ 8.40 (d, J = 8.4 Hz, 1 H), 7.97 (m, 2H), 7.76 (t, 1 H), 7.59-7.66 (m, 2H), 7.19-7.23 (m, 5H), 6.92-7.1 8 (m, 5H), 5.32 (s, 2H), 4.87 (br s, 2 H), 1 .33 (s, 9H). \n\n\n Example 50 \n\n\n 2-(2,4-Difluoro-phenyl)-N-[2-pyridin-4-yl-4-(quinolin-2-ylmethoxy)-phenyl]acetamide \n\n\n\n\n\n\n\n\n The title compound was prepared following the procedure described for Example 1 , but starting from 2-pyridin-4-yl-4-(quinolin-2-ylmethoxy)-phenyl amine (Intermediate 18, 0.131 g, 0.400 mmol), benzotriazol-l -yloxytris(dimethylamino)phosphonium hexafluorophosphate (0.442 g, 1.0 mmol), N,N-diisopropylethylamine (2 mL) and 2,4-difluorophenyl acetic acid (0.075 g, 0.428 mmol) to afford 0.040 g of the desired product; Ή NMR (300 MHz, CDC1\n3\n): δ 8.57 (br s, 2H), 8.38 (d, J = 7.2 Hz, 1 H), 8.30 (d, J = 7.2 Hz, I H), 7.93-7.53 (m, 7H), 7.26- 7.16 (m, 2H), 7.03 (br s, 1 H), 6.84-6.81 (m, 2H), 5.57 (s, 2H), 3.61 (s, 2H). \n\n\nExample 51 \n\n\n 2-(2,4 Difluorophenyl)-N-methyl-N-[2-pyridin-4-yl-4-(quinolin-2-ylmethoxy)- phenyljacetamide \n\n \n\n\n\n\n\n To a solution of 2-(2,4-difluoro-phenyl)-N-[2-pyridin-4-yl-4-(quinolin-2-ylmethoxy)- phenyl]acetamide (Example 50, 0.040 g, 0.083 mmol) in tetrahydrofuran was added (60%) sodium hydride (0.004 g, 0.1 mmol) at 10-15°C and stirred for 30 min. To this mixture was added methyl iodide (0.013 g, 0.091 mmol) and stirred for 12 hours. The reaction mixture was quenched in water and extracted with ethyl acetate. The organic layer was concentrated to afford 0.03 g of the desired product; Ή NMR (300 MHz, DMSO-<¾): \n'\n6 8.66-8.65 (br d, 1 H), 8.47-8.44 (br d, 1 H), 8.02-8.00 (br d, 2H), 7.82-7.72 (m, 2H), 7.62 (t, J = 7.8 Hz, 1 H), 7.48-7.41 (m, 3H), 7.28 (s, 2H), 7.13-7.04 (m, 3H), 6.95-6.93 (m, 1 H), 5.48 (s, 2H), 3.39 (m, 2H), 2.97 (s, 3H). \n\n\n Example 52 \n\n\n 4,4,4-Trifluoro-N-pyridin-3-ylmethyl-N-[4-(quinolin-2-ylmethoxy)-phenyl]-butyramide \n\n\n\n\n\n\n\n\n To a solution of 4,4,4-trifluoro-N-[4-(quinolin-2-ylmethoxy)-phenyl]-butyramide (Intermediate 19, 0.075 g, 0.200 mmol) in N,N-dimethylformamide under nitrogen atmosphere, was added suspension of sodium hydride (0.024 g, 0.588 mmol) in NN- dimethylformamide (5 ml) and the mixture was stirred at room temperature for 30 min. To this mixture was added 3-chloromethyl pyridine (0.030 g, 0.218 mmol) at -20°C and stirred at room temperature for 24 hours. The reaction mixture was quenched in ice cold water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulphate, concentrated and purified by column chromatography to afford 0.025 g of the desired product as pale yellow liquid; Ή NMR (DMSO-i/\n6\n): δ 8.44-8.32 (m, 3H), 8.02-7.99 (m, 2H), 7.95 (t, J = 6.9 Hz, 1 H), 7.75-7.59 (m, 3H), 7.33-7.29 (m, 1 H), 7.17 (d, J = 8.7 Hz, 2H), 7.10 (d, ./ = 9.6 Hz, 2H), 5.35 (s, 2H), 4.85 (s, 2H), 2.49 (m, 2H), 2.30 (t, J = 8.1 Hz, 2H); MS (m/z): 466.35 (M+H)\n+\n. \n\n\n Example 53 \n\n 2-{4-[2-(4-Chlorophenyl)imidazo[2,l-0][l,3]benzothiazol-3-yI]phenoxy}-N-(5-methyl pyridin-2-yl)acetamide \n\n\n\n\n\n\n\n\n Prepared the solution of {4-[2-(4-chlorophenyl)imidazo[2,l-&][l,3]benzothiazol-3- yl]phenoxy}acetic acid (Intermediate 25) (0.050 g, 0.110 mmol) and 2-amino-5-methyl pyridine (0.037 g, 0.330 mmol) in DCM. The reaction mixture was cooled to 10-15°C and was added thionyl chloride (0.027 g, 0.229 mmol) drop wise followed by catalytic amount of DMF. The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was quenched with ice water and extracted the organic mass with DCM. The organic layer was concentrated and purified the crude compound by column chromatography to afford 0.012 g of the desired product; Ή NMR (300 MHz, DMSO-<¾): δ 10.54 (s, 1H), 8.19 (s, 1H), 8.02 (t, J =7.8 Hz, 2H), 7.65 (d, J= 7.8 Hz, 5H), 7.57 (d, J= 8.1 Hz, 2H), 7.51 (d, ./= 8.4 Hz, 2H), 7.34 (d, J= 8.7 Hz, 1H), 7.23 (d, J= 8.7 Hz, 1H), 6.73 (d, J= 7.8 Hz, 1 H ), 4.92 (s, 2H), 2.26 (s, 3H); MS (m/z): 526.02 (M+H)\n+\n. \n\n\nExample 54 \n\n\n 2-{4-[2-(4-Chlorophenyl)imidazo[2,l-Z)][l,3]benzothiazol-3-yl]phenoxy}-N-(5-chloro pyridin-2-yl)acetamide \n\n\n\n\n\n\n\n\n The title compound was prepared following the procedure described for Example 53, but starting from {4-[2-(4-chlorophenyl)imidazo[2,I->][l,3]benzothiazol-3-yl]phenoxy}acetic. acid (Intermediate 25) (0.080 g, 0.188 mmol), thionyl chloride (0.043 g, 0.369 mmol) and 2- amino-5-chloropyridine (0.070 g, 0.550 mmol) to afford 0.025 g of the desired product; Ή NMR (300 MHz, DMSO-i\n6\n): δ 10.87 (s, 1H), 8.42 (s, 1H), 8.14 (d, J = 8.7 Hz, 1H), 8.03 (d, J=7.8 Hz, 1H), 7.95 (d,j=9.0 Hz, 1H), 7.57 (d,J= 8.1 Hz, 2H), 7.51 (d,J=8.4 Hz, 2H), \n\n 7.33 (d, J = 9.0 Hz, 4H), 7.22 (d, J = 8.4 Hz, 2H), 6.73 (d, J = 7.8 Hz, 1 H), 4.95 (s, 2H); MS (m/z): 546.1 1 (M+H)\n+\n. \n\n\nExample 55 \n\n\n 2-{4-[2-(4-Chlorophenyl)imidazo[2, l - »][l,3]benzothiazol-3-yl]phenoxy}-N-(6-chloropyridin -2-yl)acetamide \n\n\n\n\n\n\n\n\n The title compound was prepared following the procedure described for Example 55, but starting from 2-(4-chlorophenyl)-3-(4-hydroxyphenyl)benzo[i ]imidazo[2, l - >][ ] ,3]thiazole (Intermediate 20) (0.080 g, 0.21 1 mmol) and 2-chloro-N-(6-chIoro-pyridin-2-yI)acetamide (Intermediate 28) (0.065 g, 0.317 mmol) to afford 0.022 g of the desired product; Ή NMR (300 MHz, DMSO-<¾): δ 1 1 .05 (s, 1 H), 8.09 (d, J = 7.8 Hz, 1 H), 8.04 (d, J = 7.2 Hz, 1 H), 7.90 (t, J = 8.4 Hz, 1H), 7.58 (d, J =8.1 Hz, 2H), 7.51 (d, J= 8.1 Hz, 3H), 7.34 (d, J = 7.8 Hz, 2H), 7.30-7.21 (m, 4H), 6.72 (d, J = 7.8 Hz, 1H), 4.94 (s, 2H); MS (m/z): 546.44 (M+H)\n+\n. \n\n\nExample 56 \n\n\n 2-{4-[2-(4-Chlorophenyl)imidazo[2, l -¾][l ,3]benzothiazol-3-yl]phenoxy}-N-[3-chloro-5- (trifluoromethyl)pyridin-2-yl]acetamide \n\n\n\n\n\n\n\n\n To the suspension of 4-nitrophenyl-[4-(2-chlorophenyl)imidazo[2, l -6][l ,3]benzothiazol-3-yl] phenoxy]acetate (Intermediate 26) (0.080 g, 0.143 mmol) and 2-amino-3-chloro-5- (trifluoromethyl)pyridine (0.042 g 0.215 mmol) in DMF (1.0 mL) was added sodium hydride (0.014 g, 0.357 mmol) at -10 to 0°C under nitrogen atmosphere and stirred the reaction mixture at room temperature for 2-3 hours. The reaction mixture was quenched in ice water, acidified with dilute HCl. The resultant precipitate was filtered off and purified by column \n\n chromatography to afford 0.034 g of the desired product; Ή NMR (300 MHz, DMSO-< \n6\n): δ 10.82 (s, l H), 8.87 (s, 1 H), 8.59 (s, 1 H), 8.04 (d, J = 7.8 Hz, 1 H), 7.60 (d, J = 8.1 Hz, 2H), 7.52 (d, J = 8.4 Hz, 2H), 7.33 (d, J = 8.4 Hz, 3H), 7.26 (d, J = 7.8 Hz, 3H), 6.74 (d, J = 8.4 Hz, 1 H), 5.02 (s, 2H); MS (m/z): 614.44 (M+H)\n+\n. \n\n\nExamples 57-59 mentioned in Table 6 below were prepared using Intermediate 26 and appropriate amine derivatives, by following the procedure as described for the preparation of Example 56. \n\n\n Table 6: Structure, starting material and characterization data for Examples 57-59 \n\n\n\n\n\n\n\n\nExample 60 \n\n 2-{4-[2-(4-Chlorophenyl)imidazo[2, l -0][l ,3]benzothiazol-3-yl]phenoxy} -N-(4-methyl pyridin-2-yl)acetamide \n\n\n\n\n\n\n\n\n To the suspension of 2-(4-chlorophenyl)-3-(4-hydroxyphenyl)benzo[i/]imidazo[2, ] - )] [l ,3] thiazole (Intermediate 25) (0.080 g, 0.21 1 mmol) and 2-chloro-N-(4-methylpyridin-2-yl) acetamide (Intermediate 27) (0.058 g, 0.317 mmol) in DMF (1 .0 mL) was added potassium carbonate (0.058 g 0.423 mmol) and it was stirred at 90-100 °C for 5 hours. The reaction mixture was cooled at room temperature and quenched in ice water, acidified with di lute HC1. Resultant solid was filtered off and purified by column chromatography to afford 0.01 9 g of the desired product; Ή NMR (300 MHz, DMSO-<¾: δ 10.55 (s, 1 H), 8.21 (d, ./ = 4.8 Hz, 1 H), 8.03 (d, J = 7.2 Hz, 1 H), 7.96 (s, 1 H), 7.57 (d, J = 7.8 Hz, 2H), 7.5 1 (d, J = 8.4 Hz, 3H), 7.33 (d, ./ = 9.0 Hz, 2H), 7.23 (d, J = 8.4 Hz, 3H), 7.00 (d, J = 8.4 Hz, 1 H ), 6.73 (d, J = 8. 1 Hz, 1 H), 4.93 (s, 2H), 2.33 (s, 3H); MS (m/z): 526.02 (M+H)\n+\n. \n\n\nExamples 61 -68 mentioned in Table 7 below were prepared using appropriate starting material, by following the procedure as described for the preparation of Example 60. \n\n\nTable 7: Molecular structure, starting material and characterization data for Examples 61 -69 \n\n\n\n\n\n\n\n\n\n\n acetamide \n\n\n\n\n\n\n\n ethyl-N-pyridin-2-ylacetamide \n\n\n Example 69\n\n\n -{4-[2-(4-Chlorophenyl)imidazo[2, l -¾][l ,3]benzothiazol-3-yl]phenoxy}-N-methyl- V-phenylacetamide \n\n\n \n\n The mixture of {4-[2-(4-chlorophenyl)imidazo[2, l -6][l ,3]benzothiazol-3-yl]phenoxy}acetic acid (Intermediate 25, 0.050 g, 0.1 14 mmol), BOP (0.060 g, 0.137 mmol) and DIPEA (0.028 g, 0.229 mmol) was stirred at room temperature for 15-20 mins. To this mixture, N- methylaniline (0.015 g, 1.2 mmol) was added and stirred the reaction mixture at room temperature for 14 hours under nitrogen atmosphere. The reaction mixture was quenched in ice water, acidified with dilute HC1, filtered off the solid and purified by column chromatography to afford 0.012 g of the desired product; Ή NMR (300 MHz, DMSO-c¼): δ 8.03 (d, ,/ = 7.8 Hz, 1 H), 7.50 (d, J = 6.3 Hz, 8H), 7.33 (m, 5H), 7.02 (s, 2H), 6.69 (d, J = 9.0 Hz, 1 H), 4.59 (s, 2H), 3.25 (s, 3H); MS (m/z): 525.03 (M+H)\n+\n. \n\n\nExamples 70-72 mentioned in Table 8 below were prepared using appropriate starting material, by following the procedure as described for the preparation of Example 69. \n\n\nTable 8: Structure, starting material and characterization data for Examples 70-72 \n\n\n \n\n Exam. Molecular structure and Starting Spectral data \n\n\n No. chemical name material \n\n\n 2-{4-[2-(4-Chlorophenyl) (t, J = 34.8 Hz, 1 H), 6.70 (d, J imidazo[2, l -Z>][l ,3] = 7.8 Hz, 1 H), 4.84 (s, 2H); benzothiazol-3-yl]phenoxy} MS (m/z): 51 1.72 (M+H)\n+\n. N-phenylacetamide \n\n\nPharmacological activity \n\n\nThe illustrative examples of the present invention are screened for PDE 10A activity according to a modified procedure described in Sette, C, lona, S. and Conti, M., J. Biol. Chem. 269 ( 12), pp. 9245-9252, 1994. \n\n\nln-vitro screening assay for PDE10A inhibitors: \n\n\n PDE10 enzyme hydrolyses cAMP / cGMP to metabolically inactive 5'-AMP / 5 '- GMP. Inhibition of PDE10 enzyme activity can be quantitated by using a two step radiometric assay. In this assay, PDE10 enzyme converts \n3\nH-cAMP/\n3\nH-cGMP to \n3\nH-AMP/ \n3\nH-GMP which is then converted to \n3\nH-adenosine / \n3\nH-guanosine using snake venom nucleotidase. The radioactivity released in the supernatant is quantitated as an indicator of PDE 10 enzyme activity. \n\n\n Test compounds or reference compounds such as dipyridamole, IBMX (Calbiochem) and papaverine (Sigma) were dissolved in dimethylsulfoxide (DMSO) to prepare 1 .0 mM stock solution and diluted suitably to get the desired concentration. Final concentration of DMSO in the reaction was 3 % (v/v). Substrate mixture was prepared by mixing H-cAMP (GE Healthcare) and 1 .0 mM cold cAMP (Sigma) in order to get 0.5 μθί and 1 .0 μΜ final concentrations of each respectively in the assay buffer. 1 .0 mg/mL of snake venom nucleotidase (Sigma) was prepared in D/w. Dowex (AG1 -X8 from Biorad) slurry was mixed with water and ethanol at 1 : 1 : 1 ratio. The assay was carried out using suitably diluted PDE10A enzyme preparation (BPS Biosciences) to get around 1 -20 % substrate hydrolysis to ensure linear reaction kinetics. \n\n\n PDE10A assay was carried out in 200 μΙ_. reaction volume by addition of assay buffer containing 10 mM Tris-HCl (pH 7.4), 0.2 mM MgCl\n2\n, . test compound at required concentration and diluted enzyme. Reaction mixture was incubated at 30 °C for 30 min. The reaction was stopped by heating the plate in boiling water bath for 5 min and then cooling on an ice bath for 1 5 min. This was followed by addition of 50 μΐ, of Crotalus atrox snake venom 5'-nucleotidase and incubation at 30 °C for 30 min. Thereafter, 400 μΕ of Dowex was added and incubated on an ice bath for 1 5 min. Reaction mixture was centrifuged and \n\n supernatant was used for quantifying radioactivity in the samples. Reaction was measured as counts per minute (cpm) using Packard Biosciences plate reader. An enzyme control without test compounds was run to quantitate maximum PDEI OA reaction. Inhibition of enzyme activity was calculated as a percent of control reaction. IC50 values were calculated from dose response curve by nonlinear regression analysis using GraphPad Prism software. \n\n\n The compounds of the present invention were screened using the above assay procedure and the results obtained are given in Table 9. Percentage inhibition of human - PDEI OA enzyme at 1 .0 μΜ and 10.0 μΜ concentrations are given in Table 1 along with IC50 (nM), wherein \"A\" refers to an IC50 value of less than 100 nM, \"B\" refers to an IC50 value in range of 100.01 -250 nM, \"C\" refers to an IC\n50\n value in range of 250.01 -500 nM and \"D\" refers to an IC50 value of greater than 500 nM. \n\n\nTable 9: In-vitro screening results of compounds of present invention \n\n\n Example No. percentage inhibition at IC\n50\n (nM) \n\n\n 1 μΜ 10 μΜ \n\n\n 1 58.54 93.35 D \n\n\n 2 66.03 95.24 D \n\n\n 3 31.55 77.79 ~ \n\n\n 4 72.44 92.16 C \n\n\n 5 88.73 96.29 A \n\n\n 6 36.80 64.61 -\n\n\n7 18.72 47.53 ~ \n\n\n 8 19.34 39.00 ~ \n\n\n 9 17.42 37.09 -\n\n\n10 1 1.60 21 .76 -\n\n\n12 32.68 56.88 \n\n\n 13 74.1 5 86.79 B \n\n\n 14 82.96 97.20 A \n\n\n 1 5 91 .10 97.53 A \n\n\n 16 83.07 96.40 B \n\n\n 17 65.83 90.99 D \n\n\n 18 84.84 96.88 B \n\n\n 19 76.62 96.39 B \n\n\n 20 40.60 72.63 — \n\n Example No. percentage inhibition at 1C\n50\n (nM)\n\n\n1 μΜ 10 μΜ\n\n\n21 43.45 85.94 ~\n\n\n22 22.17 66.40 ~\n\n\n23 91.46 98.87 A\n\n\n24 80.24 96.42 C\n\n\n25 80.71 97.35 A\n\n\n26 63.86 95.09 C\n\n\n27 85.28 98.67 A\n\n\n28 21.17 69.96 ~\n\n\n29 68.07 94.90 B\n\n\n30 68.75 96.3 1 C\n\n\n3 1 36.22 86.98 -\n\n\n32 75.53 99.75 B\n\n\n33 29.07 80.69 —\n\n\n34 36.46 73.41 -\n\n\n35 73.35 95.44 C\n\n\n36 78.59 99.04 B\n\n\n37 36.81 56.92 ~\n\n\n38 86.94 98.47 A\n\n\n39 88.77 98.64 A\n\n\n40 89.19 96.34 A\n\n\n41 87.12 99.29 A\n\n\n42 43.99 44.62 ~\n\n\n43 58.13 81 .30 D\n\n\n44 50.90 73.25 -\n\n\n45 46.75 88.14 —\n\n\n46 96.06 100.30 A\n\n\n47 14.36 73.13 —\n\n\n48 16.01 71 .59 -\n\n\n49 34.07 39.88 \n\n\n 50 04.78 07.98 - \n\n Example No. percentage inhibition at IC\n50\n (nM)\n\n\n1 μΜ 10 μΜ\n\n\n51 06.91 43.63 -\n\n\n52 80.81 96.71 B\n\n\n53 20.39 48.90 ~\n\n\n54 12.39 24.61 ~\n\n\n55 0.00 3.35 ~\n\n\n56 00 00 ~\n\n\n57 16.99 19.96 —\n\n\n58 1 8.03 26.53 -\n\n\n59 1 1 .72 26.62 —\n\n\n60 3 1 .89 32.42 -\n\n\n61 84.32 88.81 B\n\n\n62 17.40 41.41 ~\n\n\n63 82.40 97.75 A\n\n\n64 58.16 82.10 ~\n\n\n65 76.78 94.56 A\n\n\n66 78.32 89.21 B\n\n\n67 83.63 95.45 A\n\n\n68 76.6 91.50 B\n\n\n69 09.19 27.73 -\n\n\n70 57.57 58.83 -\n\n\n71 14.15 32.30 -\n\n\n72 43.91 46.19 ~"
  }
]